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Short abstract 
 
Last century advances in molecular biology and biotechnologies enabled us to 
understand the exceptionally broad repertoire of nucleic acids functions. For a long 
time DNA was regarded as a rigid molecule with the sole purpose to store and 
transmit genetic information. However, this idea has been completely overtaken with 
the discovery of the catalytic activity of specific RNA molecules. In effect, the early 
1970s and the embryonic works on antisense oligonucleotides paved the way for our 
current understanding and use of oligonucleotides (ONs) and their analogues in 
numerous and very different application fields, such as gene modulation, i.e. the 
antisense and antigene strategies, new generation drugs, i.e. the aptamers, but also 
nanotechnologies. My research activity is included in this general context and, in 
particular, has been devoted to unravelling ON uses in a broad range of fields, which 
goes from the development of novel drug candidates to gene regulation and 
implementation of new approaches for the simple construction of biosensors. 
Specifically, my search has been focused on:  
 Realization of novel antiviral aptamers and consolidation of a new, cost effective 
and quick binding assay for the optimization of already reported aptamers, not 
achievable through the universally accepted method for the individuation of 
selective and efficient aptamers, the SELEX method.      
 Studies on already reported protocols for the functionalization of Porous Silicon 
(PSi) matrices, in view of the development of optical DNA-based biosensor and 
discovery of a new efficient protocol for the PSi-friendly in situ oligonucleotide 
synthesis.   
 Chemical synthesis and structural and biological characterization of PNA 
sequences for the inhibition of a miRNA, designated as responsible for the down-
regulation of the Cystic Fibrosis disease-gene. 
The achievement of these goals required a combination of chemical synthesis, with 
the optimization of existing protocols, and techniques for the biophysical and 
biological characterization of our biomolecules. 
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Long Abstract  
 
I progressi degli ultimi decenni nella biologia molecolare e nelle biotecnologie hanno 
consentito di riconoscere l’incredibile repertorio funzionale degli acidi nucleici. Per 
molto tempo gli acidi nucleici sono stati visti unicamente come molecole rigide, la cui 
sola funzione fosse quella di conservare e trasmettere l’informazione genetica. 
Tuttavia tale idea è stata definitivamente superata con la scoperta dell’attività 
catalitica di specifiche molecole di RNA. [1] In effetti, data la specificità 
dell’appaiamento di tipo Watson-Crick e la plasticità di tali molecole, esse sono ormai 
universalmente riconosciute quali strumenti di eccezionale versatilità in svariati 
ambiti, tra cui quello nanotecnologico, biosensoristico, farmacologico. In questo 
contesto, con il loro pionieristico lavoro sull’inibizione del genoma del virus del 
sarcoma di Rous mediante impiego di oligonucleotidi antisenso, Zamecnick e 
Stephenson hanno dato inizio nel 1978 a quella che è stata successivamente definita 
“la nuova grande ondata della rivoluzione biotecnologica”.[2,3] Gli oligonucleotidi 
(ON) sono brevi sequenze sintetiche di acido deossiribonucleico o ribonucleico, con 
un notevole repertorio di applicazioni, che spaziano dalla modulazione delle funzioni 
geniche alla costruzione di biosensori allo sviluppo di nanomateriali. [4,5] Negli ultimi 
anni il notevole potenziale degli ON come strumenti terapeutici nella modulazione 
genica è stato ampiamente esplorato. In questo ambito, gli ON trovano 
principalmente applicazione nella strategia antisenso, nella strategia antigene e 
come aptameri.                 
Il silenziamento dell’espressione genica avviene nella strategia antisenso mediante 
impiego di sequenze oligonucleotidiche complementari a molecole di mRNA; esse 
una volta legato specificamente il bersaglio ne impediscono il riconoscimento da 
parte dell’apparato proteico deputato alla decodifica dell’informazione e la 
traduzione. [6] In generale, il blocco sterico della traduzione si ottiene quando l’ON 
antisenso è diretto contro l’estremità 5’ del target, inibendone così l’interazione con il 
macchinario della traduzione; il secondo meccanismo attraverso il quale essi 
agiscono è rappresentato dalla degradazione mediata da RNasi-H, che avviene 
quando l’ON antisenso lega il bersaglio in un qualsiasi sito, formando così una 
eteroduplex RNA/DNA. [7] L’interesse rivolto verso questa strategia è testimoniato 
dall’approvazione per uso clinico dell’analogo oligonucleotidico, Fomivirsen, contro 
retiniti indotte da citomegolvirus e dagli studi su molti altri ON antisenso, già in fase 1 
o 2 di sperimentazione clinica. Nella strategia antigene l’inibizione dell’espressione 
genica avviene mediante l’impiego di ON che riconoscono specificamente sequenze 
situate nel solco maggiore della doppia elica di DNA, instaurando legami ad idrogeno 
di tipo Hoogsteen con le basi puriniche ed originando così una tripla elica. [8] 
L’approccio antigene rimane uno degli ambiti più affascinanti di applicazione degli 
ON, consentendo, in linea teorica, interventi di mutagenesi sito diretta e di terapia 
genica. Sebbene si tratti teoricamente di una strategia ristretta a tratti 
polipurinici•polipirimidinici, grandi sforzi sono stati e sono, tuttora, condotti per 
estendere il repertorio di sequenze bersaglio, tramite il disegno razionale di opportuni 
derivati. Infatti, sebbene il principio su cui si basano strategia antisenso ed antigene 
possa sembrare semplice e gli approcci stessi facilmente attuabili, nella pratica 
l’impiego di ON per la modulazione dell’espressione genica trova importanti ostacoli, 
tra cui si annoverano principalmente il raggiungimento del sito nel quale essi devono 
funzionare, che richiede il passaggio attraverso membrane cellulari idrofobiche e la 
suscettibilità degli ON alla degradazione enzimatica operata da endo- ed 
esonucleasi.                                                                           
 3 
 
In virtù di tali considerazioni, negli ultimi decenni la ricerca di ON strutturalmente 
modificati, che potessero sopperire alle limitazioni delle controparti naturali e, 
pertanto, funzionare quali strumenti terapeutici, ha ottenuto notevole slancio e 
condotto ad analoghi dotati di affascinanti proprietà. [9] In generale si distinguono tre 
tipi di modifiche: modifiche al gruppo fosfato, modifiche allo zucchero e modifiche 
all’intero scheletro. [10] Alla terza generazione di analoghi, più correttamente noti 
come ON mimici, appartiene l’Acido Peptido Nucleico (PNA), ormai universalmente 
riconosciuto come mimico di notevole rilevanza biotecnologica. [11]   
Il PNA è un analogo in cui lo scheletro zucchero-fosfato è completamente sostituito 
da uno scheletro di natura poliammidica, dato dalla ripetizione di  unità di N-(2-
amminoetil)-glicina, a cui le basi azotate del DNA sono legate mediante un linker 
metilen carbonilico. Data la presenza delle stesse basi azotate del DNA, situate ad 
una distanza che mima la distanza nell’acido nucleico, il PNA è in grado di 
riconoscere ed ibridizzare con sequenze complementari di DNA o RNA ed, in effetti, 
la mancanza di cariche nello scheletro rende gli ibridi PNA/DNA e PNA/RNA 
notevolmente più stabili rispetto alle duplex naturali. Un’ulteriore conseguenza della 
natura poliammidica dello scheletro è che la formazione degli ibridi è indipendente 
dalla concentrazione salina [11-14]. In virtù della estrema specificità del PNA e della 
stabilità delle eteroduplex risultanti, l’ibridazione PNA-acido nucleico è 
particolarmente sensibile ai mismatch, come evidenziato dal fatto che i PNA legano 
con elevata affinità sequenze complementari, più debolmente sequenze recanti un 
mismatch, mentre l’appaiamento non ha luogo per le sequenze recanti due 
mismatch, e questo fenomeno è stato ampiamente sfruttato per la costruzione di 
dispositivi basati sul PNA ad uso diagnostico. [15] Il PNA presenta, inoltre, elevata 
stabilità biologica; esso risulta essere, infatti, resistente alla degradazione operata da 
nucleasi e proteasi, ne consegue un tempo di vita più esteso sia in vitro che in vivo. 
Alla resistenza alla degradazione enzimatica si accompagna una maggiore stabilità 
chimica, le molecole di PNA sono, infatti, stabili in ambiente fortemente acido e, 
contrariamente a quanto osservato per il DNA, non mostrano fenomeni di 
depurinazione a seguito del trattamento in condizioni acide drastiche.  L’elevata 
stabilità in vivo, la specifica ibridazione con gli acidi nucleici e la mancanza di 
tossicità, anche a concentrazioni relativamente elevate, hanno reso i PNA molecole 
promettenti in ambito terapeutico. In virtù della loro abilità nel legarsi a molecole di 
DNA e di RNA, i PNA hanno trovato anzitutto possibilità di utilizzo quali agenti 
antisenso ed antigene. In particolare, essi sono stati ampiamente studiati per la loro 
capacità di modulare l’espressione genica attraverso inibizione della trascrizione 
mediata dal legame al DNA ed attraverso inibizione della traduzione mediata dal 
legame all’ mRNA. Numerose evidenze sperimentali, inoltre, testimoniano che 
molecole di PNA sono inibitori dei microRNA (miRNA) più efficienti rispetto agli 
inibitori oligonucleotidici.[16] Tuttavia, sebbene inizialmente siano stati utilizzati in 
ambito terapeutico, essi hanno recentemente trovato applicazione in ambito 
diagnostico e di biologia molecolare. Tra le applicazioni maggiormente esplorate si 
possono annoverare: inibizione di determinati enzimi, quali telomerasi, elicasi, 
trascrittasi inversa; mutagenesi sito-diretta; attivazione dell’espressione di geni 
endogeni; amplificazione mediante PCR; tecnica PARC (PNA Assisted Rare 
Cleavage); impiego come sonda di biosensori per acidi nucleici. [17] Sin da quando il 
PNA è stato proposto nel 1991, sono state riconosciute le sue proprietà simili, ed in 
alcuni casi superiori, al DNA ed all’RNA, con le promettenti applicazioni che ne 
derivano, tuttavia, di recente, sono state descritte anche applicazioni delle molecole 
di PNA come aptameri. [18]                     
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In effetti, un’altra intrigante applicazione di ON ed analoghi è rappresentata dagli 
aptameri, brevi sequenze di acido nucleico in grado di riconoscere e legare con 
estrema affinità target molecolari, tra cui proteine, acidi nucleici, piccole molecole 
organiche. [19] Il principale metodo di selezione di frammenti oligonucleotidici dotati 
di alta affinità e specificità è stato per la prima volta proposto nel 1990 da Tuerk e 
Gold e consiste nella Evoluzione Sistematica dei Ligandi realizzata attraverso una 
Tecnologia di Arricchimento Sequenziale (SELEX). [20] La tecnica consente di 
selezionare in vitro gli aptameri a partire da una libreria combinatoriale contenente un 
numero molto elevato di sequenze e consiste nella iterazione di due passaggi 
fondamentali: selezione di sequenze aventi affinità per il target e amplificazione degli 
aptameri con le proprietà di legame desiderate. Date le loro proprietà, gli aptameri, 
sin dalla loro introduzione, sono stati ampiamente studiati per le loro applicazioni in 
ambito terapeutico e biosensoristico. L’impiego di tali molecole nel primo ambito è 
subordinato all’esistenza di determinate caratteristiche. Anzitutto, le elevate 
dimensioni e quindi l’ampia superficie di contatto degli acidi nucleici garantiscono 
maggiori interazioni con i bersagli terapeutici rispetto alle molecole più piccole, 
conseguentemente sono richieste concentrazioni inferiori per un’efficiente inibizione 
rispetto ai farmaci tradizionali. Inoltre, l’estensione superficiale permette loro di 
discriminare tra proteine strettamente correlate tra loro, come, ad esempio, le 
isoforme della protein-chinasi C (PKC) che posseggono un grado di similitudine del 
96%. [21] In secondo luogo, il riconoscimento specifico deve essere accompagnato 
all’inibizione della funzione biologica della molecola bersaglio, a tal proposito sono 
stati proposti aptameri ad RNA in grado di riconoscere ed inibire i recettori del fattore 
di crescita endoteliale vascolare (VEGF) ed, ancora, aptameri formati da 
oligonucleotidi fosforotioati in grado di inibire la trascrittasi inversa di HIV.[22,23] In 
questo contesto, particolarmente fervida è stata la ricerca di aptameri in grado di 
interferire con la replicazione virale ed, in tal senso, nel 1994 Hotoda e colleghi, con 
la scoperta che la sequenza oligonucleotidica 5’TGGGAG3’ se opportunamente 
modificata alle estremità era in grado di inibire l’entrata di HIV-1 all’interno delle 
cellule bersaglio, hanno dato inizio ad una lunga fase, ancora non interrotta, di studi 
approfonditi sulle più opportune e funzionali modifiche da apportare alla sequenza 
originaria in vista dello sviluppo di potenti agenti terapeutici. [24-26] Gli aptameri 
esibiscono una notevole propensione ad assumere una varietà di motivi strutturali 
secondari e terziari e, di fatti, l’assunzione della corretta conformazione è 
intimamente connessa con il riconoscimento e l’interazione selettivi col target. Tra le 
varie architetture, la struttura non canonica a quadrupla elica, G-Quadruplex, è stata 
individuata in svariati aptameri; tra questi possiamo annoverare il primo aptamero per 
il quale è stata caratterizzata la struttura quadruplex, cioè il TBA, (Thrombin Binding 
Aptamer), un pentadecamero ricco in guanine che adotta in soluzione una struttura 
G-quadruplex intramolecolare e che è in grado di legare ed inibire la trombina, 
proteina farmacologicamente rilevante, uno degli aptameri leganti l’RNasi-H1 ed, 
ancora, molti degli aptameri proposti come agenti antivirali, tra cui 93del, T30695 e la 
già accennata sequenza proposta da Hotoda. [24, 25, 27,28] 
Le strutture G-Quadruplex sono strutture costituite da quartetti coplanari di guanine, 
stabilizzati da legami idrogeno di tipo Hoogsteen, emerse negli ultimi decenni per la 
loro implicazione in processi di rilevanza biologica. [29] Sequenze ricche in guanina 
in grado di associarsi in strutture a quadrupla elica sono state individuate, infatti, a 
livello delle regioni telomeriche del genoma umano, nelle regioni di switch delle 
immunoglobuline, nei promotori di diversi oncogeni. [30, 31] A ciò si aggiungono 
ulteriori motivi di interesse: le G-Q, come già accennato, costituiscono lo scaffold di 
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numerosi aptameri ed, inoltre, per le loro intrinseche proprietà sono state proposte 
per la costituzione di nanomateriali. [32, 33] Come mostra l’elevato numero di lavori 
in questo ambito, l’arrangiamento G-Q presenta un elevato grado di polimorfismo, e 
dunque dà origine ad  un’ampia famiglia di strutture stabili, caratterizzate da 
un’architettura di base comune, ma elementi di riconoscimento ben definiti e 
differenziati. La plasticità conformazionale di queste interessanti strutture permette la 
regolazione fine del riconoscimento del target, ma anche la possibilità di sviluppare 
strutture molecolari superiori; elementi, questi, estremamente utili in vista dello 
sviluppo di nuovi aptameri, nonché di strumenti diagnostici e di interesse 
biosensoristico.                 
In effetti, un’altra interessante applicazione delle G-Q e degli ON in generale è 
rappresentata dallo sviluppo di biosensori. [34]             
I biosensori sono dispositivi analitici che convertono un evento biologico in un 
segnale quantificabile e processabile. Tipicamente un biosensore è costituito da tre 
elementi fondamentali: i) un recettore o sonda che riconosce l’analita, ii) 
un’interfaccia che trasforma l’evento biologico in un segnale, che viene trasmesso al 
iii) trasduttore, l’elemento deputato alla conversione del fenomeno in un segnale 
elettronico amplificabile. [35] La ricerca in questo campo ha vissuto una crescita 
esponenziale negli ultimi decenni, a causa delle applicazioni di tali dispositivi in 
settori quali la diagnostica, e quindi il monitoraggio ed il controllo in campioni di 
diversa natura di sequenze di DNA correlate a virus, malattie genetiche ed altri 
agenti patogeni, nonché la rilevazione in svariate matrici di inquinanti ed altri 
contaminanti. Sequenze oligonucleotidiche o analoghe sono particolarmente adatte 
alla costituzione di biosensori, considerando l’interazione forte e specifica tra le 
coppie di basi di filamenti complementari. Infatti, il principio su cui si fondano i 
biosensori a DNA consiste nell’ibridazione, in altri termini essi si basano 
sull’immobilizzazione di una sequenza oligonucleotidica sintetica ad un idoneo 
supporto solido, con sequenza complementare al target ricercato. Sensori 
elettrochimici o piezoelettrici rispondono alla ibridazione con un segnale amplificabile 
e quantificabile. Una delle problematiche più comuni nella costruzione di un 
biosensore a DNA è costituita dalla bioconiugazione, il legame, cioè, della sonda 
organica al supporto inorganico. La strategia più comune e documentata, in tal 
senso, è rappresentata dalla immobilizzazione della sonda sintetizzata ex situ sul 
supporto solido. In ogni caso, visti i notevoli vantaggi della sintesi di ON in situ sul 
supporto costituente il dispositivo, importanti sforzi sono stati, negli ultimi anni 
effettuati per sviluppare protocolli che ne garantissero la rapida ed economica sintesi 
in situ su tali matrici. Di recente, la ricerca nell’ambito dei biosensori basati su DNA è 
andata di pari passo con quella dei dispositivi basati su aptameri, le cui interessanti 
caratteristiche strutturali e proprietà di riconoscimento li hanno fatti emergere in 
ambito biosensoristico sui tradizionali anticorpi.                  
È in questo ampio contesto che si colloca il mio progetto di tesi, volto 
all’approfondimento delle applicazioni di ON ed analoghi in ambiti cha vanno dalla 
progettazione di nuovi candidati farmaci allo sviluppo di nano dispositivi. In dettaglio, 
il mio lavoro si è focalizzato su: 
 
 Realizzazione di nuovi aptameri anti-HIV basati su TEL-Oligonculeotidi 
L’obiettivo di questa parte del progetto si è concretizzato nella realizzazione ed 
ottimizzazione di nuovi putativi aptameri di piccole dimensioni, partendo da aptameri 
antivirali precedentemente riportati da noi, in modo da migliorarne parametri 
farmacodinamici e farmacocinetici ed, al contempo, salvaguardarne l’attività 
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biologica. Questo tipo di ricerca, contestualmente, ci ha consentito di sviluppare un 
nuovo saggio per lo studio delle affinità di legame tra aptameri e target, la cui 
principale caratteristica è quella di non richiedere l’intera proteina bersaglio, con 
notevole risparmio economico e di tempo. Come già ampiamente discusso, gli 
aptameri esibiscono proprietà tali da renderli estremamente affascinanti nell’ottica 
dello sviluppo di nuovi agenti terapeutici. In tal senso, la comunità scientifica è stata, 
sin dalla loro introduzione, profondamente impegnata nella ricerca di aptameri 
antivirali. Nel 2010 Oliviero et al. hanno proposto oligonucleotiditi tetra ramificati 
(TEL-ON), in grado di assemblarsi in strutture G-Q eccezionalmente stabili, quali 
potenziali candidati per il potenziamento dell’attività antivirale della sequenza 
TGGGAG, proposta precedentemente da Hotoda come aptamero antivirale. I risultati 
estremamente positivi relativamente alla stabilità ed attività di questi analoghi 
dell’aptamero di Hotoda, hanno indotto lo stesso gruppo ad esplorare ulteriori 
modifiche sulla sequenza originaria. [36] Nel 2012 D’Atri et al. hanno riportato la 
sintesi e la caratterizzazione strutturale e biologica di una mini-libreria di TEL-ON, 
opportunamente modificati ad ambedue le estremità, al fine di valutare gli effetti di 
variazioni alla sequenza nucleotidica originaria sull’attività. [37] Forti dei risultati 
ottenuti da questi studi, abbiamo deciso successivamente di sfruttare una 
combinazione di tecniche guidate da simulazioni in silico ed un nuovo e rapido 
saggio di binding per ottenere un nuovo approccio per l’ottimizzazione e lo studio 
delle proprietà di legame di aptameri analoghi agli aptameri precedentemente 
riportati ma di minori dimensioni. In tal modo, si è voluta individuare la dimensione 
più piccola dello scaffold tale da migliorare l’intero scale-up del processo produttivo 
salvaguardando o, se possibile, migliorando le proprietà biologiche.        
La seconda parte del presente progetto è stata dedicata al disegno, sintesi e 
caratterizzazione di nuovi aptameri basati su strutture G-Q sovramolecolari. In lavori 
precedenti, il nostro gruppo di ricerca ha riportato gli ottimi parametri termodinamici 
di strutture G-Q di ordine molecolare superiore, aventi sequenza CGGXGGT (con X 
= A, C, G and T). [38] Le indagini strutturali condotte su tali sequenze hanno 
mostrato che esse sono in grado di formare dimeri altamente stabili di G-Q, in cui 
ogni blocco di G-Q tetramolecolare interagisce con il blocco adiacente mediante 
interazioni idrofobiche tra i residui di dC posti alle estremità. Le strutture in questione 
hanno stabilità e parametri termodinamici altamente riproducibili, tali da renderli 
estremamente interessanti nell’ottica dello sviluppo di nuovi aptameri. In questo 
contesto, abbiamo disegnato ON tetra ramificati, di sequenza analoga alla sequenza 
CGGXGGT, opportunamente modificati all’estremità 5’ e ne abbiamo studiato i 
parametri termodinamici e biologici.  
 
 Coniugazione di oligonucleotidi su supporti solidi: studi su biosensori basati 
su DNA                   
I biosensori basati su DNA, ovvero dispositivi che trasformano eventi di 
riconoscimento e ibridazione in segnali quantificabili, trovano applicazione nella 
diagnostica medica, nel monitoraggio di inquinanti ambientali, nella veicolazione di 
farmaci etc. In questo contesto, la trasduzione ottica ha trovato grande diffusione 
nella costruzione di tali dispositivi ed, in particolare, uno dei materiali più utilizzati 
risulta essere il Silicio Poroso (PSi), date le sue interessanti proprietà fisiche e 
morfologiche. [39] Ciò nonostante, in letteratura solo pochi lavori riportano la sintesi 
in situ di sequenze oligonucleotidiche su tali supporti. In ogni caso, la sintesi di 
biomolecole in situ, su matrici solide da utilizzare per la costruzione di biosensori, 
mostra svariati vantaggi se paragonata alla immobilizzazione ex situ, ovvero la 
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tecnica più comune di bioconiugazione; tra questi possiamo annoverare la maggiore 
densità di sonda a DNA, la possibilità di funzionalizzazione locale, la possibilità di 
automazione dell’intero processo. Pertanto, considerati i notevoli vantaggi dati dalla 
sintesi di ON in situ su supporti di PSi ed, al contempo, le problematiche ad essa 
connesse, riconducibili alla chimica della sintesi stessa, alquanto aggressiva nei 
confronti dei silicio poroso, l’obiettivo di questa ricerca è stato quello di individuare ed 
ottimizzare un nuovo approccio sintetico compatibile con i protocolli e i reattivi 
standard della sintesi oligonucleotidica, tali da salvaguardare lo scheletro del 
supporto solido. Questo studio apre, dunque, la strada alla costruzione rapida ed 
economica di biosensori a DNA.  
 
 Analoghi oligonucleotidici: il PNA e la sua applicazione quale inibitore di 
miRNA                  
L’obiettivo di questa parte del progetto si è configurato nel disegno e nella 
caratterizzazione di sequenze di PNA anti-miRNA, dirette contro il miRNA miR-509-
3p, responsabile della down-regolazione del gene malattia della Fibrosi Cistica.          
I microRNA (miRNA) costituiscono una classe di brevi sequenze di RNA non 
codificanti, espresse in molte specie, tra cui animali, piante e virus. Essi sono 
coinvolti nella regolazione genica a livello post-trascrizionale e, come mostrato da 
numerose evidenze sperimentali, sono implicati in processi quali lo sviluppo, il 
metabolismo, l’apoptosi, nonché nella patogenesi di molte malattie. Di recente,  
Amato et al., a seguito di studi condotti per identificare nuove mutazioni del gene 
CFTR connesse all’insorgere della Fibrosi Cistica,  hanno riportato l’identificazione di 
tre Polimorfismi del Singolo Nucleotide (SNP), uno dei quali, c.*1043A>C, è 
localizzato in una regione del gene responsabile del legame al miRNA noto come 
miR-509-3p. Tale SNP aumenta l’affinità del miRNA in questione per il gene, 
determinando, come conseguenza, una ridotta espressione della proteina CFTR in 
vitro. [40]                  
In considerazione del fatto che il PNA è stato riconosciuto quale migliore inibitore di 
miRNA rispetto agli ON ma, al contempo, lunghe sequenze di PNA sono difficilmente 
sintetizzabili e soffrono di ridotta solubilità in acqua, soprattutto se chimicamente 
funzionalizzate, il nostro gruppo ha progettato brevi sequenze di PNA, di sequenza 
perfettamente complementare alla seed region del miR-509-3p, cioè le sette basi 
all’estremità 5’ deputate all’espletazione della funzione, e studiato, attraverso 
tecniche di caratterizzazione chimico-fisica e biologica, la capacità di tali sequenze di 
riconoscere selettivamente, nonostante le ridotte dimensioni, il miRNA bersaglio ed 
impedirne il legame al gene. 
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Preface 
 
During my PhD project, I worked on the design, synthesis and structural 
characterization of several biomolecules, with different kinds of applications. First of 
all, my attention has been focused on the synthesis of novel putative anti-HIV 
aptamers and, contextually, on the design of a novel and cost-effective binding 
assay, to study the affinity between aptamers and their target. Secondly, in view of 
the simple and easy development of DNA-based optical biosensors, we exploited 
several chemical protocols to achieve the direct ON synthesis on PSi matrices, 
ultimately succeeding in the identification of a PSi-friendly protocol for the in situ 
synthesis on PSi support. Finally, but not less intriguing, we explored the properties 
of PNA as efficient inhibitor of miRNA function. To achieve these goals, we exploited 
a combination of chemical synthesis and structural characterization via spectroscopic 
techniques, as well as biological assays.  
The results of this work, often obtained in collaboration with other research groups, 
are discussed in the following reports: 
 
 Analytical Chemistry,  (2016);  88, 2327-34 
In this work, by using a platform based on in silico driven techniques and fluorescent 
techniques, we developed new aptamers endowed with significant antiviral 
properties. 
 
 Nanoscale Research Letters, (2014); 9, 317 
In this report, we exploited several chemicals procedures to obtain the feasible 
synthesis of mixed-sequence oligonucleotides on aminosilane-modified porous 
silicon photonic structures. 
 
 BioMed Research International, (2014); 2014, 610718-28 
I worked on the synthesis of small anti-miRNA PNA, to be used for the selective 
inhibition of a miRNA involved in the down-regulation of the CF disease gene.  
 
Finally, during these years, I have been also involved in other works concerning the 
study of the interaction between nucleic acids and putative ligands and the chemical 
synthesis and structural characterization of small organic molecules. The findings of 
these works are reported in: 
 European Journal of Organic Chemistry (2015), 2015(34), 7550-7556. 
 European Journal of Organic Chemistry (2015), 2015(10), 2244-2249. 
 Molecules (2014), 19(7), 9339-9353. 
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CHAPTER 1  
 
Oligonucleotides and analogues: a 'great wave in the biotechnology revolution' 
 
1.1 Introduction  
 
The idea of nucleic acids as only carriers for the storage and transmission of the 
genetic information has long been overtaken with the discovery of the catalytic 
activity that nucleic acid molecules can perform in a variety of organisms. [1] In 
particular, driven by the progress of the last decades in the acquisition of genetic 
information and in the manipulation of small quantities of these molecules, a great 
number of technologies emerged using DNA, RNA and derivatives with diagnostic, 
research and technological utility. In this sense, nucleic acids are attractive for a 
number of reasons. First of all, most man-made manipulations require recognition 
and binding events and in this context, nucleic acids, in contrast with proteins, obey 
to the relatively simple Watson and Crick rules; secondly, the spatial location of 
nucleic acids is concentrated, thus allowing the specific targeting of these molecules; 
finally, in respect to other macromolecules, they are easier to process and modify. As 
a consequence, it is, by the time, ascertained that nucleic acids and derivatives offer 
great opportunities and promise for the biotechnologies.          
In this wake, with their pioneering work on the theoretical and therapeutic potential of 
oligonucleotides, Zamecnick and Stephenson started what has been called 'the next 
great wave of the biotechnology revolution'. [2] Oligonucleotides (ON) are short 
nucleic acid polymers, with a plethora of applications, ranging from research to 
nanotechnology. Despite around 40 years have passed since the proposal of 
oligonucleotides as pharmaceutical and nanotechnological tools, the interest of the 
scientific community towards them not only has not decreased, but it rather has 
critically grown. In effect, the fields covered by ON applications are increasingly many 
and include diagnostic and therapeutic applications, such as DNA microarrays, gene 
therapy, antisense and antigene approaches for the inhibition of undesired genetic 
functions; nanotechnological applications, such as biosensing, ribozymes and 
nanodevices and finally novel therapeutics, such as DNA vaccines and aptamers. [3-
6]                     
During the last decades, in fact, the use of oligonucleotides as agents for gene 
modulation has been widely investigated. Oligonucleotides and analogues can be 
used to correct genetic disorders or to silence gene expression and, in this context, 
the discovery of RNA interference has strengthened the potential of this approach. 
Moreover, the use of oligonucleotides as therapeutic and diagnostic tools, opened 
the possibility of elucidating complex gene expression patterns in genomic 
experiments. In a similar context, clinical trials have tested the ability of 
oligonucleotide molecules, designated as aptamers, to sequestrate and inhibit 
pathogenic proteins and other relevant biological targets. [7, 9]          
Another intriguing application of ONs is connected to the field of nanotechnology. In 
fact, the use of biomolecules offers great promise in the small scale approaches, and 
in this context, nucleic acids are particularly fascinating due to their ability of self-
organization, selectivity and processability. [10] 
Briefly, the issues here presented, as regards the ONs applications, will be: the 
antisense strategy, the antigene strategy, the use of oligonucleotides as aptamers 
and the application of ONs in the biosensing context.  
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1.2 Oligonucleotides in the antisense strategy  
 
The exploitation of exogenous oligonucleotides to block or modulate gene functions 
was first introduced by Zamecnick and Stephenson in 1978, who inhibited the 
expression of Rous sarcoma virus by the introduction of antisense oligonucleotides 
complementary to segments of the 35S RNA of the virus. 
Antisense oligodeoxyribonucleotides (ODN) are short synthetic strands of DNA that 
consist of 15 to 20 nucleotides. Since the affinity and the specificity of the ODNs 
towards their target results from hybridization interaction and the selectivity of 
Watson-Crick base pairing, they are able to target their complementary sequences of 
RNA by duplex formation and inhibit protein biosynthesis (Fig. 1). In principle, they 
can interfere with each step of nucleic acid metabolism, preferentially with 
transcription, splicing and translation.  
 
 
Figure 1.Schematic representation of the antisense approach 
 
 
The mechanisms by which antisense ODNs may induce biological effects are 
complex and virtually numerous. In general, the inhibition of translation from mRNA 
into protein by ODNs may occur via two major mechanisms: an occupancy-only 
mechanism and the activation of RNase H. [11] 
Antisense ODNs are able to block the ribosome translocation sterically by 
hybridization; more specifically, in this case, the arrest derives from the very high-
affinity interaction between the ODN and the targeted mRNA by Watson-Crick base 
pairing, thus sterically blocking the translation of a transcript into a protein.  
A second inhibitory mechanism operates in cells and is mediated by the cellular 
enzyme RNase H. The precise recognition elements for the enzyme is not known; 
however, the RNA:DNA heteroduplex is recognized by this enzyme and results in 
subsequent RNA cleavage.  
Since they were first proposed by Zamecnick and Stephenson in 1978 to inhibit viral 
replication in cell culture, a number of similar applications have been proposed. 
Antisense therapeutic agents are being investigated in vitro and in vivo for use in 
treating human immunodeficiency virus infection, hepatitis B virus infection, herpes 
simplex virus infection, papillomavirus infection, cancer, restenosis, rheumatoid 
arthritis, and allergic disorders. Different ODNs are in clinical trials against many 
diseases such as cytomegalovirus (CMV) ocular infections, as well as in the control 
of haematological disorders including Crohn’s Disease. [12, 13] In addition, there is 
already one FDA-approved product, formivirsen (Vitravene), for the treatment of 
human CMV-induced retinitis. 
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Even if antisense technology is a relatively young field, a high number of current 
papers and reviews prove the great progress and prospects in the field and 
numerous companies are working on the development of novel antisense 
oligonucleotides (Table 1).  
 
 
Compound Type of oligo Disease target Gene 
target Phase 
ISIS13312 2′-Modified PS CMV retinitis N.A. I/II 
ISIS2302 PS Crohn's disease ICAM-1 II/Pivotal 
  Psoriasis ICAM-1 II   Renal transplant rejection ICAM-1 II   Rheumatoid arthritis ICAM-1 II   Ulcerative colitis ICAM-1 II G3139 (Genta) N.A. Cancer N.A. I 
ISIS2503 PS Cancer Ha-ras I 
ISIS3521 PS Cancer PKC-α II 
ISIS5132 PS Cancer c-raf II 
LR-3001 (Inex) PS Chronic myelogenous 
leukemia bcr-abl I 
 
Table 1. trials of antisense therapeutics; PS= phosphorothioate, N.A.= not available  
 
 
 
1.3 Oligonucleotides in the antigene strategy 
 
ONs can selectively recognize and bind to double-helical DNA, at the level of specific 
sequences, by forming Hoogsteen or reverse-Hoogsteen type hydrogen bonds; in 
this case, modulation of gene expression by ONs may occur via triplex forming 
oligodeoxynucleotides (TFOs).  
TFOs allow the possibility to target the chromosomal DNA, with the resulting 
inhibition of the transcriptional events as a consequence. In effect, the antigene 
strategy is one of the most intriguing fields of triplex application to selectively control 
gene expression. 
Conceptually, antigene approaches offer many advantages over antisense: usually 
two gene copies per cell are available to target rather than multiple copies of mRNA 
that are continually being transcribed; a persistence block of the transcriptional 
process; and simultaneous inhibition of all splice variants.  
As regards the ways of action, TFOs are, generally, short, synthetic single-stranded 
DNAs that can inhibit gene transcription by forming DNA triple helices in a sequence 
specific manner on polypurine-polypyrimidine tracts; in particular, they can bind with 
a high specificity of recognition the major groove of double helical DNA by forming 
Hoogsteen type bonds with purine bases of the Watson-Crick base pairs, resulting in 
triple helix formation. [14] In doing so, triplex-forming oligonucleotides (TFOs) can 
selectively inhibit gene expression at the transcriptional level or repair genetic defect 
by direct genome modification in human cells.  
A TFO can be classified on purine or pyrimidine motif, on the basis of its composition 
and its relative binding orientation in respect to the DNA target site.  
In the former, the purine TFO binds, in an antiparallel orientation, to purine-rich 
strands of DNA via reverse Hoogsteen bonds, forming A·A:T, G·G:C or T·A:T base 
triplets ( with the first base of the triplet belonging to the TFO). This kind of binding 
requires no base protonation and is largely pH independent.  
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In the latter, a TFO composed of cytosine and thymine binds, in a parallel orientation, 
to the purine rich strands of DNA via Hoogsteen bonds. Thymines bind to adenine in 
the A:T base pairs, while protonated cytosines bind to guanines in the G:C base pairs 
(Fig. 2). 
 
 
 
Figure 2. Basic features of a triple helix formation. A. Schematic model of the relative orientation of 
the TFO. B. Pyrimidine binding motif: the pyrimidine TFO binds to the polypurine strand of DNA in a 
parallel orientation. C. Purine binding motif: the purine TFO binds to a polypurine strand of DNA in an 
antiparallel orientation. 
 
 
However, current strategies for oligonucleotide-directed triple helix formation suffer 
from important constraints. In particular, given the fact that the binding requires 
polypurine-polypyrimidine tracts, there are important restrictions on the permitted 
target sequences, moreover pyrimidine ONs usually do not bind to DNA at 
physiologically pH without further modifications and, finally, the inefficient way to 
deliver ONs within the nucleus. 
Nevertheless, the antigene strategy continues to draw the scientific interest and great 
efforts have been doing to overcome its drawbacks. Because of homopurine and 
homopyrimidine sites are common in gene promoter regions and often overlap 
binding motifs for transcription-regulatory proteins, TFOs have been shown to inhibit 
transcription factors binding to purine-rich motifs and have been tested to block 
transcription of various genes in vitro and in intact cells. [15] 
One of the most relevant and fascinating application of the antigene strategy is the 
gene cancer therapy. In 2012, Tonelli and co-workers proposed the exploitation of an 
ON analogue, i.e. the Peptide Nucleic Acid (PNA), as antigene tool to correct the 
expression of MYCN gene in the treatment of aggressive alveolar 
rhabdomyosarcoma in mice. [16] 
 
 
1.4 ON analogues 
 
The need for antisense and antigene oligomers with improved features has been 
widely recognized by the scientific community and has led to the development of 
chemical modifications to improve the ODN features.  For example, given their 
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susceptibility to nucleases, oligonucleotides have often been found to be unstable in 
biological fluids, thus limiting their therapeutic applications. 
To overcome these problems, various chemically modified oligonucleotides have 
been synthesized, incorporating modifications to the phosphodiester backbone, 
sugar or nucleobases portions. In this context, modifications on the backbone, sugar 
or nucleobases, as well as conjugation, are aimed at improving the classical 
drawbacks of the natural counterparts, such as nuclease resistance, affinity, 
bioavailability, biodistribution and immune response. 
In general, on the basis of the kind of modification, the ON analogues are 
distinguished in analogues of the first generation, of the second generation and of the 
third generation. 
 
 
1.4.1 First generation analogues 
 
The analogues of the first generation are characterized by the substitution of one of 
the non-bridging oxygen atoms in the phosphate group. [17] As a consequence, the 
final compound possesses a chiral phosphodiester much more resistant to the 
nucleases. This class includes: the phosphorothioates 1, the methylphosphonates 2, 
the phosphoramidates 3, the phosphorotriesters 4 and the phosphorodithioate 5 (Fig. 
3).  
 
 
 
 
 
 
Figure 3. Structures of the ON analogues belonging to the first generation of analogues. 
 
Unfortunately, all these derivatives display a lower affinity for the complementary 
RNA molecules. Moreover, the creation of a new centre of chirality reduce the final 
synthetic yields, as a result of the preparation of equal amounts of diastereoisomers. 
Nevertheless, phosphorothioate oligodeoxynucleotides (PS-oligos), thanks to their 
beneficial properties, including the chemical stability and the favourable 
pharmacokinetic properties, have been studied intensively in both in vitro and in vivo 
models, showing biological activity against a variety of molecular targets and a 
considerable number of this kind of compounds entered in the clinical trials for the 
treatment of various diseases, such as cancer, inflammation and viral infection. For 
example, the very first antisense compound introduced in the market, known as 
Vitravene, is a 2-deoxyphosphorothioate. [18] 
 
1.4.2 Second generation analogues 
 
The second generation of backbone modifications includes analogues characterized 
by the modification on the sugar moiety, through the introduction of alkyl groups on 
 -W- -X- -Y- -Z- 
1 -O- -P(O)S-- -O- -CH2- 
2 -O- -P(O)CH3- -O- -CH2- 
3 -O- -P(O)NHR- -O- -CH2- 
4 -O- -P(O)OR- -O- -CH2- 
5 -O- -P(S)S-- -O- -CH2- 
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the 2' position of the sugar. These modifications were proposed by the medicinal 
chemists to enhance analogues properties, such as nuclease resistance and cellular 
absorption and, above all, to reduce the cytotoxicity. The 2’-modifications initially 
proposed were the 2′-O-alkyls, the 2′-O-alkyls with glycol ether linkages, the 2′-F and 
2′-O-aminoalkyls. Among these, taking into account the drawbacks of these 
analogues in terms of resistance to the nucleases,  mainly two kinds of analogues 
stand out: 2′-O-(methoxyethyl) or 2-O-MOE and 2′-O-(aminopropyl) or 2′-O-AP (Fig. 
4). [17] 
 
 
Figure 4. Structures of 2’-O-MOE on the left and 2’-O-AP on the right. 
 
The first one showed +2°C increase in binding affinity compared to the first 
generation drugs and a nuclease resistance at approximately the same level of the 
2′-deoxyphosphorothioate modification. On the other hand, the 2′-O-(aminopropyl) 
analogues, by virtue of their cationic alkyl chain present at the 2′-position, offered the 
highest resistance against nucleases.             
To further improve the features of these last compounds, the scientific community 
planned to go beyond the 2’-O-MOE and 2’-O-AP modifications, designing a further 
class of analogues. The third class of modified oligonucleotides is that in which the 
sugar-phosphodiester backbone has been replaced entirely. Because of the 
structural changes on the native backbone, they are better known as ON mimics. 
 
 
1.4.3 ON mimics: the PNA 
 
The third class of ON analogues includes: Locked Nucleic Acids (LNAs), morpholinos 
and Peptide Nucleic Acids (PNAs). These analogues can form both duplexes and 
triplexes, are characterized by improved biostability and have been extensively 
studied both for therapeutic and diagnostic applications. 
LNAs were first introduced by Singh et al. and represent a novel class of constrained 
ON analogues in which the ribonucleoside is linked between the 2′-oxygen and the 
4′-carbon atom with a methylene unit (Fig. 5). 
 
Figure 5. Chemical structure of LNA 
 
The structural features of LNA make it a powerful and versatile tool in terms of affinity 
toward the complementary DNA and RNA molecules and thermodynamic stability of 
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the resulting duplexes and triplexes. Thanks to their noteworthy mismatch 
discrimination, LNAs have been employed for the design of SNP (Single Nucleotide 
Polymorphisms) assays and, also, for the construction of therapeutic DNAzymes and 
LNAzymes with intrinsic endonucleolytic activity. 
Morpholinos were initially described in 1985 by Summerton. In these molecules, 
morpholino subunits are easily synthesized starting from the inexpensive 
ribonucleosides, converted in the morpholinos by the introduction of an amine. They 
exhibits optimal base-stacking and water solubility (Fig. 6). 
 
 
Figure 6. Chemical structure of morpholino analogues 
 
Morpholinos have been experimented as antisense tools and to correct splicing 
errors in pre-mRNAs. Even more interestingly, some of their most fascinating 
applications comprehend their use to dissect the temporal progression of embryotic 
development.  [19-21] 
Finally, the third mimic is the Peptide Nucleic Acid (PNA), developed by the 
biochemist Peter Nielsen during the 1980s.[22]        
PNA is a powerful biomolecular tool with a variety of important applications in 
biotechnology.             
PNA is a DNA/RNA mimic in which the phosphate deoxyribose backbone is replaced 
by uncharged N-(2-aminoethyl)-glycine linkages (Fig. 7). Nucleobases, attached 
through methylene carbonyl linkages to the glycine amino group, recognize 
complementary sequences by standard Watson-Crick pairing. Because PNAs have a 
neutral backbone, hybridization is not affected by the intrastrand repulsion and 
occurs with enhanced affinity and rates of association. Moreover PNAs do not appear 
to be substrates for nucleases or proteases and absence of a repetitive charged 
backbone also prevents PNAs from binding to proteins that normally recognize 
polyanions, avoiding a major source of nonspecific interactions.        
As regards its production, the key step in the subunits synthesis is represented by 
the selective alkylation at the N9 position of the purine or the N1 position of the 
pyrimidines, as showed in figure 7. Due to the peptide nature of its backbone, the 
PNA subunits are generally assembled through the well-established Solid Phase 
Peptide Synthesis (SPPS) protocols and the synthesis is suited to automation and, 
therefore, can be easily performed on automated synthesizers. 
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Figure 7. A Key steps in PNA subunit synthesis. B Chemical structure of PNA 
 
 
In the last few years PNAs have emerged as promising tool for gene therapeutic 
drugs design. As ON, in principle, peptide nucleic acids were used to selectively 
inhibit gene expression at the transcriptional level or at the translational level. But 
very recently another interesting application has emerged: it has been demonstrated 
that PNA based ASOs (antisense oligonucleotides) are more effective ASOs of 
miRNA than DNA ASOs [23]. 
As regards the antigene strategy, PNAs should be capable of arresting transcriptional 
processes by virtue of their ability to form a stable triplex structure or a strand-
invaded complex with DNA [24]. Such complexes can create a structural hindrance to 
block the function of RNA polymerase, thus working as antigene agents.  
Moreover, antisense peptide nucleic acids offer the promise of therapeutic effect with 
few or no toxic effects, by virtue of their enhanced selectivity in respect to traditional 
oligonucleotides. Normally, the PNA antisense effect is based on the steric blocking 
of either RNA processing, transport into cytoplasm, or translation. Started from the 
results of in vitro translation experiments involving rabbit reticulocyte lysates, it has 
been concluded that PNAs are capable of inhibiting translation at targets overlapping 
the AUG start codon [25].  Finally, but not less intriguing, peptide nucleic acids can 
be used as miRNA inhibitors, thereby open the possibilities of studying the function of 
genes involved in many pathologies and modulating their expression.      
Currently, various technologies to investigate the mechanisms of miRNA function 
have been well documented. It has been observed that oligonucleotide analogues 
inhibit microRNA function essentially by a steric block, RNaseH-independent and 
RISC-independent, through complementary binding of the ON to the microRNA 
sequence [26]. Chemical modifications of antisense oligonucleotides are important 
not only to improve their affinity for target miRNAs but also to protect the ON against 
nuclease degradation. For these reason various modified ONs and analogues have 
been studied to this purpose. Many studies using PNAs to explore miRNA 
functionality have been reported: different PNA oligomers have been proven to be 
effective at blocking miR-122, a miRNA whose function has been linked to lipid 
metabolism [26], miR-221 involved in the chondrogenic differentiation of chick limb 
mesenchymal cells [27] and miR-UL148D involved in the human cytomegalovirus 
infection [28].                                                                 
In conclusion, PNAs exhibit several notable properties,  such as high chemical and 
thermal stability, resistance to enzymatic degradation and stable binding to their RNA 
or DNA targets in a sequence-specific manner, for these reasons they have been 
exploited in a variety of contexts, including the antigene and antisense strategy, 
diagnostic applications and, more recently, as aptamers.  
A 
B 
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1.5 ONs as aptamers 
 
The biotechnological relevance of oligonucleotides and analogues can be expanded 
due to the emergence of other relevant applications, such as the design of aptamers 
aimed at binding and inhibiting specific molecular targets.  
The word aptamer comes from the Latin “aptus”, to fit, and the Greek stem, “meros”, 
part or region, and is referred to RNA or DNA molecules, generally 25-50 nucleotides 
in length, endowed with noteworthy affinity and selectivity towards molecular targets, 
mainly proteins.[29] The basic concept of joining nucleic acids to proteins has 
naturally emerged with the advent of genetic engineering, which opened the 
possibility to discover and exploit highly specific interactions between proteins and 
ON sequences, such as, just to mention a few, the interaction between the restriction 
enzymes and their target cleavage sequences or transcription factors and their target 
DNA promoter elements. From the late 1980s the idea of modulating protein function 
through nucleic acid sequences has been successfully settled in for the development 
of a new class of therapeutics. 
Aptamers are obtained from puzzled pool with several combination of molecules. The 
process through which they are selected from a randomly synthesized library 
containing up to 1015 different molecules, for their affinity towards their targets, is 
known as Systematic Evolution of Ligands by Exponential enrichment (SELEX) and 
was developed in the laboratories of Larry Gold of the University of Colorado during 
the 1990s. After this iterative process, the resulting nucleic acid molecules can be 
chemically modified in order to provide them with additional properties and, above all, 
to extend their half-life in biological fluids. [30]          
The broad applications of aptamers range from diagnostics to therapeutics, 
biosensors and also tools for unravelling fundamental cellular processes. They are 
often seen as “chemical antibodies”, but, in respect to antibodies, they are relatively 
small, free from cell-culture contaminants, offer easy chemical synthesis and 
possibility of conjugation  and modification and avoid immune response. For these 
reasons, enthusiasm in developing therapeutic aptamers is still strong and the 
scientific community is to date deeply involved in the search of these novel drug 
candidates, facing at the same time the drawbacks, like the instability in biological 
media and the low bioavailability.                     
The developing area of aptamer research has seen in 2004 the FDA approval of 
pegaptanib for the treatment of choroidal neovascularization associated with age-
related macular degeneration. The clinical use of pegapatanib can be seen as a 
milestone in drug development, constituting the first aptamer used for human 
treatment. Although important challenges remain, this area is in the pipeline, with 
more than ten candidates undergoing clinical trials, with applications against a variety 
of diseases, from cancer to diabetes. [31,32]  Some of the most extensively studied 
aptamers have G-rich consensus sequences that allow them to fold into stable four-
stranded structures, known as G-quadruplex.[33] As for the other biological 
molecules, also for the aptamers the folding into specific secondary and tertiary 
structures play a fundamental role in the recognition and binding phenomena. The 
attempts to enhance target specificity and other aptamers features highlighted the 
importance of finely predict and know the three-dimensional structures of these novel 
drug candidates. 
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1.5.1 G-Quadruplexes: a general overview  
 
G-rich ON sequences have the natural propensity to fold in unusual secondary 
structure, named G-Quadruplex (G-Q), whose fundamental unit is represented by 
planar G-quartet assemblies, held together by Hoogsteen hydrogen bonds and 
stabilized by monovalent cations. Owing to the evidence of G-Q formation within the 
vertebrate genomes, [34] great interest arose on these non-canonical structures 
since their discovery, and the scientific community is still deeply involved in 
disclosing their relation with relevant biological processes. Not less fascinating, due 
to their architectures and sensitivity to the presence of specific cations and ligands, 
they have been and are, even now, exploited for the application in nanotechnology 
and the design of biosensors and DNAzymes. [35] 
Although the G-Q core is always the same, G-Quadruplexes are characterized by 
extremely high variability in regards to the folding topology, loop orientation, 
molecularity and glycosidic orientation of the sugar bases. [36] To simplify the 
structural complexity of G-Q, we can carry out a first classification on the basis of the 
number of strands; in this way we can distinguish between unimolecular G-Q, made 
up of only one G-rich ON strand and bimolecular and tetramolecular G-Qs, formed 
from the association of two or four ON strands respectively.          
G-Qs can be also classified on the basis of orientation of the strands and the 
connecting loops. Propeller type loops are those which connect the bottom G-quartet 
to the top G-quartet of adjacent strands with the same orientation; lateral loops, also 
known as edge-wise loops, link adjacent strands, while diagonal loops join opposite 
strands (Fig. 8) 
 
Figure 8. Propeller loops (left), lateral loops (centre) and diagonal loops (right) 
 
The strands orientation generates a further distinction: G-Q structures possessing all 
the strands in the same orientation are parallel quadruplexes, while opposite 
orientation of the strands give rise to antiparallel or hybrid quadruplexes. In general, 
parallel quadruplexes have all the guanosine glycosidic angle sin the anti-
conformation, while antiparallel quadruplexes show both anti and syn glycosidic 
angles.   
Moreover, variations on the orientations adopted by the stacked bases lead to 
different groove dimensions, i.e. the cavities surrounded by the phosphodiester 
backbone. In general, qudruplexes characterized by lateral or diagonal loops are 
structurally simple, in contrast grooves in quadruplex with only propeller loops have 
more complex structures, as shown in figure 9 for the sequence 
d[AGGG(TTAGGG)3]. [37] 
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Figure 9. Different structures of the human monomolecular quadruplex formed from the telomeric 
sequence d[AGGG(TTAGGG)3]. (A) groove structure of a G-Q with a diagonal and two lateral loops, 
(b) with three propeller loops, (c) with one propeller and two lateral loops. 
 
Finally, a fundamental role is played by monovalent cations on the folding and 
thermodynamics of G-Qs. In fact, their localization within the G-Q core reduce the 
strong negative electrostatic potential generated by the guanine O6 oxygen atoms. In 
this context, the most extensively studied ions are K+ and Na+. Their different 
behaviour as regards their location within the cavity result from their dimension: the 
smaller sodium cations can reside in plane with the G-quartet, whereas potassium 
can coordinate between two tetrads. [38] 
 
 
1.5.2 Biotechnological relevance of G-Quadruplexes 
 
A markedly high number of examples in literature witness the broad range of 
applications of G-Qs at a biotechnological level.                
Owing to the high density of G-quadruplex-forming sequences in genomic regions 
adjacent to transcriptional start sites, G-Q structures have so far emerged as a new 
class of molecular targets for gene regulation and anticancer drugs development. In 
fact, G-rich sequences are broadly distributed in regions of human genome, including 
telomere ends, immunoglobulin switch regions and regulatory elements of oncogene 
promoters such as c-myc, k-ras, c-kit and so on. [39-43]                        
Since a great number of observations come out on the inside of their regulatory role, 
G-Qs represent a great promise as target in the anticancer treatments. In this sense, 
one of the first proposed application came from the realization that G-rich sequences 
A 
B 
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in the telomers, by virtue of their structuration in quadruple helices, can inhibit 
telomerase activity, thus preventing cell immortalization. A wide number of small 
molecules have been explored for their capability to interact and stabilize telomeric 
G-Qs and, among these, for the cyclic polyoxazole natural product telomestatin and 
the synthetic compounds BRACO19 and RHPS4 evidences of antitumor activity have 
been reported in xenograft models. Similarly, an inhibition of the transcriptional 
events of the proto-oncogenes MYC and hTERT has been achieved upon the 
addition of G-Q ligands TMPyP4 and telomestatin derivative  S2T1-6OTD, as 
reported by Balasubramanian et al.[44-47] These and many other observations make 
G-Q structures one of the most challenging targets in the anti-cancer treatments. 
Conformational plasticity of G-Qs allows the possibility to exploit them at a diagnostic 
level, by fine tuning their formation and interaction with their targets. In this context, 
an exciting trend in biotechnology sees the use of aptamers that selectively 
recognize targets differentially expressed in diseased cells for bioimaging and for 
helping the diagnosis of the disease. For example, AS1411 is a multifunctional 26 nt 
G-rich aptamer, that easily form two G-Q assemblies in presence of potassium 
cations used, by virtue of its binding to excessively expressed nucleolin on cancer 
cells, for the diagnosis and treatment of cancer. On the other hand, the sensitivity of 
G-Qs for metal ions has been exploited for the design of detectors of K+, Ag+, Hg+ 
etc. In this wake, the exceptionally high stability of G-Qs in organic solvents like 
ethanol, methanol and other dehydrating agent, in addition to their high conductance, 
makes them suitable building blocks for the construction of electronic nanodevices. 
Similarly, catalytically active G-Qs have been exploited for the construction of 
DNAzymes, as reported by Liu et al. that developed a colorimetric sensor for 
thrombin by incorporating hemin into the complex G-Q TBA aptamer/thrombin. [48] 
Finally, a variety of reports explored the bioconjugation of G-Qs to magnetic 
nanoparticles for biosensing applications. 
 
 
1.6 ONs based biosensors 
 
Research in the field of ON based biosensors has become very popular in the last 
decades. Biosensors are analytical tools that combine biological materials, such as 
proteins, DNA/RNA and other selective chemicals and physicochemical signal 
transducer. In this context, ONs are particularly well suited because they allow the 
possibility to convert highly selective hybridization phenomena to readable analytical 
events. Specifically, electrochemical biosensors based on oligonucleotides gained 
remarkable attention for the task of monitoring and control of specific DNA 
sequences related to microorganisms, viruses and inherited diseases and, also, for 
detecting the presence of infectious agents in various environmental matrices. [49] 
As regards the first possibility, ON biosensors found application to distinguish genetic 
materials from infectious organisms and to detect genetic mutations associated to 
disease phenotypes, such as cancer, neurodegenerative diseases etc. For example, 
several papers described the design and application of biosensors based on single-
stranded ON as probe for the detection of DNA sequence related to Hepatitis B virus. 
[50] In 2009, Mao et al. showed the rapid and sensitive detection of circulating cancer 
cells, by developing an aptamer-nanoparticle strip biosensor (ANBS), i.e. a biosensor 
based on the conjugation to gold nanoparticles of ON sequences selectively 
recognizing receptors on cancer cells in blood. [51] Similarly, a great number of ON 
biosensors have been designed for the direct and indirect detection of pathogenic 
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bacteria; in 2012 Zhang et al. reported a biosensor, incorporating magnetic 
nanoparticles and gold nanoparticles as transducer, with target-specific DNA probe 
for the detection of Salmonella enterica.[52] The same principle is used to realize 
biosensors for food contaminants and environmental pollution monitoring. The need 
for such biosensors is linked to the increasing exposition to hazardous chemical that 
provoke excessive immune response, cancer and other diseases. Electrochemical 
devices incorporating DNA sequences have been proposed for the detection of 
heavy metals, such as Pb2+, Hg2+, but also antibiotics ant toxins.              
These and many other examples highlight the promise and the potential of ON-based 
biosensors to consolidate a new era of easy, cost-effective and rapid diagnostics. 
 
 
 
1.7 Aim of my research work 
 
My research project is set in a wide context aimed at exploiting the several features 
and applications of oligonucleotides and analogues. In this context, my attention has 
been focused on the study of G-Q forming aptamers and their potential antiviral 
activity, the design and resolution of chemical issues linked to the design of novel 
kinds of ON based biosensors and the exploitation of ON analogues, such as PNA, in 
the field of gene modulation. 
Notably,  the project included: 
 
 The implementation of novel anti-HIV aptamers based on tetra-end-linked DNA  
The aim of this part of the project was to select very short ON aptamers, starting from 
previously reported antiviral G-Q forming aptamers, in order to enhance their 
pharmacodynamic and pharmacokinetic parameters and safeguard their biological 
activity.  
As already discussed, aptamers offer great promise as novel therapeutics. Among 
these, particularly fascinating are those endowed with antiviral activity, as witnessed 
by the huge body of literature on this topic.  
In 2010 Oliviero et al. proposed the use of Tetra-End-Linked Oligonucleotides (TEL-
ON), which form very stable TEL-quadruplex structures, as promising candidates to 
improve the antiviral activity against HIV-1 showed by the 6mer G-Q forming 
sequence TGGGAG, known as Hotoda’s aptamer. The promising findings as regards 
the favorable thermodynamics and activity of these analogues gave confidence about 
the possibility to further modify the original sequence. In 2012 D’Atri et al. reported 
the synthesis and structural and biological characterization of a mini-library of Hotoda 
analogues TEL-ONs, modified at both the 3’ and 5’ ends, in order to assess the effect 
of different nucleotide sequence on the antiviral activity. [53-54] 
In the wake of these studies, we decided to exploit a combination of in silico driven 
techniques and novel and cost-effective binding assay to consolidate a new 
approach for the individuation of the smallest and more active analogue of the TEL-
aptamer previously designated by us as the best anti-HIV aptamer. The main goal of 
this search has been to provide a new method for the optimization of therapeutic 
aptamers, not achievable by the SELEX method.  
The second part of this search has been devoted to the design, synthesis and 
characterization of new high ordered G-Q aptamers. In previous works, our research 
group proved the good thermodynamic parameters of G-Q assemblies having the 
sequences CGGXGGT (with X = A, C, G and T). [55-56] Structural studies on them 
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showed that these sequences are able to fold into stable dimers of parallel G-Qs, 
provided with high thermal stability and reproducible folding assembly. These 
properties make them good candidates for the development of novel putative 
aptamers. In this frame, we designed novel TEL-analogues of the sequence 
CGGXGGT, conveniently modified at their 5’-terminus, and studied them for their 
kinetics and antiviral activity.  
 
 Conjugation of oligonucleotides onto solid supports: studies on DNA-based 
biosensors     
DNA-based biochips, i.e. devices constituted by ONs as molecular recognition 
element and a transducer element, have interesting applications in nanoelectronics, 
biomolecular computations, cellular imaging and drug delivery. Optical transduction 
has been widely exploited for the design of such biosensors and, in this context, 
porous silicon (PSi) is one of the most used material, owing to its attractive 
morphological and physical features. Nevertheless, to date only few reports showed 
the in situ synthesis of ON sequences onto PSi matrices. [57] 
However, in situ synthesis of ONs onto solid supports presents several advantages in 
respect to ex situ immobilization; for example, increasing of DNA probe density, the 
process automation, the possibility of surface local functionalization, just to mention a 
few. Taking into account the advantages of in situ synthesis and, at the same time, 
the hurdles of the entire process, associated to the chemistry used for the ONs 
growth and the intrinsic properties of the silicon matrix, the aim of this part of the 
project was to allow the direct synthesis on PSi platforms of mixed ON sequences by 
standard reagents and protocols, by exploring different chemical protocols. In this 
way, we ultimately obtained a more convenient production of functionalized biochips. 
 
 Oligonucleotide analogues: PNA and its use as miRNA inhibitor 
The aim of this work was to design anti-miRNA PNA sequences for the inhibition of 
miR-509-3p, a miRNA involved in the down-regulation of cystic fibrosis disease-gene 
expression.  
The chemical features of the ON mimic PNA have made it an attractive tool in the 
field of gene regulation. In this context, it has been demonstrated that anti-miRNA 
ASOs (antisense oligonucleotides) based on PNA are more effective than ASOs 
based on DNA, thus opening the possibilities of studying the function of genes 
involved in many pathologies and modulating their expression. Recently, Amato et al. 
proposed specific sequences of peptide nucleic acid as new inhibitors of miR-509-3p. 
[58] Because of the not trivial synthesis of the tested sequences, my objective has 
been the optimization of the chemical and physical characteristics of these PNAs. By 
means of computational simulations, chemical synthesis, biophysical and biological 
characterization we succeeded in obtaining novel PNAs with enhanced features. 
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CHAPTER 2 
 
Oligonucleotides as aptamers: the implementation of novel anti-HIV aptamers 
based on tetra-end-linked DNA 
 
 
2.1 Introduction 
 
Since the last century the global epidemic diffusion of HIV infection required the 
urgent development of antiviral therapeutics. The story of anti-HIV aptamers is 
studded with examples of DNA or RNA species tested for their activity against the 
virus and the exceptionally high number of reports in this field confirms the 
considerable promise of this strategy. [1-7]       
The event that triggers the entry of HIV-1 into the host cell, the T-lymphocytes, is 
represented by the recognition and binding of an envelope glycoprotein on the 
surface of the virus, gp120, to the CD4 glycoprotein and a chemokine receptor 
expressed on the surface of the host cells. [8] Since this event initiates cell fusion, it 
has been universally validate as a relevant target for drug discovery. Nevertheless, 
some of the most studied anti-HIV aptamers are those inhibiting other targets. The G-
Q forming aptamers 93del, first published by Patel’s group, is probably the subject of 
the most deep research. [9] 93del and the structural analogue T30695 are potent 
inhibitor of HIV-1 integrase, the viral enzyme responsible of the integration of the 
retro-transcribed viral genome into the nuclear host genome, and exhibit anti-
integrase activity in the nanomolar range. However, due to their mechanism of 
action, this kind of aptamers require an efficient delivery system into the infected 
cells. For this reason, one of the most challenging approach is to achieve the 
inhibition of the entry of the virus into the host cell, in order to avoid the realization of 
suitable ON delivery system.  
In 1998 Hotoda and co-workers first reported that conjugation with aromatic groups 
at the 5’-end of the G-Q forming hexadeoxyribonucleotides 5′TGGGAG3′ dramatically 
provided them with anti-HIV activity. [10, 11] These molecules were shown to be able 
to bind the third variable region of gp120, the V3 loop, thus preventing the entry of 
the virus into the target cells. Since that, an incredible number of modifications were 
reported to enhance the antiviral activity of the Hotoda aptamer. Indeed, the most 
interesting feature of this sequence is represented by its intrinsic mechanism of 
action that, unlike other reported aptamers, do not require an efficient ON delivery 
system into the cells. In 2010 Oliviero et al. proposed some tetra-end-linked 
oligonucleotides (TEL-ODNs) containing the sequence TGGGAG, as new modified 
aptamers with noteworthy anti-HIV activity. [12] In fact, the comparison between the 
proposed analogue, modified at both the 5’ and 3’ termini with the tertz-butyldiphenyl 
groups and the tetra-end-linker moieties respectively, and the same sequence 
lacking of the TEL moiety showed the better thermodynamic parameters and the 
enhanced biological activity of the proposed aptamer. In 2012 the same research 
group designed a mini-library of analogues, having TGGGXG (where X = G, C or T) 
sequences, bearing the same modifications of the previously reported analogue, in 
order to probe the influence of the different nucleotides on the structural and 
biological properties of such quadruplexes. [13] The structural and biological 
investigations on these sequences identified TEL-[TBDPSTGGGGG]4, 4, as the best 
candidate for further SAR studies.  
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In this frame, we decided to go beyond these promising results by designing new 
shorter analogues of 4 with the final aim of optimizing their pharmacodynamics and 
pharmacokinetics and the scale-up of the process. In the novel sequences the 
TGGGG strands were shortened by one, two and three G-quartet arrays (Fig. 1). The 
sequences were synthesised and tested for their antiviral activity. At the same time, a 
novel and cost-effective binding assay was set up to avoid the manipulation of the 
whole viral glycoprotein. 
 
 
Figure 1. Schematic representation of the investigated TEL-ODNs 
 
Contextually, our attention was attracted by the development of new putative 
aptamers endowed with a similar TEL-based structure, but able to form high ordered 
species, in order to investigate the promising structural features of our high ordered 
G-Q complexes in the context of the design of novel aptamers. Specifically, in 
previously reported works, our research group showed that particular ON sequences, 
by virtue of their 5’ sticky ends, are able to form stable G-Q dimers, also called 
octamers. [14, 15] The biophysical characterization of these assemblies highlighted 
that the octamers were formed by two adjacent G-Q building blocks held together by 
5’ π-π stacking interactions. In this frame, we decided to design new putative 
aptamers, characterized by a dC residue at the 5’-termini, required for the 
interactions between two adjacent G-Q building blocks, and study their propensity to 
form high ordered assemblies. Moreover, the importance of the terminal residues at 
the 5’-ends was analyzed by designing two analogues with the final dC residues 
capped with an hydrophilic and an hydrophobic group respectively. The resolution of 
the chemical issues associated to the development of these molecules and their 
biophysical characterization, in association with their biological activity studies, were 
an important part of my final research activity. 
 
 
2.2 Results and discussion 
  
In 1998  the X-ray crystal structure HIV-1 gp120 core complexed with a two-domain 
fragment of human CD4 and an antigen-binding fragment of a neutralizing antibody 
was reported, showing the importance of the V3 loop for the binding with the co-
receptor on the surface of the host cell. [16] These findings, in addition to the 
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proposed mechanism of action for Hotoda sequence and their analogues, led us to 
perform preliminary in silico docking simulations in order to assess the capability of 
the new analogues to fold in the correct secondary structure, retaining at the same 
time the affinity for the target.  
The results showed that 1-3, despite the smaller size, can indeed bind the V3 loop by 
direct interaction of the phosphate backbone atoms and the hetero-atoms of 
guanines (Fig. 2). In particular, the phosphate backbone atoms of three different 
strands interact with the side chains of Glu197, Thr195, Thr194 and Tyr193 of the V3 
loop in all the complexes, defining a common binding site. 
 
Figure 2. Molecular models showing the interactions between aptamers 1-3 and the V3 loop of gp120 
 
These encouraging results led us to proceed with the synthesis and biophysical 
characterization of 1-3.TEL-ODNs have been prepared according to the previously 
reported protocol: DNA solid phase synthesis was performed on an automated 
synthesizer following the phosphoramidite chemistry. Once synthesised, CD 
measurements have been performed in order to verify that the absence of an 
increasing number of G-quartets, compared to the reference sequence, did not affect 
the original parallel arrangement (Fig. 3). 
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Figure 3. Dichroic profiles of 1-3 in 100 mM K+ buffer at 25°C and, in the box, G-tetrad-specific imino 
proton region (10-12 ppm) of 1H NMR spectra of TEL-ODNs 1-4 acquired at 25 °C in 100 mM K+ 
buffer (D2O/H2O 9:1). 
 
The overall CD spectra were recorded in 100 mM K+ buffer. As we can see from 
figure 3, the profiles of 1 and 2 are in agreement with the formation of quadruplex 
assembly, showing a positive maximum at about 260 nm and a negative minimum 
close to 240 nm, which are characteristics of parallel G-quadruplexes. [17, 18] On the 
other hand, CD spectrum of 3 does not appear to be superimposable to that of a 
typical G-quadruplex structure. This result can be ascribed to the difficult 
arrangement of the sequence, probably due to the absence of a favourable number 
of G-quartets. 
The formation of the desired G-Q structures was also proved by means of 1H-NMR 
experiments. NMR analysis confirmed for 1-3 the presence of G-Qs in solution as 
well, whereas, as expected, 3 did not show the ability to form quadruplex assemblies.  
Once performed the structural characterization, we exploit a fluorescence quenching 
assay to assess the capability of the analogues to bind their natural target, the V3 
loop. In drug discovery, the occurrence of false positives is one of the major obstacle 
in the search for lead compounds that can be developed into drugs. This new 
method, based on the use of a EnVision plate reader, has recently been reported as 
a high-speed, low cost and quantitative assay to measure affinity constants and 
kinetic parameters of binding events. One of its major advantage is that 
nonspecifically binding compounds did not quench the fluorescence of the target. [19] 
In fact, this methodology is based on the quenching of the fluorescence following the 
interaction between a fluorescently labelled target and its specific ligand, or 
viceversa. For this purpose, we previously synthesize the 35 aminoacids V35 
peptide, whose sequence matches the V3 loop used for the previous docking 
simulations, bearing a Fluorescein Isothiocyanate (FITC) residue at the N-terminus, 
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as the target of the tested aptamers. In this way, we avoided the manipulation of the 
entire, more expensive viral glycoprotein. In particular, V35-Fluo and V-35 were 
manually synthesized according to Fmoc protocols and purified by RP-µHPLC (see 
fig. 4 for the sequence of V35-Fluo peptide).  
 
 
 
Figure 4. Synthetic scheme of the manual synthesis of V35 and V35-Fluo. 
 
Binding experiments were initially performed on 4, whose binding affinity was already 
estimated by SPR, by incubating 50 nM of V35-Fluo with 10 µM of 4. In the presence 
of 4 the fluorescence signal of V35-Fluo decreased compared to the fluorescence of 
the same amount of peptide dissolved in buffer. Then, to monitor changes in 
fluorescence unrelated to the binding of V35-Fluo to the aptamer, the measurements 
were carried out by incubating V35-Fluo and 4 in the presence of the unlabeled V35 
peptide at the concentration of 25µM (Fig. 14, panel a). In the presence of V35 the 
fluorescence signal of V35-Fluo was not affected by the presence of the aptamer, 
thus indicating that the decrease of V35-Fluo fluorescence was due to the aptamer 
binding. The binding of 4 for V35-Fluo was also measured for several dilutions of 4, 
in order to calculate the Kd value (Fig. 5 panel b) and in a time course experiment. 
The addition of 4, at t=0, provoke the quenching of the fluorescence of V35-Fluo, 
then V35 was added to displace 4 specifically bound to V35-Fluo. As already seen, 
after the addiction of V35, a restoration of the fluorescence of V35-Fluo is observed. 
 
CHAPTER 2 
OLIGONUCLEOTIDES AS APTAERS 
37 
 
 
Figure 5. Binding experiments of V35-Fluo and 4 
 
 
The positive outcomes of the pilot experiment gave us confidence to perform the 
same experiments on 1-3. The fluorescence assays were carried out on 1-3 and 5, a 
TEL-ON analogue lacking of anti-HIV activity, and allowed us to quantify the Kd for all 
the putative aptamers. However, despite the good results on these last compounds, 
the Kd measured for 4 resulted somehow higher than that obtained by the SPR 
experiments. The possible reason of this behaviour could be ascribed to the actual 
interaction of the aptamer with the target, that in the whole protein acquire a well-
defined three dimensional structure. In fact, the crystal structure of the V3 loop shows 
that it acquires an hairpin conformation stabilized by a disulfide bridge. On the basis 
of this observation, we decided to repeat the same experiments using a folded 
version of the peptide, obtained by an appropriate oxidation treatment. The affinity 
was measured for 1-5; while the value obtained for 5 remains low, the last measures 
for 1-3return values significantly higher than the previous ones, and in particular 
close to that obtained for the parent aptamer4 by SPR (Fig. 6).  
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Figure 6. Affinity of TEL-ODNs 1-5 for reduced V35-Fluo (red, empty circles) and oxidized V35-Fluo-
oxi (oxi, full circles). 
 
As regards the anti-HIV activity, the biological assays have been undertaken in 
collaboration with Dr. Jan Balzarini at Rega Institute for Medical Research of Leuven, 
Belgium. The antiviral activity against HIV-1 and HIV-2 was measured as the 
concentration of aptamer able to reduce the virus-induced cytopathicity by 50% 
(EC50) in human CD4+ T-lymphocyte CEM cell cultures. As we can see from table 3, 
the new analogues 1 and 2 retain high antiviral activity, in the submicromolar range. 
Interestingly, consistently with docking findings, also 3 shows significant antiviral 
activity, even if it does not fold into a stable G-Q structure.  
 
 
Table 1. Anti-HIV studies on TEL-ODNs 1-5 
 EC50
a (µM)  IC50
b (µM) CC50
c (µM) 
 HIV-1 HIV-2 HUT-78/HIV-1+SupT1  
1 0.18 ± 0.0071 6.3 ± 0.71 3.9 ± 0.21 >100 
2 0.16 ± 0.028 1.3 ± 0.21 1.8 ± 1.3 >100 
3 0.74 ± 0.11 5.1 ± 0.92 10 ± 0.7 >100 
4 0.041± 0.007* ≥ 2*  >2* 
5 ≥ 2* 2*  >2* 
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In the second part of the project, we focused our attention on the synthesis and 
structural characterization of new high ordered G-Q aptamers. In 2013 D’Atri et al. 
demonstrated that the ON sequence CGGXGGT, where X is A,T,C or G, is able to 
form dimers of tetramolecular G-Qs through the 5’-5’ stacking of two G-Q subunits in 
presence of suitable concentrations of potassium cations. The resulting octamers 
show high thermal stability and reproducible folding assembly, that are interesting 
features in view of developing novel putative aptamers. Taking into account these 
considerations, we designed TEL-ONs embodying the sequence 5’CGGAGG3’ , 
where the dG residues at the 3’-end are conjugated to the tetra-end-linker moiety, 
while the dC residues at the 5’ termini are required for the dimerization process, as 
highlighted by Borbone et al. [14, 15] Moreover, we decided to synthesize two 
analogues of the TEL-[G2AG2C]4resulting sequence, characterized by the 5’ termini 
capped with two different groups, the lipophilic dimetoxytritil- group and the 
hydrophilic glucose derivative respectively, in order to assess the influence of these 
different conjugations on the dimerization process and, eventually, on the biological 
activity.  
The resulting sequences, TEL-[CG2AG2]4,I, TEL-[DMTCG2AG2]4,II, TEL-[GluCG2AG2]4, 
III, have been synthesized through the standard phosphoramidite chemistry. 
Moreover, to obtain II we did not perform the final deblocking step, while for the 
obtaining of III we performed the final coupling step with a non-standard, manually 
synthesized glucose derivative phosphoramidite. The higher apolarity of II was 
exploited to facilitate the successive purification by means of RP-HPLC, whereas I 
and III were purified by means of anion exchange. After synthesis and purification, 
the biophysical characterization has been carried out. In order to verify if the TEL-
ONs are able to fold into stable G-Q structures and eventually form high ordered 
assemblies, preliminary dichroic experiments have been performed (Fig. 16). 
Notably, the annealing procedure, i.e. the folding process, and the CD experiments 
have been undertaken adopting the same protocols as those used for CGGXGGT 
sequences to promote the multimerization process. The dichroic experiments 
highlighted the presence in solution of G-Q structures, showing the typical shape 
diagnostic for parallel G-Q assemblies. Interestingly, an additional negative peak is 
detectable at 290 nm and, as already reported, is ascribable to additional stacking 
interactions involved in high ordered quadruplex species. 
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Figure 16. Dichroic profiles of I-III in 1 M K+ buffer and, in the bottom right, non denaturing gel analysis 
for the sequences TGGGGT (line 1), CGGAGGT (line 2), I, (line 3), II, (line 4), III, (line 5). 
 
 
To further provide an insight on the molecular size of our species, native 
polyacrylamide gel electrophoresis has been performed. Figure 16 shows the PAGE 
of: TGGGGT (line 1) used as tetramolecular quadruplex size marker, CGGAGGT 
(line 2) used as dimeric quadruplex size marker, TEL-[CG2AGG2]4 (I, lane 3), TEL-
[DMTCG2AG2]4 (II, lane 4), TEL-[GluCG2AG2]4 (III, lane 5). As expected, CGGAGGT 
forms stable octamers in solution in our conditions, thus showing a typical slow-
migrating band. The comparison between CGGAGGT, used as control, and I and II 
demonstrate the formation of high ordered assemblies also for these last sequences; 
whereas the migration profile of III, that shows a major band migrating like an 
octamer and a faster less defined band, may be diagnostic for the presence in 
solution of both high order structures and tetrameric  quadruplexes. 
Finally, to assess whether the formation of stable octamers is somehow connected to 
antiviral activity, biological assays have been carried out. On the basis of the 
structural features of these novel sequences, we decided to test them for their activity 
against HIV. As in the previous case, the antiviral activity is calculated as the 
concentration of aptamer able to reduce the virus-induced cytopathicity by 50% 
(EC50) in human CD4+ T-lymphocyte CEM cell cultures. The results show that, even 
though the overall sequences are able to form octamers and possess very similar 
sequences, only II has significant biological activity.  
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2.3 Conclusions  
 
The first part of the search allowed us to obtain a new solid and cost-effective 
method for the rapid measure of the affinities between aptamers, as drug candidates, 
and their target. By combining in silico simulations and a novel and rapid binding 
assay, we succeeded in developing new aptamers that, despite the smaller 
dimensions, are still endowed with significant antiviral properties. Importantly, this 
platform is suited to the feasible optimization of aptamers and other drug candidates.  
In the second part of this research work, we developed new TEL-ONs, conveniently 
modified at their 5’-termini, and studied their capability to undergo multimerization 
process together with their biological properties. Thanks to the techniques for the 
biophysical characterization, we observed that suitable modifications at the 5’-sticky 
ends did not prevent the formation of stable high ordered structures based on G-Q 
building blocks. Moreover, the findings on the biological activity of these putative 
TEL-aptamers led us to conclude that the apolarity of the groups attached at the 5’-
ends is a fundamental discriminating factor on the mechanism of action. However 
further studies are required to elucidate the role of the conjugations on this kind of 
sequences. 
 
 
2.4 Experimental Section 
 
2.4.1General Instrumentation 
Automated solid-phase oligonucleotide synthesis was performed on a 8909 DNA 
Synthesizer(Applied Biosystems). UV measures for the determination of the ON 
concentrations were performed on a  . CD measurements were performed on a 
JASCO J-715spectropolarimeter equipped with a Peltier Thermostat JASCO ETC-
505T using 0.1cm path length cuvettes. NMR spectra were acquired on Varian 
UNITYINOVA 500MHz, 700 MHz and Mercury Plus 400 MHz spectrometers and 
processed using the Varian VNMR software package.  
 
2.4.2 Synthesis of TEL-ONs            
The syntheses of TEL-ONs 1-3 and I-III were performed on an automated 
synthesizer through the standard solid-phase phoshoramidite chemistry. In the case 
of TEL-ON II, we did not perform the final deblocking step, while III was obtained 
using 50 mg/mL of the glucose derivative phosphoramidite, whose synthesis has 
been reported by Adinolfi et al. [20] After the synthesis, deprotection and detachment 
of the ONs from the solid support were achieved via treatment of the resin in 
aqueous ammonia at 55°C for 17 h. The combined filtrates and washings were dried, 
redissolved in water, analysed and purified by HPLC on an anion exchange column 
(Macherey-Nagel, 1000-8/46, 4.4x50mm, 5 μm) as regards 1-3 and I and III, whereas 
for II we used a reverse-phase column (). In the former case, purification was 
achieved using a linear gradient from 0 to 100% B in 30 min, flow rate = 1 mL/min 
and detection at 260 nm (buffer A: 20 mM NaH2PO4 aq. solution pH 7.0, 
containing20% (v/v) CH3CN; buffer B: 20 mM NaH2PO4 aq. solution pH 7.0, 
containing 1MNaCl and 20% (v/v) CH3CN); in latter we used a linear gradient from 
0% to 100% B in 30 min, flow rate = 1,2 mL/min and detection at 260 nm ( buffer A: 
0,1 M triethylammonium  bicarbonate buffer, eluent B:  CH3CN). After HPLC 
purification, the oligonucleotide samples were desalted on a biogel column (BIORAD) 
eluted with H2O/CH3CH2OH (9:1 v/v). 
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2.4.3 Synthesis and oxidation of V35 and V35-Fluo peptides       
The manual syntheses of V35 and V35-Fluo peptides were carried out using the 
standard Fmoc protocol for the Solid Phase Peptide Synthesis (SPPS) on a 2-
Chlorotrytil resin. To obtain V35-Fluo, 5-Carboxyfluorescein coupling on the free N-
terminal group was performed using 1.5 equivalent of 5-FAM and 3.0 equivalents of 
DIPEA in DCM:DMF 1:1 by volume. The peptides were released from the resin with 
TFA/Et3SiH/H2O 90:5:5 for 3 h. The reaction crudes were purified by RP-HPLC on a 
semi-preparative C18-bonded silica column (Phenomenex, Jupiter 4µ Proteo 90Å, 
1.0 x 25 cm) using a gradient of CH3CN in 0.1% aqueous TFA (from 10 to 90% in 40 
min) at a flow rate of 5.0 mL/min. The product was obtained by lyophilization of the 
appropriate fractions after removal of the CH3CN by rotary evaporation. The correct 
three-dimensional structure was adopted by the peptides by means of an oxidation 
treatment. A final concentration of 2 mM of DL-Dithiothreitol (DTT) was added to a 
solution containing 60 μM of V35-Fluo. The solution was gently stirred for 2 h to 
obtain the preliminary intermolecular and intramolecular disulphide bridges reduction. 
The sample was then treated with 4 mM of the oxidizing agent N,N,N′,N′-
tetramethylazodicarboxamide (DIA) and analyzed by RP-HPLC, in the same 
conditions as reported above, to compare the retention times before and after the 
treatment with the reducing and oxidizing reagents (Fig. 17) 
 
 
Figure 17. HPLC purification profiles of V35-Fluo peptide before (black line) and after (V35-Fluo-oxi; 
blue line) the oxidation process with DTT/DIA. 
 
 
2.4.4 CD spectroscopy measurements         
TEL-ODN samples (1×10-5 M) were annealed adopting the standard reported 
protocol for 1-3, whereas a different procedure was used for I-III. In this case, the 
dimerization process was promoted by dissolving the ONs in 1 M Potassium buffer 
(100 mM KH2PO4 and 900 mM KCl) and heating at 90 °C for 5 min followed by 10 
min at high temperature and quick cooling at 4 °C. The overall samples were stored 
at 4°Covernight before measurements. CD spectra were recorded in the 320-200 
nmwavelength range, in 0.1 cm path length cuvette,  as an average of 3 scans (100 
nm/min, 1 s response time, 1 nm band width) and normalized by subtraction of the 
background scan containing only the buffer. Thermal denaturation experiments were 
carried out in the temperature range of 5-90 °C by monitoring CD values at 264 nm at 
a heating rate of0.5 °C/min. 
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2.4.5 NMR spectroscopy measurements 
The NMR samples were prepared in 0.2 ml of buffer (90% H2O/10% D2O), 
containing 0.1 M K+ at pH 7.0, and NMR spectra were recorded in the temperature 
range 25-90 °C on Varian UNITYINOVA 700 MHz spectrometer. 
 
 
2.4.6 Biological evaluation assays 
The methodology of the anti-HIV assays was as follows: ~ 3 x 105 human 
CD4Tlymphocyte(CEM) cells were infected with 100 CCID50 of HIV(IIIB) or HIV-
2(ROD)/mland seeded in 200 μL wells of a 96-well microtiter plate containing 
appropriate dilutions of the test compounds. After 4 days of incubation at 37°C, HIV-
induced syncytia formation in the CEM cell cultures was examined microscopically. 
Data represent the mean (± SD) of 3 independent experiments. 
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CHAPTER 3 
 
Conjugation of oligonucleotides onto solid supports: studies on DNA-based 
biosensors     
 
 
3.1 Introduction 
 
Biosensors are microelectronic devices normally consisting of two components: a 
highly specific recognition element and a transducer that converts the molecular 
recognition event into a quantifiable signal. Depending on the biological elements 
employed, biosensors have found applications in a variety of fields, such as clinical 
diagnosis, food analysis, environmental monitoring. However, the choice of the most 
suitable materials, in the context of the fabrication process, in not trivial, in particular 
as regards the individuation of sensitive, cheap and simple transducer material. [1]   
In the last decades, the development of science in this field allowed the recognition of 
Porous Silicon (PSi) as smart material for the design of different sensors with 
improved features. [2] For example, the limited surface area of many traditional 
sensors is one of the main factors inhibiting efficient detection of small molecules. In 
this sense, PSi offers several advantages for biosensing applications due to their 
large available surface area for molecular detection and size-selective filtering of 
contaminant species. However, many other properties make it an attractive 
transducer material; first of all, its refreactive index is widely tuneable and is changed 
by each substance that penetrates into its pore, moreover, once oxidized, the porous 
silicon surface can be further functionalized using common silane chemistry. These 
attractive properties explain the great number of reports concerning the use of PSi in 
chemical and biological sensing.[3-6]                      
In general, a great number of biosensors applications require the functionalization 
onto their the surface of oligonucleotides. [7] ON biochips rely on the selective 
recognition phenomenon resulting from the hybridization between the ON probe and 
the sought-for target and, thanks to the robust interaction between the 
complementary strands, they have been so far proposed for the detection of the viral 
genetic material or inherited diseases, and many other applications.        
In effect, one of the main hurdle in the fabrication of a biosensor is represented by 
the bio-conjugation, i.e. the immobilization of the biological probe onto the solid 
surface. [8-10] Historically, the preparation of PSi surface for the bio-conjugation has 
been achieved through two main processes: (i) direct absorption via hydrophobic 
interactions, (ii) formation of intermediate layers that allow the attachment of the 
biomolecules through covalent bonds. [11, 12] In this frame, lots of chemical 
protocols have been reported in literature to achieve surface functionalization of PSi 
nano-materials and they include the “activation” of the PSi surfaces by specific 
chemical groups, such as -SH, -NH2, -COOH, which can form stable bonds with the 
biological probe.[13] In this context, it is important to note that, even if far from 
simple, in situ synthesis of biomolecules, ONs in our case, exhibit lots of advantages 
comparing to ex situ absorption. In particular they include: the increasing of DNA 
probe density, the process automation and the possibility of surface local 
functionalization. [14] 
Recently, De Stefano et al. proposed the in situ synthesis of a polythimine 
oligonucleotide strand on PSi matrices, previously passivated with the alkylisilane 3-
aminopropyltriethoxysilane (APTES) and 3-aminopropyldimethylethoxysilane 
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(APDMES), to explore the feasibility of the common ON synthetic protocols for the 
growth of ON sequences on silicon matrices. [15, 16] The choice of a polythimine 
strand can be found in the consideration that, giving the dT residue chemical 
structure, synthesis and deprotection processes do not need the use of chemicals 
corrosive against PSi (Fig. 1).  
 
 
 
Figure 1. Chemical structures of the common phosphoramidites used for the ON synthesis. Round 
circles underline the base labile protecting groups on the nucleobases.  
 
 
In effect, the in situ synthesis of mixed ON sequences, i.e. composed by the other 
nucleobases as well, is not trivial due to the chemistry used for the ONs growth, quite 
aggressive against PSi solid support: PSi suffers from the exposure to alkaline 
solutions, normally required for the deprotection of the nucleobases. In the first 
instance, we eluded this problem by the direct synthesis of the above-mentioned 
polythimine strand on PSi matrix. Furthermore, this preliminary study gave us the 
possibility to optimize the protocols for the passivation of the support with alkylsilanes 
and for the ON growth.  
However, the common DNA biochip applications need mixed ON sequences for the 
selective detection of the target. For this reason we focused our efforts on the 
exploitation of various chemical protocols for the ON deprotection, to allow the direct 
synthesis on PSi matrices of mixed ON sequences by standard reagents and 
protocols, with noteworthy economic advantages, and to preserve the stability of PSi 
during all the phases of growth and sensing.  
 
 
3.2 Results and Discussion 
 
The principal issue to be solved in facing direct ON synthesis on PSi matrices 
consists in the structure sensitivity of PSi towards basic solutions. [17] Taking into 
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account that aqueous ammonia disrupts the silicon skeleton but it is required for the 
deprotection of the common nucleobases, we firstly addressed our searches to the 
individuation of reported protocols for the in situ DNA synthesis which could be PSi-
friendly. It is well known that exposure to K2CO3/MeOH dry is a suitable deprotection 
strategy for ON sequences covalently bonded to PSi support. However this kind of 
approach requires expensive ultra-mild phosphoramidites. For this reason, in the 
attempt to find a cheaper protocol, compatible with the common phosphoramidites 
and reagents, we tested a saturated methanolic dry ammonia solution (NH3/MeOH) 
for its ability to preserve PSi skeleton and at the same time deprotect DNA 
nucleobases.             
First of all, we performed preliminary studies on controlled pore glasses resins (CPG 
resins), namely the traditional supports used for the standard ONs solid phases 
synthesis. The resins, dG/dC/dA-CPG were treated with dry ammonia and Thin Layer 
Chromatography (TLC) was performed to check the progress of the detachment 5 
and 24 hours later. The TLCs demonstrate that dry ammonia allows the complete 
deprotection of the monomers, succeeding even in the faster removal of the 
protecting groups with respect to the standard aqueous ammonia.              
Once obtained this positive outcome, we explored the exposure of PSi devices to dry 
ammonia to verify if this alternative strategy could preserve the chemical stability of 
the silicon layer. To this aim, two kinds of devices were exploited: APTMES-
functionalized PSi device and APDMES-functionalized PSi device (PSi-Ma-NH2 and 
PSi-Mb-NH2 respectively). The comparison between the devices after exposure to the 
standard aqueous ammonia solution and after treatment with our deprotecting 
solution highlighted the feasibility of the proposed conditions. In fact, as showed in 
figure 2, no blue shift is detectable after exposure to dry ammonia for both the 
explored devices, thus indicating that corrosion did not occur.  
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Figure 2. (A) Left: Reflectivity spectra of APTES-modified PSi microcavity before (solid line) and after 
30 (dashed line) and 60 (dotted line) min of incubation in 33% NH3 at 55°C. Right: Reflectivity spectra 
of APTES-modified PSi microcavity before (solid line) and after (red dashed line) exposure to 
NH3/MeOH dry solution at RT. (B) Left: Reflectivity spectra of APDMES-modified PSi microcavity 
before (solid line) and after 30 (dashed line) and 60 (dotted line) min of incubation in 33% NH3 at 
55°C. Right: Reflectivity spectra of APDMES-modified PSi microcavity before (solid line) and after (red 
dashed line) exposure to NH3/MeOH dry solution at RT.  
 
These results gave us confidence to perform direct synthesis on PSi supports of a 
mixed ON sequence.               
Therefor, we choose the 19-mer sequence 5'GATTGATGTGGTTGATTTT3’and 
performed its synthesis on both the functionalised devices, APTES- and APDMES-
modified PSi supports, with standard protocols, by intoducing them  in a suitable 
column reactor to be used in the automated synthesizer. [18]In particuar, considering 
the chemical-physical nature of the supports, the common protocol adopted for ON 
growth on the commercially available resins was modified in order to enhance the 
coupling yield, by increasing the coupling times. The protocol requires iterative cycles 
of: 
- Deblocking: removal of the 5′-dimethoxytrityl (DMT) protecting group from the 
support-bound 5′-terminal nucleotide with the deblocking solution of 
trichloroacetic acid in dichloromethane 
- Coupling: reaction of the protected phosphoramidite dissolved in dry 
acetonitrile and activated via protonation by weakly acidic tetrazole (0.45 M in 
acetonitrile with the 5’-OH ON terminal group 
- Oxidazion: oxidation of the unstable phosphite triester linkage to the more 
stable phosphotriester by a standard oxidizing solution of iodine in 
pyridine/acetonitrile 
- Capping: acylation of the unreacted 5′-OH ON terminal groups by acetic 
anhydride in pyridine and tetrahydrofuran to minimize deletion products and 
simplify the purification process 
(A) 
(B) 
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The amount of dimetoxytrytil- group (DMT) released during the growth steps was 
used to obtain a measure of the functionalization yield. In particular, the DMT 
concentration, calculated through UV spectroscopy, led us to conclude that for both 
the devices after the fifth coupling cycle, at about tha halfway of the growth, the 
functionalization yield dropped (Fig. 3). Contextually, we performed optical reflectivity 
experiemts to check the stability of the supports,toward the standard reagents, after 
the syntheses. Figure 3 also shows the reflectivity spectra for APTES- and APDMES- 
modified devices, which, by showingred shifts of 60 and 70 nm respectively, indicate 
that ON had growth on both the supports. 
 
 
Figure 3. Reflectivity spectra of APTES- and APDMES-modified PSi microcavities before and after 
ON synthesis. (A) Left: reflectivity spectra of APTES-modified PSi microcavity before (solid line) and 
after (dashed line) ON synthesis. Right: corresponding UV intensity vs ON synthesis. (B) Left: 
reflectivity spectra of APDMES-modified PSi microcavity before (solid line) and after (dashed line) ON 
synthesis. Right: corresponding UV intensity vs ON synthesis. 
 
 
Once verified the feasibility of the synthetic protocols and the integrity of the 
supports, the deprotection of the ONs from the base labile phosphates and 
nucleobases protecting groups, was performed by the previously validated exposure 
of the devices to the dry ammonia solution over night at room temperature. Once 
again, the characterization of the supports was performed via optical reflectivity.  
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Figure 4. Reflectivity spectra of APTES-modified PSimicrocavity functionalized with oligonucleotides 
before (solid line) and after (red dashed line) the deprotection process with gaseous ammonia 
solution. (B) Reflectivity spectra of APDMES-modified PSimicrocavity functionalized with 
oligonucleotides before (solid line) and after (red dashed line) the deprotection process with gaseous 
ammonia solution. 
 
The blue shifts of only 2 and 4 nm, ascribable to the removal of the protecting  
groups from the nucleobases, clearly indicate the chemical stability of the ON-
functionalized PSi devices to our proposed deprotection strategy.           
Finally, a further confirm of the medium yield of the entire process came from the 
HPLC purification of the ON strands ultimately detached from the supports. The 
purification profile shows multiple less defined peaks, confirming the presence on the 
PSi supports of different length ON sequences (Fig. 5).  
 
 
 
 
Figure 5. HPLC assay performed on PSi-APDMES-ON device after the removal of the ON sequences 
 
 
 
 
3.3 Conclusions 
 
In this study, we firstly demonstrated the ability of dry NH3 as alternative and effective 
deprotecting strategy to preserve the integrity of silicon supports. To perform direct 
ON synthesis on PSi supports, we used standard protocols and reagents, with 
noteworthy time and cost saving. The strategy here presented can, in the next future, 
allow the easy and rapid synthesis of mixed sequences of ONs, in view of the design 
of optical DNA biosensors. The medium-yield synthetic process observed could be 
principally due to the average pore size and, for this reason, projecting photonic 
devices with pore dimensions greater than that value could significantly increase the 
yield synthesis.  
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3.4 Experimental Section  
 
3.4.1 ON in situ synthesis                    
Solid-phase ON syntheses were performed on a PerSeptive Biosystem Expedite 
8909 DNA automated synthesizer. The 19-mer mixed-sequence oligonucleotide 5′-
GATTGATGTGGTTGATTTT-3′ was assembled on two different aminosilane-
modified microcavities, following phosphoramidite chemistry by 19 growing cycles. 
PSi structures PSi-Mg,h-NH2 (Mg = APTES, Mh = APDMES)  were introduced in a 
suitable column reactor to be used in the automated synthesizer; the syntheses were 
performed according to the scheme reported in Figure 6, through the standard 
protocols that involves iterative cycles of: deblocking, coupling, oxidation, capping. 
 
Figure 6. Synthetic procedure for solid-phase synthesis of aminosilane-modified mesoporous silicon 
 
 
3.4.2 Deprotection strategies           
The devices PSi-Ma,b-NH2 (Ma = APTES, Mb = APDMES) were left in contact with 
33% aqueous ammonia at 55°C for different times to investigate the effect of 
standard ON deprotection condition (55°C for 17 h) on the PSi matrix. Contextually, 
the exposure to dry ammonia solution (NH3/MeOH dry) was also explored as an 
alternative deprotection strategy. To this aim, the aminosilane-modified samples PSi-
Me,fNH2 (Me = APTES, Mf = APDMES) were exposed to dry ammonia overnight at 
RT. The dry ammonia was generated by dissolving NaOH pellets in a sidearm flask 
containing aqueous ammonia; the generated gas was passed through a KOH drying 
tube and bubbled into a flask equipped with a rubber septum and containing 
anhydrous MeOH at 0°C. 
 
3.4.3 Spectroscopic reflectometry measurements        
Reflectivity spectra of PSi optical structures were obtained by a simple experimental 
setup: a white light was sent on PSi samples through a Y optical fibre (Avantes, 
Apeldoorn, The Netherlands). The same fibre was used to guide the output signal to 
an optical spectrum analyser (Ando AQ6315A, Tokyo, Japan). The spectra were 
acquired at normal incidence over the range 600 to 1,200 nm with a resolution of 5 
nm. The reflectivity spectra shown in the graphs are the average of three 
measurements for each sample. 
 
3.4.4 High-performance liquid chromatography studies        
The purification and control of the synthesized ONs was carried out using a Jasco 
PU2089 PLUS HPLC system (Easton, MD, USA) equipped with an anion exchange 
column (1000-8/46, 4.4 × 50 mm, 5 μm, Macherey-Nagel, Düren, Germany) using a 
linear gradient from 0% to 100% B in 30 min, flow rate = 1 mL/min and detection at 
260 nm (buffer A: 20 mM NaH2PO4 aq. solution, pH 7.0, containing 20% (v/v) 
CH3CN; buffer B: 20 mM NaH2PO4 aq. solution, pH 7.0, containing 1 M NaCl and 
20% (v/v) CH3CN). 
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CHAPTER 4  
 
Oligonucleotide analogues: PNA and its use as miRNA inhibitor 
 
 
4.1 Introduction 
Peptide Nucleic Acid (PNA) is an oligonucleotide mimic characterized by a 
pseudopeptide backbone with the standard nucleobases attached as side chains. As 
it was first reported in 1991 [1, 2], the number of papers and applications of this ON 
mimic has exponentially growth, principally due to its broad range of exciting 
properties. [3] The PNA hallmarks, in fact, are its stability and hybridation properties, 
that, together with the neutral charge of its backbone, make it a versatile tool in the 
diagnostic and gene modulation fields.PNA is commonly exploited as gene targeting 
agent for both elucidation of gene function and drugs development, as versatile tool 
for the design of diagnostics, as molecular beacon. [4-9] However, recent progresses 
highlight the great promise of another fascinating application, i.e. the use of PNA as 
microRNA modulator [10, 11].           
MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression 
post-transcriptionally, by targeting specific mRNA molecules and inhibiting their 
translation. [12] A markedly high number of evidences showed that they play a 
pivotal role in diverse physiological and disease processes and, as a consequence, 
have been so far proposed as potential therapeutic targets. [13-17] The discovery of 
miRNAs has drastically revolutionized the approaches for gene modulation; since 
they were discovered, an incredibly high number of agents have been proposed as 
anti-miRNA tools, thus allowing the elucidation of their biological role and, eventually, 
their inhibition in pathological processes. Synthetic anti-miRNA oligonucleotides 
(AMOs) have been extensively explored in this context and proved to work primarily 
by steric blocking the miRNA recognition and binding to the target. [18-20] Giving the 
drawbacks of the therapeutic use of oligonucleotides, various chemical modification 
have been exploited to improve ON performances and potency as anti-miRNA 
agents. In this context, PNAs has showed chemical and structural features 
successful for blocking miRNA expression. Among the genetic disorders for which 
AMOs approach has been proposed, Cystic Fibrosis takes on a great relevance.            
Cystic fibrosis (CF),the most common, genetically acquired, life-shortening chronic 
illness affecting young Caucasians today, is an inherited disorder characterized by 
chronic airway inflammation. CF is a disease that affect the secretory glands and is 
caused by mutations in the CFTR gene encoding the CFTR chloride channel 
expressed by most epithelial cells. [21] This gene is expressed, at different level, in 
specialized epithelial cells of the airway, in pancreatic duct, intestinal and male 
genital duct epithelium. A complex pattern of regulatory elements has been 
characterized within the gene, such as elements flanking the locus and elements 
within the introns, but, although these cis-elements are probably the most relevant for 
CFTR regulation, it is well established that post-transcriptional regulation plays a key 
role as well. For example, various miRNAs have emerged as elements involved in 
the post-transcriptional CFTR regulation. In this sense, it is important to note that little 
is understood regarding miRNA functions in the airway epithelium under normal or 
diseased conditions, but  there is a growing understanding that altered expression of 
miRNA is involved in the CF phenotype. [22]  As demonstrated by the increasing 
number of papers in this scientific topic, modulation of miRNAs involved in the CF 
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phenotype represents a new therapeutic paradigm for CF.          
In 2013 Amato et al. showed that mutations in the 3'-UTR of the CFTR gene may 
play a pathogenic effect increasing the affinity for a miRNA, known as miR-509-3p, 
thus confirming the potential of miRNAs as therapeutic targets. [23] In a recent work, 
Yin and co-workers explored the capability of a PNA sequence to selectively 
inhibitmiRNA-4661-3p. [24]                               
The promising results reported in this kind of approaches led our group to propose 
the use of peptide nucleic acids (PNAs) as inhibitors of miR-509-3p. In a previous 
work, a negatively charged PNA, 14 bases long, conveniently modified at its termini, 
in order to allow its delivery and individuation within the cells, and complementary to 
the 5’-terminus of miR-509-3p,was proposed for the selective inhibition of the miRNA. 
The in vitro studies demonstrated that the PNA was able to recognize the target 
within the cells, thus preventing the recognition and down regulation of the gene. [25] 
However, taking into account that the synthesis of long (14-20 bases) and conjugated  
PNAs is difficult, expensive and, most important, longer PNAs suffer from poor 
solubility, which is a fundamental property for their manipulation and delivery, we 
decided to focus our attention on a shorter sequence. In particular we projected and 
carried out the synthesis and structural characterization of a short PNA sequence 
aimed at binding and inhibiting miR-509-3pand proved its ability as efficient miRNA 
modulator. 
 
4.2 Results and Discussion 
As demonstrated by various reports [23, 26], miR-509-3p is able to repress CFTR 
expression by binding the 3’-UTR of the gene. Considering that its expression is 
enhanced in CF epithelia and, in particular, increases during infection and 
inflammation, it has been generally recognized as an important therapeutic target to 
rescue CFTR expression and prevent the pathogenic effects of the disease in those 
phenotypes where a correct copy of the gene is available.           
In this frame, we designed a 7 base long PNA fully complementary to the 5’-end of 
miR-509-3p and tested it as miRNA inhibitor. In fact, taking into account the previous 
positive findings reported by us on a 14 base long PNA as miR-509-3p inhibitor, but, 
at the same time the drawbacks associated to its synthesis, quite long, difficult and 
expensive, we decided to prove the effectiveness of a smaller PNA sequence as 
miRNA function modulator, complementary for only 7 nt to the seed region of the 
target, i.e. the region of a miRNA, of about 6-8 bases, essential for the recognition 
and binding to its target sequence and, consequently, the most important to achieve 
miRNA inhibition. In this way, we could adopt a synthetic protocol more simple and 
rapid, compatible with the PNA functionalization and, at the same time, with the 
production of soluble molecules. To this purpose, preliminary Molecular Dynamics 
(MD) simulations have been exploited to predict the behaviour of the new PNA/RNA 
heteroduplexes and evaluate the feasibility of our hypothesis about the effectiveness 
of the shorter anti-miRNA PNA sequence. The comparison between the long PNA 
(PNA1) and the novel shorter PNA (PNA2) showed that both PNAs form similar 
heteroduplexes, assuming a conformation resembling the canonical A-type RNA 
helix (Figure 1).  
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Figure 1. Superimposition of the MD average structures of miR-509-3p/PNA1 complex (a)and of miR-
509-3p/PNA2 complex (b). Duplexes regions are represented in licorice colored by atomtype (carbon 
in cyan, oxygen in red, nitrogen in blue, phosphate in brown, and hydrogen in white). The miR-509-3p 
single strand regions are represented in spheres colored by MD run (blue, run 1; green, run 2; red, run 
3). 
 
On the basis of the positive outcomes, we proceeded with the synthesis of the 7-
bases long PNA. The oligomer was provided with a negatively charged tetra peptide 
tail at the C-end in order to facilitate the cellular uptake and enhance its water 
solubility and conjugated at the N-terminus to the fluorescent group, to allow its 
simple visualization during in vitro experiments. Contextually a PNA oligomer with the 
same size and different composition in bases was synthesized as scramble 
sequence, i.e. negative control. Figure 2 shows the base composition of our anti-
miRNA PNA2, the scramble sequence, PNA3, and the previously tested PNA1, i.e. 
the 14-base long anti-miRNA PNA.  
 
 
 
Figure 2. Structures and sequences of miR-509-3p and PNA1–3. PNA sequences are written from C- 
to N-terminus. 
 
 
The overall sequences were synthesized through the Fmoc-solid phase protocol on a 
Rink amide resin and were equipped with the same conjugations at both their termini: 
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a peptide tail composed by two glycines and two negatively charged serines at the C-
end and, as regards PNA1 and PNA2, a Fluorescein Isothiocynate (FITC) residue 
attached at the N-terminal using an ethoxyehtyl (AEEA) linker. To this scope, we 
used an “on line” synthetic approach in which, at first, the peptide tract was 
assembled, then the PNA portion was constructed and, in the case of PNA1 and 2, 
conjugated to the fluorophore group. After the synthesis, the oligomers were 
detached from the support, lyophilized and characterized by means of spectroscopic 
techniques.  
Circular Dichroism and UV-vis spectroscopic techniques, in fact, were exploited to 
obtain an insight into the occurrence of the recognition between the RNA sequence 
and our PNA. To this aim, we preliminarily prepared the miR-509-3p/PNA 
heteroduplexes, in the ratio 1:1.5 and 1:5.  
The UV spectrum of miR-509-3p/PNA2 complex displays a lower value of 
absorbance than the arithmetic sum of each component alone. These findings, in line 
with those reported for PNA1, highlight the occurrence of stacking interactions 
between the miRNA and the PNA sequence (Fig. 3). 
 
 
  
 
 
Figure 3. (A) UV spectra of miR-509-3p (dashed line), PNA2 (solid line), miR-509-3p/PNA2 mixture (1 
: 1.5) (dotted line), and the arithmetical sum (dashed-dotted line). (B) UV melting profile of miR-509-3p 
alone (dashed line) andmiR-509-3p/PNA2 mixture (1 : 1.5 dotted line). 
 
 
The figure above shows also the UV-melting profile of the miR-509-3p/PNA2 mixture 
in the ratio 1:1.5. This experiment further confirm the formation of the heteroduplex, 
since a sigmoid curve at 260 nm, typical of duplex/single strand transition is 
observed. Moreover, the calculated apparent melting Temperature of the mixture is 
40°C, while the same value for the RNA alone is 20°C, which can be ascribed to the 
less stable secondary structures of the RNA alone.  
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Circular Dichroism was also exploited to characterize our structures. CD spectra of 
each component alone and of the mixture are reported in figure 4 and, once again, 
confirm the capability of the PNA to bind the target. Indeed, the dichroic profile of the 
mixture is that of a typical antiparallel RNA/PNA heteroduplex, showing maxima near 
220 and 260 nm and minima at 196 and 235 nm.  
 
 
Figure 4. CD spectra of miR-509-3p alone (dashed line), PNA2 alone (solid line), and miR-509-
3p/PNA2 mixture (1: 1.5) (dotted line). 
 
 
To further investigate on the recognition phenomena, we also carried out 
Electophoresis Mobility Shift Assay (EMSA) experiments (Fig. 5). 
 
 
 
Figure 5. EMSA of PNA2 alone (lanes 1), miR-509-3p alone (lanes 2), miR-509-3p/PNA2 1 : 1.5 
(lanes 3), and miR-509-3p/PNA2 1 : 5 (lanes 4) visualized by FITC (a) or EtBr (b) staining. The 
superimposition of FITC and EtBr stained gels is shown in (c). 
 
 
The figure above shows the same gel visualized by FITC and ethidium bromide 
stains and their superimposition. PNA 2 alone, in lane 1, is able to migrate by virtue 
of its negatively charged peptide tail; the formation of the RNA/PNA complex is 
A B C 
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evidenced by the visualization of a upwards-shifted band, slower than the two 
components alone, for both the 1:1.5 and 1:5 ratios, in lanes 3 and 4 respectively.  
Once obtained robust proves concerning the binding events, we wanted to explore 
the recognition phenomena in a biological context, by setting in vitro experiments. To 
this aim, we examined the ability of PNA2 to revert the decrease of luciferase activity 
due to the transfection of miR-509-3p in A549 cells. A reporter luciferase construct 
sensitive to miR-509-3p for the presence of the 3’-UTR of the gene, the pLuc-CFTR-
3’UTR plasmid, was used to transfect A549 cells. Then, the cells were transfected 
with miR-509-3p; as expected, the introduction of the miRNA induces the luciferase 
activity reduction up to 40%. Successively, PNA2 was transfected by means of 
commercially available Attractene cationic lipid transfection reagent. As we can see 
from figure 6, that shows microscopy image of A549 cells 24 hours after the 
transfection, PNA2 was uptaken by the cells.  
 
 
 
 
Figure 6. Representative uptake of FITC-labelled PNA2 by A54 cells 
 
 
 
More interestingly, PNA2, but no PNA3, was able to rescue luciferase activity in a 
dose-dependent manner. This last result led us to conclude that, even within the 
cells, our anti-miRNA PNA is able to selectively recognize and bind its target, thus 
preventing its recognition to the 3’-UTR of the gene (Fig. 7).  
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Figure 7. Inhibition of miR-509-3p effect by PNA2. Different dosesof PNA2 were transfected in A549 
cells. A significant inhibition ofmiR-509-3pwas observed using PNA2 in a dose-dependent manner. *𝑃 
values < 0.02, **𝑃 values < 0.002.The 7-mer poly-thymine PNA3had no effect on miR-509-3p. 
 
 
4.3 Conclusions  
 
In this work, we presented the use of a small PNA sequence as miRNA function 
modulator. The chemical features of PNA make it a versatile tool in the field of gene 
modulation and, to date, several works have witnessed its potency in this context. 
However, beyond the classical and consolidated application as antigene and 
antisense agent, another interesting and less explored field can benefit from its 
properties, the miRNA modulation field. The RNA/PNA heteroduplexes are 
exceptionally stable and this aspect, in association to the PNA stability in biological 
media, are extremely intriguing for the exploration of miRNA role and the modulation 
of their function in pathological processes.             
In a previous work, our group reported the positive findings relative to the use of a 14 
base long PNA complementary to the 5’-terminal region of miR-509-3p, a miRNA 
involved in the pathological progress of Cystisc Fibrosis. [25]In 2011 Obad et al. 
reported the efficient silencing of a miRNA by a very small LNA, only 8 base long.[27] 
In this frame, our interest towards short PNA sequences was triggered by the 
experimental observation that the synthesis of long PNA sequences in not trivial, in 
particular for conjugated PNAs, and, above all, long PNAs suffer from poor solubility 
in water. These considerations, in addition to the numerous computational evidences 
that showed that a complementarity of only 7 bases at the 5’-terminus of miRNAs is 
sufficient for their activity modulation in vivo, led us to design and test a novel very 
small PNA sequence as miR-509-3p modulator. A combination of spectroscopic 
techniques was firstly used to explore the capability of our PNA to bind the RNA 
target and the successful findings obtained were then confirmed by the biological 
assays. These studies demonstrate that the activity of miR-509-3p can be inhibited 
by a short PNA targeting only the seed region of the miRNA. Therefore the here 
presented results further strengthen the potential of PNA as anti-miRNAs agent, in 
particular considering the significant advantages in terms of cost and times required 
by the PNA synthesis.  
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4.4 Experimental Section 
 
4.4.1 Molecular Modelling              
The initial structures of the heteroduplexes formed by miR-509-3p with PNA1 and 
PNA2 were built by using the NMR structure of the 6-mer 
RNA(GAGUUC)/PNA(GAACTC) heteroduplex (PDB ID = 176D) [28]. Starting from 
the lowest energy NMR structure, one nucleotide was added aligning a duplicate of 
the reference structure on the PNA backbone. Once the 7-mer heteroduplex was 
obtained, the bases were mutated to match the PNA2 sequence. Watson-Crick 
canonical pairs were then refined using distance restraints on the first seven bases of 
miR- 509-3p/PNA2 heteroduplex. The same procedure was used to build the miR-
509-3p/PNA1 heteroduplex, starting from the refined structure of miR509-3P/PNA2 
heteroduplex. The equilibration of the systems and production of MD simulations 
were performed using the Amber 12 suite of programs [29, 30]. The Leap module of 
Ambertools13 was used to create parameter and topology files for the MD 
simulations using the ff99SB force field for RNA and standard amino acids. For PNAs 
parameterization we used the Sanders et al. force field for PNA [31] downloaded 
from the RESP and ESP charge database (R.E.DD.B. http://q4md-
forcefieldtools.org/REDDB Project ID = F93) [32], whereas the parameters for serine 
phosphate were taken from reference [33]. TIP3P water molecules were added with 
a minimum spacing of 10.0A from the box edges to the ˚ RNA:PNA molecules and 
Na+ counterions were added to each system to reach the neutralization of the 
system. The geometry of the system was minimized in four steps as follows: (1) 
optimization of hydrogen atoms (500 steps of steepest descent and 4,500 steps of 
conjugate gradient); (2) optimization of water molecules and counterions (2,000 steps 
of steepest descent and 8,000 steps of conjugate gradient); (3) further optimization of 
hydrogen atoms, water molecules, and counterions (3,500 steps of steepest descent 
and 11,500 steps of conjugate gradient); (4) final optimization of the whole system 
(2,500 steps of steepest descent and 8,500 steps of conjugate gradient). 
Thermalization of the system was performed in four steps of 60 ps, increasing the 
temperature from 10 to 298 K. Concomitantly, interstrand distance restraints were 
applied to the RNA:PNA heteroduplex to preserve all base pairs canonical Watson-
Crick bond, allowing 0.1A movement from the equilibrium bond distance ˚ (either 
closer or farther). Thus, the force constant applied during thermalization was set to 
32 kcal mol−1 A˚ −2 and was gradually reduced in the next step to 10 kcal mol−1 A˚ 
−2 and subsequently decreased by increments of 5 kcal mol−1 A˚ −2in the next 
stages. Then, an additional step of 250 ps was performed in order to equilibrate the 
system density at constant pressure (1 bar) and temperature (298 K). Finally, an 
extended trajectory covering was run using a time step of 2 fs. SHAKE was used for 
those bonds containing hydrogen atoms in conjunction with periodic boundary 
conditions at constant pressure and temperature, particle mesh Ewald was used for 
the treatment of long range electrostatic interactions, and a cutoff of 9A was used for 
nonbonded interactions. ˚All production simulations were repeated in triplicate with 
random seeding for initial velocities and extended to 20 ns. In order to further assay 
the stability of the RNA:PNA heteroduplexes, we extended one run of PNA2 up to 50 
ns, for a total simulation time of 90 ns for PNA2 and 60 ns for PNA1. The structural 
features were determined using the Curves+ software package [40], and visualization 
of trajectories was performed in VMD, while the trajectory analyses were performed 
using Ambertools13. 
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4.4.2 Synthesis of miR-509-3p and PNAs          
Synthesis of miR-509-3p and PNAs. The miR-509-3p mimic (2-OMe modified) was 
synthesized and purified by the oligonucleotide synthesis facility at CEINGE-
Biotecnologie Avanzate (Naples, Italy).                  
PNA 2 and PNA3 were synthesized by standard Fmoc-solid phase strategy, using 
Fmoc-Bhoc protected monomers purchased from Link Technologies. MBHA resin, 
after swelling in DCM for 30 minutes and washings in DMF, was treated with 
deblocking solution (20% piperidine in DMF) to allow the deprotection of the –NH2 
functions on the resin. During the peptide and PNA synthesis the Fmoc group was 
removed by a treatment with a 5% DBU in DMF solution (5 min).Couplings of the 
standard aminoacids and the PNA monomers were performed using 5 equivalents of 
monomer, HATU and DIPEA and 6.5 equivalents of Lutidine, for 1 hour at room 
temperature. For Fmoc-L-Ser(PO(OBzl)OH)-OH coupling time was prolonged to 15 
hours. For the coupling with the fluorescent group the FITC monomer (5 eq., 0.2 M) 
was dissolved in DMF/DIPEA (2.5:97.5 v/v) and the solution was added to the resin, 
which was gently shaken in the dark for 15 h. The detachment of the oligomers from 
the support was achieved by treating the resin with TFA/anisole/ethanedithiol 
(9:0.5:0.5; v/v/v) for 3.5 h and the products were precipitated with cold diethyl ether. 
After centrifugation and washings with diethyl ether, the oligomers were dissolved in 
water and lyophilized.  
 
4.4.3 PNA purification                      
The purifications were performed by HPLC using a RP-18 column (Merck, RT 250–
10 5 𝜇m) eluted with a linear gradient from 10% to 90% of eluent B in eluent A in 30 
min, where eluent A is 0.1% TFA in water eluent B: 0.1% TFA in acetonitrile. For 
these purifications the UV/VIS detector was set at 495 nm corresponding to the 
maximum of absorption of FITC. The collected yellow fractions were lyophilized and 
stored at −20∘ C in the dark. The structures of PNA2 and PNA3 were confirmed by 
MALDI-TOF mass spectrometry on a Bruker Autoflex I instrument using 𝛼-cyano-4-
hydroxycinnamic acid, 10 mg/mL in acetonitrile-3% aqueous TFA (1 : 1, v/v) as the 
matrix.  
PNA2 m/z calculated 2812, found 2813 [M + H]+ 
PNA3 m/z calculated 2864, found 2865 [M + H]+ 
 
4.4.4 Preparation of miRNA/PNA heteroduplexes        
The miR-509-3p/PNA heteroduplexes (1:1.5 or 1:5) were prepared in100mM KCl and 
10mMK2HPO4 containing buffer, by heating the mixture of the samples at 90°C for 
5min and slowly cooling at room temperature for 12 h. The concentration of each 
PNA sample was estimated by quantitative UV at 90°Cusing the following molar 
extinction coefficients: PNA1 𝜀=149.6mL 𝜇mol−1 cm−1, PNA2 𝜀 = 69.7mL 𝜇mol−1 
cm−1,PNA3 𝜀=61.6mL𝜇mol−1cm−1, and miR-509-3p 𝜀=205.0mL 𝜇mol−1 cm−1. 
 
4.4.5 UV and UV-melting studies                     
The UV spectra were recorded on a Jasco V-530 UV spectrophotometer equipped 
with a Peltier-type temperature control system (model PTC-348WI). Thermal 
denaturation experiments were performed in the temperature range 5–90°C by 
monitoring the absorbance at 260 nm at the heating rate of 0.5∘C/min. The apparent 
Tm was estimated from the maximum in the first derivative of the melting profile. 
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4.4.6 CD and CD-melting studies            
CD spectra were recorded with a JascoJ-715 spectropolarimeter equipped with a 
Peltier Thermostat Jasco ETC-505T using 0.1 cm path length cuvettes. CD 
measurements were registered in the range 220–320 nm with a scan rate of 100 
nm/min and 2nm bandwidth. The concentration of miR-509-3p/PNA2 and miR-509-
3p was 1.0 × 10−5 M. The spectra were signal-averaged over at least three scans and 
baseline was corrected by subtracting the buffer spectrum. 
 
4.4.7 Cell line, construct and transfection                           
A549 human lung carcinoma cells were purchased from ATCC (Manassas, USA). 
Cells were maintained in Dulbecco’s modified Eagle’smedium (Gibco Invitrogen, 
USA) with 10% heat inactivated fetal bovine serum (HyClone, USA) without the 
addition of antibiotics. Luciferase construct bearing the 3’-UTR of CFTR gene [23] 
was used as miR-509-3p sensitive. Transfection of A549 cells with miRNA-mimics 
(Qiagen, Germany, EU) or PNA was performed with Attractene Transfection Reagent 
(Qiagen) as previously reported [25]. Briefly, cells seeded in 96-well plates were co-
transfected with the luciferase reporter constructs and the miR-509-3p mimic. 24 h 
after, the cells were transfected with anti-miR-509-3p PNA. The transfection 
efficiency (≈ 80%) was assessed by measuring the percentage of fluorescent cells 
relative to the total number of cells. The luciferase activity level was measured 24 h 
after transfection using the Dual-Glo Luciferase Assay System (Promega 
Corporation).The relative reporter activity was obtained by normalization to the 
Renilla luciferase activity. 
 
4.4.8 Electrophoresis Mobility Shift Assay                            
The miR-509-3p mimic (2’-OMe-modified) was synthesized by the oligonucleotide 
synthesis facility at CEINGE-Biotecnologie Avanzate(Naples, Italy). As previously 
reported [25], the miRNA and PNA were annealed in 1X NE Buffer 2 (50mMNaCl, 
10mMTris-HCl, 10mMMgCl2, 1mMDTT, and pH 7.9 at 25∘C) for2 h at room 
temperature. All the reactions were loaded into 20% polyacrylamide gels in 0.5X Tris-
Borate-EDTA (TBE) buffer and run at 140V for 3 h. The fluorescence signal was 
acquired placing the wet gel directly on the plate of the Typhoon 8600 scanner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
OLICONUCLEOTIDES ANALOGUES: THE PNA 
67 
 
4.5 References 
 
1. Nielsen PE, Egholm M, Berg RH, Buchardt O, 1991. Sequence-selective 
recognition of DNA by strand displacement with a thymine-substituted 
polyamide.Science. 254(5037):1497-500. 
2. Hyrup B, Nielsen PE, 1996. Peptide nucleic acids (PNA): synthesis, properties 
and potential applications. Bioorg. Med. Chem. 4:5–23 
3. Eriksson M, Nielsen PE, 1996. Solution structure of a peptide nucleic acid-
DNA duplex. Nat. Struct. Biol. 3:410–413. 
4. Fraser GL, Holmgren J, Clarke PBS, Wahlestedt C, 2000. Antisense inhibition 
of delta-opioid receptor gene function in vivo by peptide nucleic acids. Mol. 
Pharmacol. 57: 725–731. 
5. Gotfredsen CH, Schultze P, Feigon J, 1998. Solution structure of an 
intramolecular pyrimidine–purine–pyrimidine triplex containing an RNA third 
strand. J. Am. Chem. Soc. 120:4281–4289. 
6. Hamilton SE, Simmons CG, Kathiriya IS, Corey DR, 1999.Cellular delivery of 
peptide nucleic acids and inhibition of human telomerase. Chem. Biol 6:343–
351. 
7. Kuhn H, Demidov VV, Coull JM, Fiandaca MJ, Gildea BD, FrankKamenetskii 
MD, 2002. Hybridization of DNA and PNA molecular beacons to single-
stranded and double-stranded DNA targets. J. Am. Chem. Soc. 124:1097–
1103. 
8. Mologni L, Nielsen PE, Gambacorti-Passerini C, 1999. In vitro transcriptional 
and translational block of the bcl-2 gene operated by peptide nucleic acid. 
Biochem. Biophys. Res. Commun. 264:537–543. 
9. Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR, 1996. Inhibition of 
human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14:615–
619. 
10. Oh SY, Ju YS, Park H, 2009.A highly effective and long-lasting inhibition of 
miRNAs with PNA-based antisense oligonucleotides. Molecules and Cells. 28: 
341-345 
11. Fabani MM, Gait MJ, 2008.miR-122 targeting with LNA/2′-O-methyl 
oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide 
conjugates. Rna 14: 336–346. 
12. Rana TM, 2007. Illuminating the silence: understanding the structure and 
function of small RNAs. Nature Reviews Molecular Cell Biology. 8: 23-36. 
13. Mann M, Barad O, Agami R, Geiger B, Hornstein E, 2010.miRNA-based 
mechanism for the commitment of multipotent progenitors to a single cellular 
fate. Proc Natl Acad Sci USA. 107: 15804–09. 
14. Hornstein E, 2010.miRNA activity directs stem cell commitment to a particular 
fate. Cell Cycle. 9: 4041–4042. 
15. Haramati S, Chapnik E, Sztainberg Y, Eilam R, Zwang R, Gershoni N, 
McGlinn E, Heiser PW, Wills AM, Wirguin I, Rubin LL, Misawa H, Tabin CJ, 
Brown R Jr, Chen A, Hornstein E, 2010. miRNA malfunction causes spinal 
motor neuron disease. Proc Natl Acad Sci, 107: 13111–13116. 
16. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just 
S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald 
A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl 
T, Martin GR, Bauersachs J, Engelhardt S, 2008. MicroRNA-21 contributes to 
CHAPTER 4 
OLICONUCLEOTIDES ANALOGUES: THE PNA 
68 
 
myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 
456(7224):980-4. 
17. Garzon R, Marcucci G, Croce CM, 2010. Targeting microRNAs in cancer: 
rationale, strategies and challenges. Nat. Rev. Drug. Discov. 9: 775–789. 
18. Freier SM, Altmann KH, 1997.The ups and downs of nucleic acid duplex 
stability: structure-stability studies on chemically-modified DNA:RNA duplexes. 
Nucleic Acids Res. 25: 4429–43. 
19. Lennox KA, Behlke MA, 2010. A direct comparison of anti-microRNA 
oligonucleotide potency. Pharm. Res.27: 1788–99. 
20. Eder PS, DeVine RJ, Dagle JM, Walder JA, 1991. Substrate specificity and 
kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in 
plasma. Antisense Res. Dev. 1(2):141-51. 
21. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan 
CR, Smith AE, 1990. Defective intracellular transport and processing of CFTR 
is the molecular basis of most cystic fibrosis. Cell. 63(4):827-34. 
22. Gillen AE, Gosalia N, Leir SH, Harris A, 2011. MicroRNA regulation of 
expression of the cystic fibrosis transmembrane conductance regulator 
gene.Biochem. J. 438(1):25-32. 
23. Amato F, Seia M, Giordano S, Elce A, Zarrilli F, Castaldo G, Tomaiuolo R, 
2013. Gene mutation in microRNA target sites of CFTR gene: a novel 
pathogenetic mechanism in cystic fibrosis. PLoS One. 8(3): e60448 
24. Brown PN, Yin H, 2013. PNA-based microRNA inhibitors elicit anti-
inflammatory effects in microglia cells. Chem Commun (Camb). 49(39):4415-
7. 
25. Amato F,  Tomaiuolo R, Borbone N, Elce A, Amato J, D'Errico S, De Rosa G, 
Mayol L, Piccialli G, Oliviero G, Castaldo G, 2014. Design, synthesis and 
biochemical investigation, by in vitro luciferase reporter system, of peptide 
nucleic acids as new inhibitors of miR-509-3p involved in the regulation of 
cystic fibrosis disease-gene expression. Med. Chem. Commun. 5: 68-71. 
26. Ramachandran S, Karp PH, Osterhaus SR, Jiang P, Wohlford-Lenane C, 
Lennox KA, Jacobi AM, Praekh K, Rose SD, Behlke MA, Xing Y, Welsh MJ, 
McCray PB Jr, 2013. Post-transcriptional regulation of cystic fibrosis 
transmembrane conductance regulator expression and function by 
microRNAs. Am. J. Respir. Cell. Mol. Biol. 49(4):544-51. 
27. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, 
Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D, Hannon 
GJ, Kauppinen S, 2011. Silencing of microRNA families by seed-targeting tiny 
LNAs. Nat. Genet. 43(4):371-8. 
28. Brown SC, Thomson SA, Veal JM, Davis DG, 1998. NMR solution structure of 
a peptide nucleic acid complexed with RNA. Science. 265(5173):777-80. 
29. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C, 2006. 
Comparison of multiple Amber force fields and development of improved 
protein backbone parameters. Proteins. 65(3):712-25. 
30. Case DA, Darden TA, Cheatham TE III, et al., 2012. “AMBER 12” University of 
California. 
31. Sanders JM, Wampole ME, Chen CP, Sethi D, Singh A, Dupradeau FY, Wang 
F, Gray BD, Thakur ML, Wickstrom E, 2013. Effects of Hypoxanthine 
Substitution in Peptide Nucleic Acids Targeting KRAS2 Oncogenic mRNA 
Molecules: Theory and Experiment. J. Phys. Chem. B. 117 (39): 11584-95. 
CHAPTER 4 
OLICONUCLEOTIDES ANALOGUES: THE PNA 
69 
 
32. Dupradeau FY, Cézard C, Lelong R, Stanislawiak E, Pêcher J, Delepine JC, 
Cieplak P, 2008. R.E.DD.B.: a database for RESP and ESP atomic charges, 
and force field libraries. Nucleic Acids Res. 36 (1) (Database issue):D360-7. 
33. Craft JW Jr, Legge GB, 2005. An AMBER/DYANA/MOLMOL phosphorylated 
amino acid library set and incorporation into NMR structure calculations. J 
Biomol NMR. 33(1):15-24. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
 
APPENDIX 
 
71 
 
APPENDIX 
 
A1 
List of publications: 
 
1. “A rapid screening platform towards new anti-HIV aptamers set on molecular 
docking and fluorescence quenching techniques”. Giorgia Oliviero, Mariano 
Stornaiuolo, Valentina D’Atri, Fabrizia Nici, Ali Munaim Yousif, Stefano 
D’Errico, Gennaro Piccialli, Luciano Mayol, Ettore Novellino, Luciana Marinelli, 
Paolo Grieco, Alfonso Carotenuto, Sam Noppen, Sandra Liekens, Jan 
Balzarini and Nicola Borbone. Analytical Chemistry, 2015, 88, 2327-2334; doi: 
10.1021/acs.analchem.5b04268 
 
2. “Synthesis and Evaluation of the Antiproliferative Properties of a Tethered 
Tubercidin–Platinum(II) Complex”. Stefano D'Errico, Giorgia Oliviero, Nicola 
Borbone, Elena Di Gennaro, Andrea Ilaria Zotti, Alfredo Budillon, Vincenzo 
Cerullo, Fabrizia Nici, Luciano Mayol, Vincenzo Piccialli and Gennaro 
Piccialli. Eur. J. Org. Chem, 2015, 7550-7556; 2015 doi: 
10.1002/ejoc.201500998. 
 
3. “Synthesis of C6 -Pyridylpurine Nucleosides by Reaction of Nebularine N1 -
Oxide with Pyridinyl Grignard Reagents”. Stefano D’Errico,Giorgia Oliviero, 
Nicola Borbone, Fabrizia Nici, Vincenzo Piccialli, Brunella Pinto, Daniele 
D’Alonzo, Luciano Mayol, and Gennaro Piccialli. Eur. J. Org. Chem, 2015, 
2244–2249; 2015 doi: 10.1002/ejoc.201403648. 
 
4. “Synthesis and Pharmacological Evaluation of Modified Adenosines Joined to 
Mono-Functional Platinum Moieties”. Stefano D’Errico, Giorgia Oliviero, Nicola 
Borbone, Vincenzo Piccialli, Brunella Pinto, Francesca De Falco, Maria Chiara 
Maiuri, Rosa Carnuccio, Valeria Costantino, Fabrizia Nici and Gennaro 
Piccialli. Molecules, 2014, 19, 9339-9353; doi:10.3390/molecules19079339. 
 
5. “Synthesis of mixed-sequence oligonucleotides on mesoporous silicon: 
chemical strategies and material stability”. Monica Terracciano, Ilaria Rea, 
Luca Stefano, Ivo Rendina, Giorgia Oliviero, Fabrizia Nici, Stefano D'Errico, 
Gennaro Piccialli, Nicola Borbone. Nanoscale Res Lett, 2014, 9, 317; doi:10.
1186/1556-276X-9-317. 
 
6. ”Exploitation of a Very Small Peptide Nucleic Acid as a New Inhibitor of miR-
509-3p Involved in the Regulation of Cystic Fibrosis Disease-Gene 
Expression”. Felice Amato, Rossella Tomaiuolo, Fabrizia Nici, Nicola 
Borbone, Ausilia Elce, Bruno Catalanotti, Stefano D'Errico, Carmine Marco 
Morgillo, Giuseppe De Rosa, Laura Mayol, Gennaro Piccialli, Giorgia Oliviero, 
APPENDIX 
 
72 
 
Giuseppe Castaldo. BioMed research international, 2014 doi: 
10.1155/2014/610718. 
 
 
 
List of Communications: 
 
1. “In silico driven techniques for the design and synthesis of new Tetra-End-
Linked analogues of the anti-HIV aptamer SA-1042 and a novel binding 
assay”. International School of Organic Synthesis. Gargnano (MI), 14-19 June 
2015 
 
2. “Chemical stability studies of mesoporous oxidized silicon for the synthesis of 
mixed-sequence oligonucleotides” F. Nici, M. Terracciano, N. Borbone, L. De 
Stefano, S. D’Errico, G. Piccialli, I. Rea, G. Oliviero – Workshop: Functional 
DNA Technology. Rome, 19-20 June 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
 
73 
 
A2 
 
Copy of the publications 
Screening Platform toward New Anti-HIV Aptamers Set on Molecular
Docking and Fluorescence Quenching Techniques
Giorgia Oliviero,†,∥ Mariano Stornaiuolo,†,∥ Valentina D’Atri,‡,§ Fabrizia Nici,† Ali Munaim Yousif,†
Stefano D’Errico,† Gennaro Piccialli,†,¶ Luciano Mayol,† Ettore Novellino,† Luciana Marinelli,†
Paolo Grieco,† Alfonso Carotenuto,† Sam Noppen,⊥ Sandra Liekens,⊥ Jan Balzarini,⊥
and Nicola Borbone*,†
†University of Naples Federico II, Department of Pharmacy, Napoli, 80131, Italy
‡University of Bordeaux, IECB, ARNA laboratory, Pessac, 33600, France
§INSERM, U869, ARNA laboratory, Bordeaux, 33000, France
¶CNR, Institute of Protein Biochemistry, Napoli, 80131, Italy
⊥KU Leuven, Rega Institute for Medical Research, Leuven, 3000, Belgium
*S Supporting Information
ABSTRACT: By using a new rapid screening platform set on
molecular docking simulations and ﬂuorescence quenching
techniques, three new anti-HIV aptamers targeting the viral surface
glycoprotein 120 (gp120) were selected, synthesized, and assayed.
The use of the short synthetic ﬂuorescent peptide V35-Fluo
mimicking the V3 loop of gp120, as the molecular target for
ﬂuorescence-quenching binding aﬃnity studies, allowed one to
measure the binding aﬃnities of the new aptamers for the HIV-1
gp120 without the need to obtain and purify the full recombinant
gp120 protein. The almost perfect correspondence between the
calculated Kd and the experimental EC50 on HIV-infected cells
conﬁrmed the reliability of the platform as an alternative to the existing methods for aptamer selection and measuring of
aptamer−protein equilibria.
Human immunodeﬁciency virus (HIV) resistance totherapy relies, at least in part, on antigenic drifts and
shifts, changes in the amino acids sequences of viral proteins
causing drug resistance and evasion from host immune
response and drug pressure. Compared to neutralizing
antibodies and small drugs, oligonucleotide aptamers targeting
viral proteins represent a promising source of new anti-HIV
drugs capable of overcoming the consequences of the drift. In
fact, due to the bigger area buried at the aptamer−protein
interface, the binding aﬃnity of aptamers for the target protein
is less aﬀected by amino acid substitutions.
In the last decades, several RNA and DNA aptamers
targeting HIV have been reported.1−10 However, new, faster,
and more reliable screening platforms toward aptamers
targeting HIV proteins remain to be developed. We here
propose an innovative platform, to the best of our knowledge
never explored so far, which uses a virtual binding assay
approach for aptamer selection and a quick in vitro ﬂuorescence
quenching assay for the measurement of aptamer−protein
equilibria. Aptamers targeting the HIV envelope glycoprotein
120 (gp120) are more eﬀective in the protection of human cells
from infection than those targeting viral protease or reverse
transcriptase (2−3 logs higher protection).4 The ﬁrst active
anti-HIV aptamers, namely, SA-104211 and ISIS 5320,12 were
shown to be capable of binding to the third hyper variable
region of gp120 (known as the V3 loop) thus protecting the
target cells from HIV infection. Upon binding, these aptamers
block the ﬁrst event leading to cell infection, the interaction of
gp120 with the coreceptor glycoprotein CD4 expressed on the
surface of target cells. The crystal structure of the complex
formed by gp120 with CD4 and the neutralizing antibody X5
(PDB ID: 2B4C)13 enlightened the structural features of the
V3 loop and its role in the binding of gp120 to CD4. The V3
loop is typically 35-amino acids in length, protrudes from the
protein core, and is closed by two cysteines forming a disulﬁde
bridge.
SA-1042 and ISIS 5320 are DNA quadruplex-forming
aptamers. DNA quadruplexes (G4s) are peculiar nucleic acid
tertiary structures that form rapidly when suitable guanine-rich
oligonucleotides are annealed in near physiological conditions.
G4s are characterized by the presence of stacked planar
arrangements of four guanines (G tetrads) held together by
eight Hoogsteen hydrogen bonds and stabilized by the
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coordination with central monovalent cations.14,15 The melting
temperatures of G4s are typically higher than the physiological
temperature, and the existence in vivo of G4s in human cells
was recently demonstrated.16,17 To improve both the resistance
to nucleases and the kinetics of quadruplex formation, we
initiated a study aimed at the synthesis of a series of new
monomolecular analogues of SA-1042 by exploiting the Tetra-
End-Linker (TEL)-oligonucleotides strategy.18,19 By varying
the TEL size and position and by changing the ﬁfth and sixth
nucleobases in SA-1042, we selected the TEL-
(3′GGGGGT5′TBDPS)4 species (4, Figure 1) as the best
candidate for further SAR studies.20,21
■ EXPERIMENTAL PROCEDURES
General Instrumentation. Automated solid phase oligo-
nucleotide synthesis was performed on a 8909 DNA-
Synthesizer (Applied Biosystems). Mass spectra of peptides
were recorded by using a MALDI-TOF-MS, Voyager DE STR
MALDI TOF mass spectrometer. CD measurements were
performed on a JASCO J-715 spectropolarimeter equipped
with a Peltier Thermostat JASCO ETC-505T using 0.1 cm path
length cuvettes. NMR spectra were acquired on Varian
UNITYINOVA 500 MHz, 700 MHz and Mercury Plus 400
MHz spectrometers and processed using the iNMR software
package (http://www.inmr.net). For the experiments in H2O,
water suppression was achieved by including a double pulsed-
ﬁeld gradient spin-echo (DPFGSE) module26,27 in the pulse
sequence prior to acquisition. Chemical shifts are reported in
parts per million (δ) relative to the residual solvent signals.
Synthesis of TEL−ODNs 1−3. TEL−aptamers TEL−
(3′GGGGT5′-TBDPSi)4 (1), TEL−(3′GGGT5′-TBDPSi)4
(2), and TEL−(3′GGT5′-TBDPSi)4 (3) were chemically
synthesized according to the previously described procedure.20
After automated solid phase synthesis, the oligonucleotides
were detached from the support and deprotected using a 33%
aqueous ammonia solution at 55 °C for 17 h. The combined
ﬁltrates and washings were dried, redissolved in water, analyzed,
and puriﬁed by HPLC on C-18 reverse phase column
(Purosphere STAR, 5 μm, 250 × 10 mm, Merck) using a
linear gradient from 0 to 100% B in 30 min, ﬂow rate = 1.2 mL/
min, and detection at 260 nm (eluent A: TEAB 0.1 M; eluent
B: CH3CN). The retention time of 1 (24 min), 2 (24.5 min),
and 3 (26 min) corresponded to that of the most retained pick
in each HPLC proﬁle due to the presence of the terminal
TBDPS lipophilic groups.
TEL−ODN Samples Annealing. 1−5 were dissolved in
100 mM potassium buﬀer (10 mM KH2PO4 aq. solution
containing 90 mM KCl, pH 7.0), and the corresponding
quadruplexes were formed by heating at 90 °C for 5 min and
slowly cooling at room temperature for 12 h. Samples were
stored at 4 °C for 24 h before measurements. TEL−ODNs
concentrations were determined in water by measuring the
absorbance at 260 nm at 90 °C using the nearest-neighbor
calculated molar extinction coeﬃcient (ε) of d(5′TGn3′) (for
1−4) or d(5′TGGGGT3′) (for 5) multiplied by 4 (the number
of strands in each TEL−ODN complex). A contribution of
8658 cm−1 M−1 was added for each TBDPS group;28 1:
calculated ε = 231 832 cm−1 M−1; 2: calculated ε = 191 432
cm−1 M−1; 3: calculated ε = 151 032 cm−1 M−1; 4: calculated ε
= 272 232 cm−1 M−1 (from ref 21); 5: calculated ε = 265 832
cm−1 M−1 (from ref 21).
CD Spectroscopy Measurements. TEL−ODN samples
(2 × 10−5 M) were annealed as described above and stored at 4
°C overnight before measurements. CD spectra of 1−3 (Figure
S-2, left panels) alone or mixed with V35-Fluo or V35-Fluo-oxi
at 1.5:1 aptamer/peptide ratio (data not shown) were recorded
at 25 °C in the 360−200 nm wavelength range as an average of
5 scans (100 nm/min, 1 s response time, 1 nm bandwidth) and
normalized by subtraction of the background scan containing
only the buﬀer. Thermal denaturation experiments on 1−3
alone (Figure S-2, right panels) or mixed with V35-Fluo or
V35-Fluo-oxi (data not shown) were also carried out in the
Figure 1. Schematic representation of TEL−ODNs 1−5 and primary structure of V35 and V35-Fluo.
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temperature range of 20−90 °C by monitoring CD values at
264 nm at a heating rate of 0.5 °C/min. The CD data of
aptamer/peptide mixtures were all superimposable with those
of the corresponding aptamer alone.
Manual Synthesis and Characterization of V35 and
V35-Fluo. The peptide synthesis (Scheme S-1) was done
manually using the Fmoc chemistry solid phase approach on a
2-chlorotrityl Resin (0.312 g, 0.8 mmol/g), swelled for 30 min
in DCM.29,30 The ﬁrst coupling was carried out using 1.0 equiv
of Nα-Fmoc-Cys(Trt)-OH, dissolved in 5 mL of DCM. The
amino acid solution was added to 2-chlorotrityl Resin. To this
mixture was added 1.0 equiv of DIEA, agitated in the shaker for
10 min, and then was added 1.5 equiv of DIEA. The mixture
was agitated vigorously for 60 min. To end-cap any remaining
reactive 2-chlorotrityl groups, a mixture of DCM/MeOH/
DIEA (80%:15%:5%) was added and mixed for 30 min. For
removing the Fmoc protecting group from the ﬁrst amino acid,
the resin was suspended in a 25% solution of piperidine in
DMF (1 × 5 min and 1 × 20 min). The following protected
amino acids were then added stepwise, Nα-Fmoc-His(Trt)-OH,
Nα-Fmoc-Ala-OH, Nα-Fmoc-Gln(Trt)-OH, Nα-Fmoc-Arg-
(Pbf)-OH, Nα-Fmoc-Ile-OH, Nα-Fmoc-Asp(OtBu)-OH, Nα-
Fmoc-Gly-OH, Nα-Fmoc-Glu-OH, Nα-Fmoc-Thr(tBu)-OH,
Nα-Fmoc-Tyr(tBu)-OH, Nα-Fmoc-Phe-OH, Nα-Fmoc-Lys-
(Boc)-OH, Nα-Fmoc-His(Trt)-OH, Nα-Fmoc-Asn(Trt)-OH,
Nα-Fmoc-Asp(OtBu)-OH, and Nα-Fmoc-Cys(Trt)-OH. Each
coupling reaction was accomplished using a 3-fold excess of
amino acid with HBTU and HOBt in the presence of DIEA.
The Nα-Fmoc protecting groups were removed by treating the
protected peptide resin with a 20% solution of piperidine in
DMF (1 × 5 min and 1 × 20 min). The peptide resin was
washed three times with DCM, and the next coupling step was
initiated in a stepwise manner. The peptide resin was washed
with DCM (3×) and DMF (3×), and the deprotection
protocol was repeated after each coupling step. The N-terminal
Fmoc group was removed as described above. Fluorescein 5-
carboxyﬂuorescein, coupling on the free N-terminal in V35-
Fluo, was carried out using 1.5 equiv of 5-FAM and 3.0 equiv of
DIPEA in DCM:DMF 1:1 by volume. The peptide was released
from the resin with TFA/Et3SiH/H2O 90:5:5 for 3 h. The resin
was removed by ﬁltration, and the crude peptide was recovered
by precipitation with cold anhydrous ethyl ether to give a white
powder which was puriﬁed by RP-HPLC on a semipreparative
C18-bonded silica column (Phenomenex, Jupiter 4 μ Proteo 90
Å, 1.0 × 25 cm) using a gradient of CH3CN in 0.1% aqueous
TFA (from 10% to 90% in 40 min) at a ﬂow rate of 5.0 mL/
min. The product was obtained by lyophilization of the
appropriate fractions after removal of the CH3CN by rotary
evaporation. Analytical RP-HPLC (Figure S-5) indicated for all
synthesized compounds a purity of >95%, and the correct
molecular weights were conﬁrmed by MALDI-TOF-MS; V35:
puriﬁed purity: 95.83%; tR: 8.992 (analytical μHPLC, 10% to
90% acetonitrile in water (0.1% TFA) over 25 min, ﬂow rate of
1.0 mL/min); MALDI-TOF-MS for chemical formula
C166H269N57O49S2, calculated mass m/z [M + H]
+ 3912.21,
found 3912.45. V35-Fluo: puriﬁed purity: 95.45%; tR: 9.512
(analytical μHPLC, 10% to 90% acetonitrile in water (0.1%
TFA) over 25 min, ﬂow rate of 1.0 mL/min); MALDI-TOF-
MS for chemical formula C187H279N57O55S2, calculated mass m/
z [M + H]+ 4270.32, found 4270.73.
Fluorescence Measurements. 50 μL of a ﬁnal solution
containing 50 nM V35-Fluo or V35-Fluo-oxi in K+ buﬀer (10
mM KH2PO4 aq. solution containing 90 mM KCl, pH 7.0) was
incubated in 96 well black Optiplates (PerkinElmer) with or
without the indicated amount of aptamers. Five minutes after
the incubation, the plates were inserted in a 2104 Envision
Multilabel plate reader (PerkinElmer). Each sample was excited
with Envision ﬁlter 102 (485 ± 14 nM; 60% T) (PerkinElmer)
and ﬂuorescence ﬁltered with an emission ﬁlter Envision ﬁlter
206 (535 ± 25 nM; 50% T) (PerkinElmer) using a normal top
mirror. For the time course experiments, the measurements
were done in a continuous mode with time intervals of 0.5 min.
After 5 and 50 min, the indicated amount of 1−5 and V35 or
V35-oxi (25 μM) dissolved in K+ buﬀer was added to each well,
respectively. The addition was performed using the automatic
liquid dispenser of the Envision. Plots were ﬁtted in Prism5
(GraphPad Software Inc., La Jolla, CA) using an inhibition
sigmoidal curve to calculate IC50.
Oxidation of V35-Fluo with DTT/DIA. A ﬁnal concen-
tration of 2 mM of DL-dithiothreitol (DTT) was added to a
solution containing 60 μM of V35-Fluo. The solution was
gently stirred for 2 h to obtain the preliminary intermolecular
and intramolecular disulﬁde bridges reduction. The sample was
then treated with 4 mM of the oxidizing agent N,N,N′,N′-
tetramethylazodicarboxamide (DIA) and analyzed by RP-
HPLC on a semipreparative C18-bonded silica column
(Phenomenex, Jupiter 4μ Proteo 90 Å, 1.0 × 25 cm) using a
gradient of CH3CN in 0.1% aqueous TFA (from 10% to 90% in
40 min) at a ﬂow rate of 5.0 mL/min to compare the retention
times before and after the treatment with the reducing and
oxidizing reagents (Figure S5).
Docking Protocol. The HIV gp120 protein structure was
downloaded by the Protein Data Bank (PDB ID 2B4C). The
molecular models of TEL−ODNs were manually generated
using the InsightII suite of programs (Accelrys, Inc.). The
Biopolymer module was employed to make the quadruplexes;
the Builder module was used to add the modiﬁed linkers at 3′-
and 5′-ends, and the Discovery3 module was applied to bring
the molecular models to their energetically minimized
structures after parametrization with the AMBER force ﬁeld.
The minimization steps were performed with a distance-
dependent macroscopic dielectric constant of 4.0 and an
inﬁnite cutoﬀ for nonbonded interactions, using 1000 cycles of
the steepest descent method followed by conjugate gradient
calculation until convergence at 0.1 rms was reached. Notably,
the Hoogsteen H-bonds maintaining the geometry of the G-
tetrads of 1 and 2 were kept during the minimization
procedure. Conversely, those of the G-tetrads of 3 were lost,
because they were aﬀected by the presence of the TEL at the
3′-end and TBDPS groups at the 5′-end. The ZDOCK server
(http://zdock.umassmed.edu)22 was used to perform all the
dockings between the TEL−ODNs and the V3 loop in gp120.
The program uses a fast Fourier transform to perform a 3D
search of all possible binding modes in the translational and
rotational space between the two molecules and evaluates each
pose by utilizing a pairwise statistical potential in the scoring
function. The resulting output is a list of transformation values,
from which models can be generated.31 A list of 2000
transformations was calculated for each docking, ranked on
the basis of the internal scoring functions, and presented
through a global energy term. The best solution from each dock
was taken into account, and to relieve any steric clashes that
might have arisen in docking, the chosen models underwent a
further minimization process with no restraints. Finally, the
PyMOL Molecular Graphics System (Version 1.5.0.4 Schrö-
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dinger, LLC) was used to visualize the binding between protein
and aptamer and to deﬁne their electrostatic interactions.
Anti-HIV Activity Assays. Inhibition of HIV-1(IIIB)- and
HIV-2(ROD)-induced cytopathicity in CEM cell cultures was
measured in microtiter 96-well plates containing ∼3 × 105
CEM cells/mL infected with 100 CCID50 of HIV per milliliter
and containing appropriate dilutions of the test compounds.
After 4−5 days of incubation at 37 °C in a CO2-controlled
humidiﬁed atmosphere, CEM giant (syncytium) cell formation
was examined microscopically (Figure S-6). The EC50 (50%
eﬀective concentration) was deﬁned as the compound
concentration required to inhibit HIV-induced giant cell
formation by 50%.
Cocultivation Assays. After washing persistently HIV-1-
infected Hut-78/HIV-1 cells to remove free virions, 105 Hut-
78/HIV-1 cells were added to 105 SupT1 cells in 200 μL wells
of a 96-well plate. The appropriate concentrations of the test
compounds were added at 5-fold serial dilutions ranging
between 100 and 0.006 μg/mL. After 20 h of incubation at 37
°C, the cells were microscopically examined for syncytia
formation. The EC50 was calculated as the concentration of an
agent required to suppress syncytia formation by 50%.
■ RESULTS AND DISCUSSION
Using our new screening platform, we here measured the
activity of three shorter analogues of 4 in which the four
TGGGGG strands were shortened by one, two, or three
guanosines (1−3 in Figure 1, respectively) to ease their
synthetic production on larger scale. At ﬁrst, we started
anticipating the binding of the putative TEL−aptamers 1−3 to
the V3 loop by performing an in silico molecular study by
docking 1−3 to the V3 loop of gp120 (PDB ID 2B4C)13 using
the ZDOCK server.22 The results showed that 1−3 can indeed
bind the V3 loop by direct interaction of the phosphate
backbone atoms and the heteroatoms of the guanines. In
particular, in all the complexes, the phosphates of three
diﬀerent strands interact with the side chains of Thr195,
Thr194, and Tyr193 deﬁning a common binding site (Figure
2). Furthermore, the side chain of Arg181 plays a key role for
the speciﬁcity of the binding, being the only one to interact
directly with the guanines involved in the formation of G-
tetrads. Additional H-bond and electrostatic interactions,
responsible for the diﬀerent interaction energies of the three
complexes, are listed in Table S-1. The results of the
computational docking study conﬁrmed in full the aptness of
1−3 to bind the V3 loop and gave us conﬁdence about their
potentiality as new anti-HIV aptamers.
Accordingly, TEL−aptamers 1−3 were synthesized and
puriﬁed following a previously described procedure,21 and
CD and NMR measurements were performed to assess
whether the reduction in the ODN length aﬀected the ability
of 1−3 to fold into the expected parallel TEL-G4s. Before
measurements, the samples were annealed in 100 mM K+ buﬀer
and stored at 4 °C overnight. The NMR (Figure S-1) and CD
spectra (Figure S-2) of 1 and 2 supported the presence in
solution of parallel G4s, whereas the data did not conﬁrm the
ability of 3 to fold into the desired G4 structure, at least in the
used annealing buﬀer. In fact, the characteristic imino proton
signals (10−12 ppm) of the exchange-protected imino protons
of guanosines involved in the formation of G-tetrads,23 and CD
proﬁles having a minimum at about 240 nm and a maximum at
about 260 nm, indicative for the presence in solution of parallel
G4 species,24 were observed only in the NMR and CD spectra,
respectively, of TEL−ODNs 1 and 2.
Diﬀerently from the existing screening platforms that use the
full-length gp120 to measure the binding aﬃnity of new
aptamers, we attempted to assess the aﬃnity of 1−3 for gp120
by using a 35 amino acids long peptide (V35 in Figure 1), as a
Figure 2. Molecular models of the interactions between aptamers 1−3
and the V3 loop of gp120. The aptamers are drawn as lines; the V3
loop is shown as a cartoon, and hydrogen bonding interactions
between the V3 loop and the aptamers are drawn as dashed lines.
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synthetic mimic of the V3 loop, using a ﬂuorescence quenching
assay.25 Hence, ﬂuorescein isothiocyanate (FITC) was installed
at the N-terminal cysteine of V35 to give the ﬂuorescently
labeled peptide V35-Fluo as described in Scheme S-1. The
amino acids sequence we chose for V35-Fluo matched that of
the V3 loop used for the docking simulations. V35 and V35-
Fluo were manually synthesized using the Fmoc-based solid
phase approach, puriﬁed by RP-μHPLC, and characterized by
electrospray mass spectrometry.
Equilibrium and kinetic binding experiments were initially
performed by incubating V35-Fluo with 4, whose binding with
the gp120 V3 loop was already studied by SPR.21 In the
presence of 4, the ﬂuorescence signal of V35-Fluo decreased
compared to that of the same amount of peptide dissolved in
pure buﬀer (Figure 3a). Fluorescence quenching could be
ascribed speciﬁcally to V35-Fluo binding to the aptamer since,
in the presence of an excess of unconjugated V35, the
ﬂuorescence signal of V35-Fluo was not aﬀected by the
addition of 4 (Figure 3a). Quenching (or increase) in
ﬂuorescence of a FITC tagged molecule can be expected
upon an event of binding mainly because of the change in the
environment surrounding the ﬂuorescence moiety and thus
aﬀecting its emission. Speciﬁc binding (amount of V35-Fluo
ﬂuorescence recovered upon addition of an excess of V35) was
measured for several dilutions of 4 and resulted in an
equilibrium Kd value of 0.63 ± 0.13 μM for V35-Fluo (Figure
3b). The binding of 4 to V35-Fluo was also measured in a time
course experiment at 0.5 min time intervals. Upon addition of 4
(Time 0; Figure 3c), a decrease in ﬂuorescence was observed.
Then, V35 was added (Time 1) to displace 4 speciﬁcally bound
to V35-Fluo. As already seen with the measurements at
equilibrium, the addition of V35 allowed V35-Fluo to regain its
original ﬂuorescence. The half time needed to displace 4 by
V35-Fluo directly correlates to its apparent koff rate (eq 1 in
Figure 3). koff rate of displacement resulting from our
measurement was 0.17 ± 0.05 min−1. kobs directly correlates
with the half time of association of 4 and together with the
measured koff can be used to calculate the apparent kon and Kd
(eq 2−4 in Figure 3). Kon and Kd measured by kinetic
measurements were 0.20 ± 0.01 μM−1 min−1 and 0.85 ± 0.21
μM, respectively.
Given the positive outcome from pilot experiments on 4,
V35-Fluo was used to estimate the aﬃnity of the new aptamers
1−3 for the V3 loop of gp120. The ﬂuorescent assay was also
performed on 5, a quadruplex forming analogue of 1−3 lacking
marked anti-HIV activity,21 and the speciﬁc binding and
Figure 3. Aﬃnity of 4 for V35-Fluo. Equilibrium binding: (a) 50 nM V35-Fluo, 10 μM 4, and 25 μM V35 were mixed according the scheme.
Speciﬁc binding correlates with the amount of V35-Fluo ﬂuorescence dequenched in the presence of an excess of V35. (b) V35-Fluo was incubated
with the indicated concentration of 4. Speciﬁc binding values (normalized to the maximum response) are plotted vs concentration of the aptamer.
Kinetic binding: (c) Binding of 4 to V35-Fluo was measured in a time course experiment. At time 0, 4 (10 μM) was added to V35-Fluo (50 nM)
and ﬂuorescence was recorded at 0.5 min time intervals. Then, V35 (25 μM) was added (Time 1) to displace 4 speciﬁcally bound to V35-Fluo
(association plateau, pass, and dissociation plateau, pdiss, are indicated).
Table 1. Equilibrium Binding Parameters (Kd, μM) of TEL−ODNs 1−5 for V35-Fluo and V35-Fluo-oxi
peptide 1 2 3 4 5
V35-Fluo 0.79 ± 0.16 1.26 ± 0.47 10.0 ± 2.1 0.63 ± 0.13 ≫10
V35-Fluo-oxi 0.20 ± 0.07 0.20 ± 0.04 0.50 ± 0.25 0.10 ± 0.02 6.3 ± 2.3
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equilibrium Kd of 1−3 and 5 were obtained as done for 4. The
results shown in Table 1 and in Figure S-3 indicated that 1 and
2 retain almost the same binding aﬃnity as 4 for V35-Fluo,
whereas weaker speciﬁc binding and higher Kd values were
found for 3 and 5.
Despite the ﬂuorescence assay set on synthetic V35-Fluo
discriminated well among aptamers binding to gp120 with high
or low aﬃnity, the Kd measured for 4 was somehow higher than
that measured by SPR for the full length gp120 (0.8 vs 0.2
μM).21 We thought that one of the possible reasons for this
decreased aﬃnity could have been the 3D conformation
adopted by V35-Fluo in solution. In fact, in the crystal
structure 2B4C, the V3 loop acquires a hairpin conformation
stabilized by a disulﬁde bond (Cys173 and Cys207). This
arrangement could inﬂuence the binding site for the aptamer
that in turn could bind better to a structured than to an
unstructured V3 loop. To stabilize V35-Fluo in a conformation
similar to the one adopted in the full-length gp120, we oxidized
V35-Fluo in a redox dithiothreitol/diamide (DTT/DIA) buﬀer
in an attempt to create a disulﬁde bond between Cys1 and
Cys35 (V35-Fluo-oxi).
As shown by the chromatographic proﬁle in Figure S-4, V35-
Fluo-oxi runs as a discrete monomeric peak proving the
oxidation reaction successful and excluding the presence of
covalently linked dimers, oligomers, and aggregates. Then, we
measured the aﬃnity of V35-Fluo-oxi for 1−5. While the
aﬃnity for 5 was still very low, the aﬃnities (Kd values) of the
oxidized peptide for 1−4 were much higher than those of the
untreated peptide (Figure 4 and Table 1), thus conﬁrming the
preference of the aptamers to interact with the V35-Fluo
peptide endowed with a speciﬁc conformation. In particular,
after the oxidation of V35-Fluo, the binding aﬃnity of 1 and 2
for V35-Fluo-oxi reached that of the parent aptamer 4
previously measured by SPR.
The anti-HIV activity of 1−3 against HIV-1 and HIV-2 was
determined in vitro by measuring the concentration of aptamer
required to reduce the virus-induced cytopathicity by 50%
(EC50) in human CD4
+ T-lymphocyte CEM cell cultures. All
shorter analogues of 4 retained a potent anti-HIV activity, with
EC50 values in the submicromolar range (see Table 2). It is
noteworthy that, in agreement with the molecular docking and
ﬂuorescence quenching studies, also the shortest aptamer 3 still
displayed a submicromolar anti-HIV activity (EC50 = 0.74 μM),
notwithstanding its CD and NMR spectra did not conﬁrm the
structuration into a stable G4 structure. Considering that in a
previous paper21 we demonstrated that neither the TEL nor the
TBDPS groups themselves, but the formation of a stable G4, is
responsible for the anti HIV activity of TEL analogues of the
Hotoda’s aptamer, the latter observation suggests that 3 could
ﬁnally fold into the bioactive G4 in the presence of the full
Figure 4. Aﬃnity of TEL−ODNs 1−5 for reduced V35-Fluo (red, empty circles) and oxidized V35-Fluo-oxi (oxi, full circles).
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gp120 protein. 1−3 were also evaluated for their inhibitory
activity against the syncytia formation in cocultures of
persistently HIV-1-infected HUT-78/HIV-1 cells and CD4+
T-lymphocyte SupT1 cells. 1 and 2 markedly inhibited the
syncytia formation in the low micromolar range.
In conclusion, we here propose a new screening platform
toward aptamers targeting the HIV gp120. Candidates are
selected and ranked by molecular docking simulations and
assayed for their binding aﬃnity to the V3 loop of gp120 using
a ﬂuorescence quenching assay. Three new shorter analogues
(1−3) of the anti-HIV aptamer 4 were synthesized and tested.
Although the anti HIV activities of 1−3 were not higher than
that of their precursor 4, the almost perfect correspondence
between the calculated binding aﬃnities and the experimental
EC50 values in HIV-infected cells conﬁrmed in full the reliability
of this rapid and cost-eﬀective alternative to the existing
methods for selecting new aptamers and measuring aptamer−
protein equilibria.
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Synthesis of C6-Pyridylpurine Nucleosides by Reaction of Nebularine N1-Oxide
with Pyridinyl Grignard Reagents
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A general synthesis of C6-pyridylpurine nucleosides is de-
scribed. The reported synthetic procedure exploits the
regioselective addition of pyridinyl Grignard reagents,
obtained by bromine/magnesium exchange between mono-
or dihalopyridines and iPrMgCl, to the C6–N1–O– moiety of
nebularine N1-oxide. The regioselective transmetallation of
Introduction
Natural nucleosides and nucleotides play a central role
in cell metabolism and in signal transduction, acting as syn-
thetic precursors and regulatory agents. In addition, they
are substrates of polymerases and, in some cases, can con-
trol the activity of these enzymes so as to regulate nucleic
acid construction. Several nucleoside and nucleotide ana-
logues have been approved for the treatment of viral dis-
eases and some of them are in clinical trials for cancer treat-
ment.[1] Therefore the preparation of modified nucleosides
and nucleotides continues to attract the interest of chemical
and biomedical research. Modifications of nucleobases can
affect the hydrogen-bonding patterns and base-pairing in
nucleic acids or confer on them peculiar properties such as
fluorescence, which allows monitoring of their fate in cells
and analysis of DNA and RNA structures.[2] Purine nucleo-
sides bearing a C substituent at C-6 represent an important
subclass of nucleoside analogues possessing a broad spec-
trum of biological activities[3] and this has prompted syn-
thetic efforts towards these substances. The introduction of
C substituents at C-6 in the purine nucleus has been mostly
accomplished by metal-mediated cross-coupling processes
starting from 6-halopurines,[3b,4] whereas N, O, and S sub-
stituents have been introduced by direct nucleophilic aro-
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unsymmetrical dihalopyridines with iPrMgCl allowed C6-
halopyridylpurine nucleosides to be obtained through the
addition of halopyridinyl Grignard reagents. The presence of
a halogenated pyridine ring in these nucleosides allows for
further useful synthetic transformations.
matic substitution.[5] We have recently discovered a new ap-
proach to accessing C6-alkyl/aryl nucleosides. In particular,
we observed that the sugar-protected nebularine N1-ox-
ide[6a] (1, Scheme 1) can regioselectively react with Grignard
reagents at the more electrophilic C-6 position leading to
adduct 2, which is re-aromatized by treatment with Ac2O/
pyridine to furnish the C6-substituted purine nucleoside 3
in high yields. We have also shown that a second alkyl/aryl
substituent can be introduced at C-2 by a similar strategy,
that is, by the addition of a Grignard reagent to the C6-
substituted nebularine N1-oxides 4 through the opening/re-
closing of the pyrimidine ring induced by the Grignard rea-
gent itself. Through this approach we have synthesized new
collections of 6-alkyl(aryl)purine nucleosides 3 and 2,6-di-
alkyl(aryl)purine nucleosides 5.[6]
Scheme 1. Reaction of nebularine N1-oxide 1 with Grignard rea-
gents. Functionalization of the C-6 and C-2 positions of the purine.
C6-Pyridinyl nucleosides are appealing nucleoside ana-
logues because the presence of a nitrogen atom in the C-6
residue can potentially alter the hydrogen-bonding capabili-
ties of the nucleoside as well as promote its coordination to
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biologically important metals, such as platinum and ruth-
enium.[7] In addition, a number of pharmaceuticals, natural
products, and active products for agriculture are pyridine
derivatives.[8] However, the introduction of a pyridinyl resi-
due at the C-6 position of purine nucleosides has scarcely
been studied. As far as we know, the only known substances
of this type are 6-(2-pyridyl)nebularine and the nucleotide
corresponding to 6-(5-bromo-3-pyridyl)nebularine (see 9a
and 9e in Table 1), both displaying interesting biological ac-
tivities. These compounds were synthesized by the Pd-cata-
lyzed cross-coupling of 6-chloropurine riboside with Rieke
organozinc reagents[9] and 5-bromopyridine-3-boronic
acid,[10] respectively. However, Hocek et al. reported the
failure to introduce 3- and 4-pyridyl residues at C-6 by
Suzuki–Miyaura coupling with the more reactive catalytic
system Pd(OAc)2/2-(dicyclohexylphosphanyl)biphenyl.[11]
These precedents and the lack of a general synthetic
procedure for obtaining C6-pyridylpurine nucleosides
prompted us to explore the addition of pyridinyl Grignard
reagents 7a–h (Scheme 2) to nebularine N1-oxide (1) by
using our procedure. We report here that it can be success-
fully applied to the synthesis of various C6-pyridinyl nucleo-
sides 9a–c and C6-halopyridinyl nucleosides 9d–h (Table 1)
in moderate-to-good yields.
Table 1. Product yields of compounds 9a–j.
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Results and Discussion
The required pyridinyl Grignard reagents 7a–h (Table 1)
were prepared by bromine/magnesium exchange between
bromopyridines 6a–h and iPrMgCl (Scheme 2). This pro-
cedure has previously been efficiently employed by Trécourt
et al. for the transmetallation of 2-, 3-, and 4-bromopyr-
idines, as well as for the regioselective transmetallation of
2,3-, 2,5-, 2,6-, and 3,5-dibromopyridines to obtain various
pyridinyl Grignard reagents.[12] Our general strategy for the
bromine/magnesium exchange makes use of a 1:1 ratio of
iPrMgCl and bromopyridines 6a–h (2 h at room temp.).
The complexes 7a–h (5 equiv.) obtained in this way were
added in one portion to 1 and the reaction mixtures
were left at room temp. for 2 h. After work-up (see
the Exp. Sect.), the crude products 8a–h were treated with
Ac2O/pyridine to form the purine rings 9a–h by re-aromati-
zation.
Scheme 2. Reagents and conditions: i) iPrMgCl, THF, 2 h, room
temp., N2; ii) 7a–h, THF, 2 h, room temp., N2; iii) Ac2O/pyridine
(4:6, v/v), 1 h, 50 °C.
Reactions of Bromopyridines 6a–c
Following our procedure, the 2-pyridyl residue could be
easily introduced at the C-6 purine position by the reaction
of 1 with 2-pyridylmagnesium chloride (7a, Table 1), and
compound 9a was obtained in a yield higher than pre-
viously reported (55%, reported 27%).[9] Compound 9b,
embodying a 3-pyridyl residue, was obtained by treating 1
with 3-pyridylmagnesium chloride (7b). The process pro-
ceeded smoothly and the product was obtained in 60%
yield. In contrast, 4-brompyridine (6c) is an unstable com-
pound and has to be prepared immediately prior to use by
neutralization of the corresponding hydrochloride salt
(commercially available). Initially we used the recom-
mended procedure in which the hydrochloride salt is treated
with a 5% aqueous Na2CO3 solution, followed by extrac-
tion with Et2O, and drying with MgSO4.[12] Disappoint-
ingly, 4-bromopyridine prepared in this way, when treated
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with iPrMgCl, gave a very low yield of the corresponding
Grignard reagent 7c, as suggested by its unproductive reac-
tion with 1.
We ascribed this failure to the difficulty in obtaining very
dry 4-bromopyridine after aqueous treatment and drying
with MgSO4. On the other hand, bromopyridine is a vola-
tile liquid and it could not be dried effectively under re-
duced pressure. We succeeded in obtaining 4-bromopyr-
idine suitable for the preparation of the Grignard reagent
by treatment of its hydrochloride salt with 1 equiv. of NaH
in dry THF. The pyridine 6c obtained was transmetallated
in situ by the addition of iPrMgCl to give the 4-bromopyr-
idinyl Grignard reagent 7c, which was immediately treated
with 1. By this procedure, compound 9c was obtained in
55% yield, which compares well with the yields of 9a and
9b. Therefore the 3- and 4-pyridyl nucleosides 9b and 9c
could be synthesized by our procedure, whereas the Suzuki–
Miyaura coupling reaction was unsuccessful.[11]
Reactions of Dihalopyridines 6d–h
Halopyridines are known to undergo a number of useful
synthetic transformations.[13] Therefore the introduction of
a halopyridine ring at the C-6 position of a purine nucleo-
side would allow its further synthetic elaboration. Thus, di-
bromopyridines 6d–g and the 2-chloro-3-bromopyridine
(6h) were transmetallated with iPrMgCl, as described for
bromopyridines 6a–6c, to furnish the corresponding Grig-
nard reagents 7d–h. Bromopyridinyl nucleosides 9d and 9e
were obtained from symmetrical dibromopyridines 6d and
6e in yields of 50 and 60%, respectively, on coupling with
1. The fully ribose-deprotected compound 9e was recently
prepared by the reaction of 6-chloropurine riboside under
Suzuki–Miyaura cross-coupling conditions in 40% yield.
Interestingly, its nucleotide derivative was active towards
human and rat DNHP1 enzymes, showing itself to be a
competitive inhibitor of dGMP binding with a micromolar
affinity.[10]
Grignard reagents prepared in the usual manner from
unsymmetrical 2,5- and 2,3-dibromopyridines 6f and 6g
and used in the coupling/aromatization sequence afforded
compounds 9f and 9g, respectively, which were analyzed by
2D NMR experiments. In particular, the correlations ob-
served in the HMBC spectrum of 9f between the 2-H and
4-H protons of the pyridine ring, which resonate at δ =
10.2 and 8.86 ppm, respectively, and C-6 at δ = 152.2 ppm
of the purine nucleus (Figure 1) clearly indicate the forma-
tion of the C3–C6 bond during the coupling step. This
confirms the expected preferential transmetallation at C-5
of the 2,5-dibromopyridine ring. On the other hand, in the
case of compound 9g, a significant correlation in the
HMBC spectrum was seen between the 4-H proton at δ
= 8.00 ppm and the C-6 purine carbon at δ = 156.5 ppm
(Figure 1), which indicates the connection C3–C6 in this
compound and, accordingly, confirms the preferential
transmetallation at C-3 of the 2,3-dibromopyridine ring.
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Figure 1. HMBC correlations between 4-H, 2-H and C-6 for 9f
and 4-H and C-6 for 9g.
In addition, we tested the preparation and reactivity of
the Grignard reagent 7h obtained from 3-bromo-2-chloro-
pyridine (6h). The transmetallation of the latter proved to
be chemoselective giving the 2-chloro-3-pyridinyl Grignard
reagent and then compound 9h, which was obtained in 65%
yield on reaction with 1. In an attempt to further expand
the scope of the process and access new C6-heteroaryl
nucleosides, we tested the introduction at this position of a
quinolyl residue. Purine ribonucleosides bearing a quinoline
ring at C-6 are unprecedented. Application of the strategy
used for bromopyridines was initially attempted and the re-
quired Grignard reagents were prepared in the usual man-
ner by treating 2-bromoquinoline (6i) and 3-bromoquinol-
ine (6j) with iPrMgCl (1 equiv.). However, the subsequent
reaction with 1 gave complex reaction mixtures from which
the expected C6-quinolyl derivative 9i was obtained in 20%
yield after purification, whereas no compound correspond-
ing to 9j could be recovered. We attributed these unsatisfac-
tory results to the low-yielding formation or the absence of
any formation of Grignard reagents 7i and 7j, respectively.
In fact, it is reported that bromoquinolines preferably un-
dergo nucleophilic attack at C–Br rather than transmetalla-
tion due to the low energy of their LUMO levels.[14] An
alternative approach to the use of quinolyl Grignard rea-
gents exploits the reactivity of lithium tri(quinolyl)magnes-
ate complexes, obtained by the transmetallation reaction of
lithium tributylmagnesate and 2- or 3-bromoquinolines, a
procedure reported to yield C-functionalized quinolones.[14]
Disappointingly, by using this procedure (data not shown),
we could not improve on the yield of compound 9i, and
again the formation of compound 9j was not observed in
this case. The structures of all the synthesized compounds
were ascertained by spectroscopic investigations (1H and
13C NMR, UV, IR, and MS data).
Conclusions
In this paper we describe the synthesis of a collection of
C6-pyridylpurine ribonucleosides exploiting the electro-
philicity of the C-6 purine position of the sugar-protected
nebularine N1-oxide towards a series of pyridinyl Grignard
reagents, prepared by transmetallation reactions between
iPrMgCl and mono- and dihalopyridines. The bromine/
magnesium exchange reactions proved to be regioselective
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when using unsymmetrical dihalopyridines, allowing
bromo- and chloropyridylpurine nucleosides to be ob-
tained. The presence of a halogen atom on the pyridinyl
residue in the latter allows for further synthetic elaborations
towards more diverse substituted nucleosides. An attempt
to extend the synthetic strategy to the preparation of un-
precedented C6-quinolylpurine nucleosides was also made
by using 2- and 3-bromoquinolines; a C6-(2-quinolyl)purine
nucleoside was obtained, but in a low yield. This result,
although unsatisfactory, is promising and prompts further
efforts towards the synthesis of this type of substance. Stud-
ies are ongoing in our laboratories both towards this goal
and to explore the reactivity of the halogenated pyridine
ring in the newly prepared nucleosides.
Experimental Section
General Methods: All the reagents were obtained from commercial
sources (Sigma–Aldrich) and were used without further purifica-
tion. 1H and 13C NMR spectra were acquired with a Varian Mer-
cury Plus 400 MHz spectrometer in CD3OD or C6D6. Chemical
shifts (δ) are reported in parts per million (ppm) relative to the
residual solvent signals: CD2HOD 3.31 ppm, C6D5H 7.15 ppm for
1H NMR; CD3OD 49.0 ppm, C6D5H 128.6 ppm for 13C NMR.
The 1H NMR chemical shifts were assigned on the basis of 2D
NMR experiments. The abbreviations s, d, dd, and m represent
singlet, doublet, doublet of doublets, and multiplet, respectively.
UV spectra were recorded with a Jasco V-530 UV spectrophotome-
ter. High-resolution MS spectra were recorded with a Bruker
APEX II FT-ICR mass spectrometer using the electrospray ioniza-
tion (ESI) technique in positive mode. IR spectra were recorded
with a Jasco FT-IR 430 spectrophotometer. Optical rotations were
determined with a Jasco polarimeter using a 1-dm cell at 25 °C;
concentrations are given in g/100 mL. Column chromatography
was performed on silica gel 60 (70–230 mesh ASTM, Merck) and
analytical TLC analyses were performed on F254 silica gel plates
(0.2 mm thick, Merck) with TLC spots being detected under UV
light (254 nm).
General Procedure for the Reaction of 1 with Grignard Reagents
7a–i. Synthesis of 9a–i: In a representative experiment, iPrMgCl
(0.12 mL, 0.24 mmol) was added to 2-bromopyridine (6a;
0.023 mL, 0.24 mmol) in dry THF (0.5 mL) at room temperature
under nitrogen. After 2 h, 1 (30 mg, 0.049 mmol) dissolved in dry
THF (0.5 mL) was added to the reaction mixture, which was then
stirred for a further 2 h (TLC monitoring: hexane/AcOEt, 3:7) at
room temperature. The reaction was then quenched by the addition
of a 1 m solution of NH4Cl (1 mL), diluted with AcOEt (10 mL),
and washed with brine (10 mL). The organic layer was separated,
dried (Na2SO4), filtered, and concentrated under rotary evapora-
tion. The crude 8a was dissolved in a mixture of Ac2O/pyridine
(4:6, 0.5 mL) and the solution kept at 50 °C for 1 h (TLC monitor-
ing: AcOEt/MeOH, 9.5:0.5). The mixture was evaporated in vacuo
and purified on a column of silica gel eluted with increasing
amounts of MeOH in AcOEt (up to 5%). The fractions containing
the product were collected and evaporated to afford pure 9a.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(3-pyridyl)nebularine (9b):
TLC monitoring (hexane/AcOEt, 1:1), purification through a col-
umn of silica gel eluted with increasing amounts of AcOEt in hex-
ane (up to 30%). Amorphous solid (19 mg, 60%). [α]D = –42.0 (c
= 1.1, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 9.92–9.88 (m,
1 H, arom.), 9.18–9.13 (m, 1 H, arom.), 9.0 (s, 1 H, 2-H), 8.75 (s,
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1 H, 8-H), 8.72–8.69 (m, 1 H, arom.), 7.69–7.63 (m, 1 H, arom.),
6.21 (d, J = 5.6 Hz, 1 H, 1-H), 4.95–4.90 (m, 1 H, 2-H), 4.49–
4.44 (m, 1 H, 3-H), 4.20–4.15 (m, 1 H, 4-H), 4.09 (dd, J = 11.3,
4.6 Hz, 1 H, 5-Ha), 3.87 (dd, J = 11.3, 3.1 Hz, 1 H, 5-Hb), 0.98
[s, 9 H, C(CH3)3], 0.96 [s, 9 H, C(CH3)3], 0.78 [s, 9 H, C(CH3)3],
0.18 (s, 3 H, CH3), 0.17 (s, 3 H, CH3), 0.16 (s, 6 H, 2 CH3), –0.016
(s, 3 H, CH3), –0.28 (s, 3 H, CH3) ppm. 13C NMR (100 MHz,
CD3OD): δ = 153.8, 153.5, 152.9, 151.9, 151.3, 146.4, 138.9, 133.2,
132.9, 125.3, 89.6, 87.4, 77.1, 73.7, 63.8, 26.6, 26.4, 26.2, 19.4, 18.9,
18.7, –4.1, –4.2, –4.3, –4.9, –5.2, –5.3 ppm. IR (neat): νmax = 2950,
2923, 2857, 1577, 1465, 1320, 1256, 1127, 834, 779 cm–1. UV
(CH3OH): λmax = 288 nm. HRMS (ESI): calcd. for C33H58N5O4Si3
[M + H]+ 672.3797; found 672.3794.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(4-pyridyl)nebularine (9c):
4-Bromopyridine hydrochloride (47 mg, 0.24 mmol) was suspended
in dry THF (1 mL) under nitrogen and the mixture cooled to 0 °C.
NaH (5.8 mg, 0.24 mmol) was added in one portion and the mix-
ture stirred for 15 min. After warming to room temp., iPrMgCl
(0.12 mL, 0.24 mmol) was added as for 6a. TLC monitoring (hex-
ane/AcOEt, 6:4), purification through a column of silica gel eluted
with increasing amounts of AcOEt in hexane (up to 30%).
Amorphous solid (18 mg, 55%). [α]D = –34.3 (c = 0.5, CH3OH).
1H NMR (400 MHz, CD3OD): δ = 9.06 (s, 1 H, 2-H), 8.81–8.74
(complex signal, 5 H, 4 arom., 8-H), 6.22 (d, J = 5.6 Hz, 1 H, 1-
H), 4.95–4.91 (m, 1 H, 2-H), 4.49–4.45 (m, 1 H, 3-H), 4.20–4.17
(m, 1 H, 4-H), 4.09 (dd, J = 11.4, 4.5 Hz, 1 H, 5-Ha), 3.88 (dd, J
= 11.3, 2.9 Hz, 1 H, 5-Hb), 0.99 [s, 9 H, C(CH3)3], 0.97 [s, 9 H,
C(CH3)3], 0.79 [s, 9 H, C(CH3)3], 0.19 (s, 3 H, CH3), 0.17 (s, 3 H,
CH3), 0.16 (s, 6 H, 2 CH3), –0.009 (s, 3 H, CH3), –0.28 (s, 3 H,
CH3) ppm. 13C NMR (100 MHz, CD3OD): δ = 154.2, 153.4, 152.6,
150.8, 146.9, 144.9, 133.5, 125.0, 89.7, 87.4, 77.1, 73.7, 63.8, 26.6,
26.4, 26.2, 19.4, 18.9, 18.7, –4.1, –4.3, –4.9, –5.2, –5.3 ppm. IR
(neat): νmax = 2956, 2923, 2851, 1569, 1412, 1254, 1091, 793 cm–1.
UV (CH3OH): λmax = 290 nm. HRMS (ESI): calcd. for
C33H58N5O4Si3 [M + H]+ 672.3797; found 672.3792.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(6-bromo-2-pyridyl)nebu-
larine (9d): TLC monitoring (CH2Cl2/AcOEt, 95:5), purification
through a column of silica gel eluted with increasing amounts of
AcOEt in CH2Cl2 (up to 5%). Oil (18 mg, 50%). [α]D = –36.7 (c =
1.1, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 9.0 (s, 1 H, 2-
H), 8.88–8.84 (m, 1 H, arom.), 8.79 (s, 1 H, 8-H), 7.97–7.90 (m, 1
H, arom.), 7.80–7.75 (m, 1 H, arom.), 6.22 (d, J = 5.7 Hz, 1 H, 1-
H), 4.95–4.90 (m, 1 H, 2-H), 4.48–4.44 (m, 1 H, 3-H), 4.20–4.15
(m, 1 H, 4-H), 4.08 (dd, J = 11.3, 4.5 Hz, 1 H, 5-Ha), 3.87 (dd, J
= 11.3, 2.9 Hz, 1 H, 5-Hb), 0.98 [s, 9 H, C(CH3)3], 0.95 [s, 9 H,
C(CH3)3], 0.78 [s, 9 H, C(CH3)3], 0.17 (s, 3 H, CH3), 0.16 (s, 3 H,
CH3), 0.15 (s, 6 H, 2 CH3), –0.021 (s, 3 H, CH3), –0.29 (s, 3 H,
CH3) ppm. 13C NMR (100 MHz, CD3OD): δ = 154.8, 154.4, 153.4,
147.1, 143.6, 141.0, 133.1, 131.3, 126.8, 89.7, 87.5, 77.1, 73.7, 63.8,
26.6, 26.4, 26.2, 19.4, 19.0, 18.7, –4.1, –4.3, –4.9, –5.2 ppm. HRMS
(ESI): calcd. for C33H57BrN5O4Si3 [M + H]+ 750.2902; found
750.2907. IR (neat): νmax = 2956, 2928, 2857, 1566, 1429, 1256,
1072, 834, 790 cm–1. UV (CH3OH): λmax = 304 nm.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(5-bromo-3-pyridyl)nebu-
larine (9e): TLC monitoring (hexane/AcOEt, 8:2), purification
through a column of silica gel eluted with increasing amounts of
AcOEt in hexane (up to 10%). Oil (22 mg, 60%). [α]D = –41.6 (c
= 0.7, CH2Cl2). 1H NMR (400 MHz, C6D6): δ = 10.48–10.46 (m,
1 H, arom.), 9.49–9.46 (m, 1 H, arom.), 8.96 (s, 1 H, 2-H), 8.71–
8.68 (m, 1 H, arom.), 8.37 (s, 1 H, 8-H), 6.22 (d, J = 4.4 Hz, 1 H,
1-H), 4.95–4.90 (m, 1 H, 2-H), 4.55–4.50 (m, 1 H, 3-H), 4.29–
4.24 (m, 1 H, 4-H), 4.01 (dd, J = 11.4, 4.2 Hz, 1 H, 5-Ha), 3.72
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(dd, J = 11.4, 2.6 Hz, 1 H, 5-Hb), 1.00 [s, 9 H, C(CH3)3], 0.96 [s,
9 H, C(CH3)3], 0.91 [s, 9 H, C(CH3)3], 0.13 (s, 3 H, CH3), 0.12 (s,
3 H, CH3), 0.094 (s, 3 H, CH3), 0.078 (s, 3 H, CH3), 0.048 (s, 3 H,
CH3), –0.082 (s, 3 H, CH3) ppm. 13C NMR (100 MHz, C6D6): δ =
153.4, 153.2, 152.9, 151.7, 150.4, 144.9, 139.7, 134.1, 133.1, 121.7,
89.9, 85.9, 76.6, 72.5, 62.9, 26.8, 26.6, 26.5, 19.2, 18.9, 18.7, –3.6,
–3.9, –4.0, –4.1, –4.7, –4.8 ppm. IR (neat): νmax = 2956, 2923, 2857,
1580, 1459, 1325, 1256, 1105, 834, 779 cm–1. UV (CH3OH): λmax
= 302 nm. HRMS (ESI): calcd. for C33H57BrN5O4Si3 [M + H]+
750.2902; found 750.2898.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(6-bromo-3-pyridyl)nebu-
larine (9f): TLC monitoring (hexane/AcOEt, 85:15), purification
through a column of silica gel eluted with increasing amounts of
AcOEt in hexane (up to 10%). Amorphous solid (20 mg, 55%). [α]
D = –41.3 (c = 0.6, CH2Cl2). 1H NMR (400 MHz, C6D6): δ = 10.2
(d, J = 2.2 Hz, 1 H, arom.), 8.92 (s, 1 H, 2-H), 8.86 (dd, J = 8.4,
2.4 Hz, 1 H, arom.), 8.35 (s, 1 H, 8-H), 7.03 (d, J = 8.4 Hz, 1 H,
arom.), 6.20 (d, J = 4.2 Hz, 1 H, 1-H), 4.88–4.83 (m, 1 H, 2-H),
4.51–4.46 (m, 1 H, 3-H), 4.25–4.20 (m, 1 H, 4-H), 3.96 (dd, J =
11.5, 4.1 Hz, 1 H, 5-Ha), 3.68 (dd, J = 11.4, 2.5 Hz, 1 H, 5-Hb),
0.96 [s, 9 H, C(CH3)3], 0.93 [s, 9 H, C(CH3)3], 0.88 [s, 9 H, C(CH3)
3], 0.075 (s, 3 H, CH3), 0.067 (s, 3 H, CH3), 0.059 (s, 3 H, CH3),
0.043 (s, 3 H, CH3), 0.013 (s, 3 H, CH3), –0.10 (s, 3 H, CH3) ppm.
13C NMR (100 MHz, C6D6): δ = 153.1, 153.0, 152.8, 152.2, 145.8,
144.7, 139.6, 132.9, 131.7, 128.5, 89.9, 85.8, 76.6, 72.4, 62.8, 26.8,
26.6, 26.5, 19.3, 18.9, 18.7, –3.6, –3.9, –4.0, –4.7, –4.8 ppm. IR
(neat): νmax = 2950, 2923, 2851, 1580, 1459, 1322, 1256, 1072, 834,
773 cm–1. UV (CH3OH): λmax = 299 nm. HRMS (ESI): calcd. for
C33H57BrN5O4Si3 [M + H]+ 750.2902; found 750.2910.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(2-bromo-3-pyridyl)nebu-
larine (9g): TLC monitoring (hexane/AcOEt, 7:3), purification
through a column of silica gel eluted with increasing amounts of
AcOEt in hexane (up to 25%). Oil (18 mg, 48%). [α]D = –32.1 (c
= 0.7, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 9.05 (s, 1 H,
2-H), 8.76 (s, 1 H, 8-H), 8.54 (dd, J = 4.8, 1.8 Hz, 1 H, arom.),
8.00 (dd, J = 7.6, 1.8 Hz, 1 H, arom.), 7.63 (dd, J = 7.6, 4.9 Hz, 1
H, arom.), 6.23 (d, J = 5.9 Hz, 1 H, 1-H), 4.95–4.90 (m, 1 H, 2-
H), 4.48–4.43 (m, 1 H, 3-H), 4.22–4.16 (m, 1 H, 4-H), 4.08 (dd,
J = 11.3, 4.7 Hz, 1 H, 5-Ha), 3.88 (dd, J = 11.3, 3.0 Hz, 1 H, 5-
Hb), 0.98 [s, 9 H, C(CH3)3], 0.95 [s, 9 H, C(CH3)3], 0.78 [s, 9 H,
C(CH3)3], 0.18 (s, 3 H, CH3), 0.16 (s, 3 H, CH3), 0.15 (s, 6 H, 2
CH3), –0.012 (s, 3 H, CH3), –0.29 (s, 3 H, CH3) ppm. 13C NMR
(100 MHz, CD3OD): δ = 156.5, 153.4, 153.2, 152.1, 147.1, 141.9,
141.3, 135.2, 133.6, 124.3, 89.7, 87.8, 77.2, 73.9, 63.9, 26.6, 26.4,
26.2, 19.4, 19.0, 18.8, –4.1, –4.2, –4.3, –4.8, –5.2, –5.3 ppm. IR
(neat): νmax = 2956, 2923, 2857, 1594, 1462, 1391, 1253, 1163, 1108,
834, 774 cm–1. UV (CH3OH): λmax = 272 nm. HRMS (ESI): calcd.
for C33H57BrN5O4Si3 [M + H]+ 750.2902; found 750.2911.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(2-chloro-3-pyridyl)nebu-
larine (9h): TLC monitoring (hexane/AcOEt, 7:3), purification
through a column of silica gel eluted with increasing amounts of
AcOEt in hexane (up to 25%). Oil (22 mg, 65%). [α]D = –28.0 (c
= 0.8, CH2Cl2). 1H NMR (400 MHz, C6D6): δ = 9.12 (s, 1 H, 2-
H), 8.34 (s, 1 H, 8 H), 8.04 (dd, J = 4.8, 1.9 Hz, 1 H, arom.), 7.76
(dd, J = 7.6, 1.9 Hz, 1 H, arom.), 6.51 (dd, J = 7.5, 4.8 Hz, 1 H,
arom.), 6.24 (d, J = 4.5 Hz, 1 H, 1-H), 4.99–4.94 (m, 1 H, 2-H),
4.57–4.52 (m, 1 H, 3-H), 4.30–4.25 (m, 1 H, 4-H), 4.03 (dd,
J = 11.4, 4.4 Hz, 1 H, 5-Ha), 3.74 (dd, J = 11.4, 2.7 Hz, 1 H, 5-
Hb), 1.01 [s, 9 H, C(CH3)3], 0.94 [s, 9 H, C(CH3)3], 0.91 [s, 9 H,
C(CH3)3], 0.13 (s, 3 H, CH3), 0.12 (s, 3 H, CH3), 0.076 (s, 6 H, 2
CH3), 0.064 (s, 3 H, CH3), 0.039 (s, 3 H, CH3), –0.087 (s, 3 H,
CH3) ppm. 13C NMR (100 MHz, CD3OD): δ = 155.8, 153.1, 152.8,
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151.2, 150.9, 145.1, 141.1, 134.3, 132.3, 122.4, 89.9, 86.0, 76.6, 72.6,
63.0, 26.8, 26.6, 26.5, 19.2, 18.9, 18.7, –3.6, –3.9, –4.0, –4.2, –4.7,
–4.8 ppm. IR (neat): νmax = 2956, 2923, 2857, 1591, 1462, 1399,
1328, 1254, 1064, 834, 774 cm–1. UV (CH3OH): λmax = 273 nm.
HRMS (ESI): calcd. for C33H57ClN5O4Si3 [M + H]+ 706.3407;
found 706.3412.
2,3,5-Tri-O-(tert-butyldimethylsilyl)-6-(2-quinolyl)nebularine (9i):
TLC monitoring (hexane/AcOEt, 7:3), purification through a col-
umn of silica gel eluted with increasing amounts of AcOEt in hex-
ane (up to 30%). Oil (7.1 mg, 20%). [α]D = –39.5 (c = 0.5, CH3OH).
1H NMR (400 MHz, CD3OD): δ = 9.14 (s, 1 H, 2-H), 8.88–8.81
(complex signal, 2 H, arom., 8-H), 8.59–8.54 (m, 1 H, arom.), 8.39–
8.37 (m, 1 H, arom.), 8.05–8.03 (m, 1 H, arom.), 7.87–7.83 (m, 1
H, arom.), 7.72–7.68 (m, 1 H, arom.), 6.27 (d, J = 5.8 Hz, 1 H, 1-
H), 5.00–4.95 (m, 1 H, 2-H), 4.51–4.46 (m, 1 H, 3-H), 4.22–4.18
(m, 1 H, 4-H), 4.11 (dd, J = 11.3, 4.7 Hz, 1 H, 5-Ha), 3.90 (dd, J
= 11.3, 3.1 Hz, 1 H, 5-Hb), 0.99 [s, 9 H, C(CH3)3], 0.97 [s, 9 H,
C(CH3)3], 0.79 [s, 9 H, C(CH3)3], 0.19 (s, 3 H, CH3), 0.18 (s, 3 H,
CH3), 0.17 (s, 6 H, 2 CH3), –0.003 (s, 3 H, CH3), –0.27 (s, 3 H,
CH3) ppm. 13C NMR (100 MHz, CD3OD): δ = 154.6, 154.5, 154.4,
153.5, 149.4, 147.1, 138.5, 133.4, 131.4, 130.8, 130.1, 129.2, 128.9,
123.5, 89.7, 87.6, 77.1, 73.9, 63.9, 26.6, 26.4, 26.2, 19.4, 19.0, 18.8,
–4.1, –4.3, –4.8, –5.1, –5.2 ppm. IR (neat): νmax = 2956, 2923, 2857,
1572, 1459, 1377, 1256, 1072, 834, 779 cm–1. UV (CH3OH): λsh =
243, 257 nm. HRMS (ESI): calcd. for C37H60N5O4Si3 [M + H]+
722.3953; found 722.3960.
Supporting Information (see footnote on the first page of this arti-
cle): 1H and 13C NMR spectra of all new compounds.
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Herein, the synthesis of a nucleoside platinum(II) complex
in which a cisplatin-like unit is joined to 7-deazaadenosine
through an amino alkyl chain installed at the C6 position of
purine was explored. The capability of the new complex to
react with DNA purine bases was confirmed by a model reac-
Introduction
More than 50 years after its discovery,[1] cisplatin (1, Fig-
ure 1) is still one of the most effective drugs for the treat-
ment of several types of tumors, including testicular, ovar-
ian, bladder, cervical, and lung cancer and head and neck
carcinomas.[2] The mechanism of action of cisplatin involves
DNA as the final target. In fact, cisplatin essentially binds
the guanine bases at the N7 position and forms stable intra-
strand adducts or interstrand crosslinks that cause severe
local changes in the secondary structure of DNA.[3] This
DNA distortion hampers its binding with crucial cellular
proteins and is recognized as DNA damage that eventually
leads to cell death by apoptosis.[4] The clinical use of cispla-
tin is partially limited by intrinsic resistance of many tu-
mors and by the insurgence of acquired resistance during
treatments.[2,5] Carboplatin (2) and oxaliplatin (3), second-
and third-generation platinum-based antineoplastic agents,
respectively, have dosages and clinical administration proto-
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tion with deoxyguanosine monophosphate, whereas its anti-
proliferative activity against A549 and Cal27 human cancer
cell lines was studied by sulforhodamine B assay in compari-
son with its unplatinated precursor and cisplatin.
cols that ameliorate the quality of life of patients, even if
they do not resolve the problems of drug resistance.[6]
Figure 1. Structures of platinum drugs 1–3 and bis-platinated nu-
cleoside complexes 4 and 5 carrying purine nucleoside scaffolds.
For these reasons, research in this field is still very active,
proposing multinuclear platinum complexes[7–10] and com-
posite molecules in which the platinum complex is conju-
gated to biologically important substances, drugs, and carri-
ers.[11–18] Furthermore, thanks to the synergistic effect that
may result, tethering between biologically active molecules
and platinum units could afford novel complexes with im-
proved drug-targeting and drug-delivery properties.[12]
Nucleosides and nucleotides (NNs) and their analogues
play a key role in the regulation of cellular processes and in
signal transduction.[19–22] Furthermore, NN analogues are
Properties of a Tethered Tubercidin–PtII Complex
Scheme 1. Reagents and conditions: (i) N,O-Bis(trimethylsilyl)acetamide (BSA), trimethylsilyl trifluoromethanesulfonate (TMSOTf),
CH3CN, 2 h, 80 °C, 60%; (ii) 9, EtOH, 5 h, reflux, 80%; (iii) trifluoroacetic acid (TFA)/CH2Cl2 (1:1), 1 h, r.t., 99%; (iv) 12, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), hydroxybenzotriazole (HOBt), N,N-diisopropylethylamine (DIPEA), 16 h, r.t., 83%;
(v) MeOH, AcONa, H2/Pd/C, 2 h, r.t., 99%; (vi) MeONa, MeOH, 1 h, r.t., 95%; (vii) K2PtCl4, H2O/MeOH (1:1), 16 h, r.t., in the dark,
70%. Bz = benzoyl, Boc = tert-butoxycarbonyl.
known to inhibit the growth of several cancer lines[23–26]
and many of them are clinically used as antiviral
drugs.[27–29] Despite this, only a few platinum complexes
carrying nucleoside scaffolds have been proposed.[30–33] In
principle, a platinum complex conjugated to a biologically
active nucleoside could combine the reactivity of the plati-
num center with the pharmacological properties of the nu-
cleoside analogue (e.g., antimetabolite activity or active
transmembrane transport). However, the properties of such
a composite molecule are not predictable because each moi-
ety of the complex can strongly influence the chemical and
pharmacological behavior of the other. In this context, we
recently focused our attention on the development of new
nucleoside dinuclear platinum(II) complexes.
In particular, we synthesized bis-platinated nucleoside
complexes 4 and 5 (Figure 1)[34,35] carrying two monofunc-
tional platinum(II) centers, the first coordinating the N7
position of the purine system and the second coordinating
the terminal amino group of an alkyl chain installed on the
purine base. These substances showed moderate (or low)
antiproliferative activities upon testing against A278, HeLa,
A549, and MCF7 cell lines.
In this paper, we describe the synthesis and the prelimi-
nary biological evaluation of a novel nucleoside platinum
complex (i.e., 17, Scheme 1) carrying a neutral cisplatin unit
conjugated to the 1,2-diamine moiety of 7-deazaadenosine
(7-deaza-A) analogue 16. 7-Deaza-A (also known as tuber-
cidin) is an interesting antimetabolite endowed with antibi-
otic and antitumor properties.[36,37] In particular, tubercidin
shows significant in vitro cytotoxicity against the murine
P388 and the human lung adenocarcinoma A549 cell
lines.[38,39] In our context, the absence of the N7 purine
atom in 7-deaza-A avoids the issue of the fast reactivity of
N7 with platinum during the coordination reaction, which
thus allows the construction of a monoplatinated complex
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involving exclusively the exocyclic 1,2-diamine function of
the linker. The capability of 17 to mimic the reactivity of
cisplatin with the DNA bases was assessed by monitoring
a model reaction of 17 with deoxyguanosine 5-monophos-
phate (dGMP) by 1H NMR spectroscopy.[40,41] The prelimi-
nary information on the antiproliferative activity of 17 and
its unplatinated precursor 16 against Cal27 and A549
tumor cell lines are also reported.
Results and Discussion
Synthesis and Characterization
Our synthetic route started with the construction of bis-
halogenated 7-deazapurine-β-d-riboside 8 (Scheme 1). The
nucleoside scaffold was prepared according to a procedure
by Seela and Ming,[42] which performs the glycosylation
step by using 7-bromo-6-chloro-7-deazapurine 6 as the ag-
lycon moiety. As outlined in that paper, the presence of the
electron-withdrawing bromine atom at the C7 position of
the purine atom makes the formation of the glycosidic bond
with suitably protected ribose moiety 7 possible in good
yields and with complete β stereoselectivity. Nucleoside 8
was then treated with mono-Boc-protected 1,3-diamino-
propane unit 9 to afford derivative 10. After quantitative
removal of the Boc group (TFA in CH2Cl2), resulting nucle-
oside 11 was treated with bis-Boc-protected 2,3-diamino-
propanoic acid (racemic mixture, 12)[43] by using EDC/
HOBt as the activating agents of the carboxylic function
to give 13 (83% yield) as a mixture of diastereoisomers.
Compound 13 was then subjected to hydrogenolysis in a
Parr apparatus by using Pd/C as the catalyst to remove the
C7 bromine. It was reported that the presence of a base
(AcONa) in the reaction mixture is indispensable to neu-
tralize HBr that is formed during the reaction.[44] The
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hydrogenolysis proceeded very cleanly to give 14 quantita-
tively after a standard workup procedure. The benzoate
protecting groups were then removed from 14 with a solu-
tion of MeONa in MeOH to give 15 after chromatographic
purification (95% yield). Finally, the Boc protecting groups
in 15 were removed by TFA treatment, and the crude was
treated with a concentrated aqueous solution of NH4OH to
affording 7-deaza-A derivative 16, as the free diamine al-
most quantitatively (98%). The reaction of 16 with K2PtCl4
in a H2O/MeOH (1:1) solution gave platinum complex 17
as a pale-yellow solid that precipitated from the reaction
mixture in 70% yield.
The structures of all intermediates and of complex 17
were supported by spectroscopic analyses. High-resolution
mass spectrometry and CHN analysis further confirmed the
structure and purity of final complex 17.
NMR Spectroscopy Study of the Reactivity of 17 towards
dGMP
To assess the capability of 17 to react with the guanine
bases of DNA as a bifunctional coordinating agent, such
as cisplatin, we incubated 17 with a fourfold excess amount
of dGMP in a water buffer containing 50 mm KH2PO4 and
50 mm KCl in a NMR tube in the dark at 37 °C. It is well
known that the chemical shifts of H8 and H1 of dGMP
complexed with platinum(II) species are very sensitive to
the geometry and the composition of the complex.[40] Thus,
we monitored the reaction by recording the 1H NMR spec-
trum every 30 min for the first 6 h and then every 6 h until
no further changes were noticed. 10% [D7]DMF was added
to the buffer to assure the complete water solubility of 17.
Figure 2. Aromatic region of the 1H NMR spectra recorded at different time points monitoring the reaction between 17 and a fourfold
excess amount of dGMP (50 mm KH2PO4, 50 mm KCl, pH 7.0, 37 °C in H2O/D2O = 9:1 containing 10% [D7]DMF). The signals of 17
and dGMP are labeled by using regular and bold-type fonts, respectively. The H8 NMR signals of dGMP complexed with 17 are labeled
with , ♦, and + (see also the Results and Discussion section).
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The reactivity of the cis-dichloroplatinum moiety of 17
towards dGMP was confirmed by the appearance of down-
field-shifted aromatic signals (δ = 8.4–9.0 ppm), attributable
to H8 of dGMP complexed with 17, already in the first
hour of incubation (Figure 2). Because of the asymmetry of
the diaminoalkyl moiety coordinated with the platinum(II)
center, up to six aromatic signals belonging to H8 of dGMP
complexed with 17 were expected [two signals for each of
the two complexes 7-deaza-A-Pt(dGMP)(Cl) and 7-
deaza-A-Pt(dGMP)(H2O); two signals for 7-deaza-A-Pt-
(dGMP)2]. This spectral complexity was observed in the
NMR spectra recorded at an incubation time 3 h. Al-
though the detailed assignment of all the dGMP H8 signals
was not accomplished, because it is beyond the scope of
this paper, the analysis of the literature data and the relative
intensity of the NMR signals recorded at increasing incu-
bation times (Figure 2) allowed us to tentatively assign
(1) the signals at δ = 8.55 and 8.62 ppm of the dGMP H8
proton of the complexes 7-deaza-A-Pt(dGMP)(Cl) and 7-
deaza-A-Pt(Cl)(dGMP) (+ in Figure 2); (2) the signal at δ
= 8.99 ppm (visible at incubation times 6 h) of the dGMP
H8 proton of one of the two aqua complexes 7-deaza-
A-Pt(dGMP)(H2O) or 7-deaza-A-Pt(H2O)(dGMP) ();
(3) the signals at δ = 8.52 and 8.65 ppm of the H8 protons
of the two dGMP in the 7-deaza-A–Pt(dGMP)2 complex
(♦). The formation of platinum–d(GMP) complexes during
the incubation time was also confirmed by the appearance
of new upfield-shifted signals for the H2, H7, H8, and H1
protons of 17 in the NMR spectra. In particular, the relative
intensity of the NMR signals of H7 and H8 before and
after coordination with d(GMP) disclosed that more than
50% of 17 reacted with one or two molecules of d(GMP)
at incubation times within 12 and 36 h (Figure 2).
Properties of a Tethered Tubercidin–PtII Complex
Antiproliferative Studies on the A549 and Cal27 Cell Lines
Compound 17, its unplatinated precursor 16, and cispla-
tin were examined by sulforhodamine B (SRB) assay[45] for
their capability to inhibit growth of the A549 and Cal27
cell lines. To this end, cisplatin was dissolved in phosphate-
buffered saline (PBS), whereas compound 16 and complex
17 were dissolved in 10% DMSO/PBS. All compounds were
diluted immediately to the final concentrations by using the
cell growth medium. The results showed that, although less
active than cisplatin, both compounds induced dose-de-
pendent growth inhibition in both cell lines after 96 h of
treatment (Figure 3). Unexpectedly, for the tested cell lines,
we observed that the antiproliferative activity of unplati-
nated precursor 16 was 1.5-fold higher than that of plati-
nated complex 17 (Table 1). Further studies are needed to
ascertain whether the lower activity of 17 is due to the
residual “tubercidin-like” activity found for 16 or to the
target “cisplatin-like alkylation” of purine bases by the
dichloroplatinum moiety.
Figure 3. Antiproliferative effect of cisplatin, 16, and 17 in the
A549 (top) and Cal27 (bottom) cell lines. Cell growth assessment
was performed by sulforhodamine B colorimetric assay (see the Ex-
perimental Section) and is expressed as the percentage of control
for each time point. Values are the mean SD from at least three
independent experiments performed in quadruplicate.
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Table 1. Sensitivity of the A549 and Cal27 cell lines to cisplatin,
16, and 17.
Compound IC50[a] at 96 h [μm] SD
A549 Cal27
Cisplatin 2.690.80 1.040.20
16 23.624.83 26.44 1.64
17 36.202.72 37.75 5.58
[a] The half-maximal inhibitory concentration (IC50) values were
computed after 96 h of treatment (mean SD from at least three
separate experiments performed in quadruplicate). SD: standard
deviation.
Conclusions
In this paper, we described the synthesis of a new nucleo-
side platinum(II) complex (i.e., 17) in which a cisplatin-like
unit is joined to 7-deazaadenosine through an amino alkyl
chain installed at the C6 position of purine. The cisplatin-
like capability of 17 to react with the purine bases of DNA
was confirmed by monitoring a model reaction with dGMP,
whereas preliminary antiproliferative data on 17 and on un-
platinated precursor 16 demonstrated that both com-
pounds, although less potent than cisplatin, were able to
inhibit the proliferation of the A549 and Cal27 human cell
lines in a dose-dependent manner. Interestingly, the anti-
proliferative activity of free diamine 16 was 1.5-fold higher
than that of platinated complex 17 on both cell lines. Stud-
ies are ongoing in our laboratories to assess the suitability
of compound 16 to chelate other metals involved in cancer
research and to construct novel unprecedented tubercidin
derivatives with polyaminoalkyl chains at the C6 position
of purine.
Experimental Section
General Methods: All reagents and solvents for the chemical syn-
theses were obtained from commercial sources and were used with-
out further purification. All cell culture media, serum, antibiotics,
and glutamine were purchased from LONZA (Basel, Switzerland).
Sulforhodamine B (SRB) was from ICN Biomedicals (Irvine, CA,
USA). 1H NMR and 13C NMR spectra were acquired with Varian
Mercury Plus 400 MHz and Varian UNITY Inova 500 MHz in-
struments by using CD3OD, (CD3)2SO, or C6D6 as solvents. A to-
tal of 450 μL of a 50 mmKH2PO4, 50 mm KCl, pH 7 buffer in H2O/
D2O (9:1) was used to record the 1H NMR spectra required to
monitor the reaction of 17 (dissolved in 50 μL of [D7]DMF) with
dGMP. A double pulsed gradient spin echo (DPFGSE) module
was included in the NMR pulse sequences to suppress the water
signal.[46,47] Chemical shifts are reported in parts per million (δ)
relative to the residual solvent signal [1H: CD2HOD δ = 3.31 ppm,
(CD3)(CD2H)SO δ = 2.54 ppm, C6D5H δ = 7.15 ppm; 13C: CD3OD
δ = 49.0 ppm, (CD3)2SO δ = 40.4 ppm, C6D6 δ = 128.6 ppm] and
were assigned by 2D NMR experiments. UV spectra were recorded
with a Jasco V-530 UV spectrophotometer. IR spectra were re-
corded with a Jasco FTIR 430 spectrophotometer. Optical rota-
tions were determined with a Jasco polarimeter by using a 1 dm
cell at 25 °C; concentrations are expressed in g100 mL–1. High-res-
olution MS spectra were recorded with a Thermo Orbitrap XL
mass spectrometer by using the electrospray ionization (ESI) tech-
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nique in positive mode. Elemental analyses were performed with a
Thermo Finnigan Flash EA 1112 CHN analyzer.
Cell Culture and Proliferation Assay: Human lung-cancer-derived
A549 cells and human tongue squamous-carcinoma-derived Cal27
cells were grown in adhesion in Dulbecco’s modified Eagle’s me-
dium. The medium was supplemented with 10% heat-inactivated
fetal bovine serum, penicillin (50 UmL–1), streptomycin
(500 μgmL–1), and glutamine (4 mmolL–1) in a humidified atmo-
sphere of 95% air and 5% CO2 at 37 °C. Cell proliferation of A549
and Cal27 was evaluated in the presence and absence of increasing
concentrations of the compounds by colorimetric assay with sulfo-
rhodamine B (SRB, ICN Biomedicals, Irvine, CA, USA). In detail,
1000cellswell–1 were seeded in 96-multiwell plates (Falcon, Becton
Dickinson Labware, Franklin Lakes, NJ, USA) in quadruplicate.
After 24 h, the cells were treated with the indicated compounds for
96 h and then the SRB assay was performed as described before.[45]
The growth was evaluated as percentage compared to untreated
cells.
Compound 10: A mixture of compound 8 (300 mg, 0.44 mmol), tert-
butyl (3-aminopropyl)carbamate (9; 383 mg, 2.2 mmol), and Et3N
(61 μL, 0.44 mmol) was heated at reflux in EtOH (12 mL). During
the reaction, a colorless solid, identified as compound 10, precipi-
tated. After 5 h (TLC monitoring: CH2Cl2/MeOH, 98:2), the sys-
tem was cooled to room temperature, and the solid was then fil-
tered, washed with cold EtOH, and dried. Colorless amorphous
solid (287 mg, 80%). [α]D = –122.1 (c = 0.1, CH2Cl2). 1H NMR
(400 MHz, C6D6): δ = 8.46 (s, 1 H, 2-H), 8.31–8.24 (m, 2 H, arom.),
8.02–7.92 (complex signal, 4 H, arom.), 7.20–6.81 (complex signal
partially covered by residual solvent signal, 10 H, 8-H and arom.),
6.75 (d, J = 5.6 Hz, 1 H, 1-H), 6.37–6.31 (m, 1 H, 2-H), 6.25–
6.16 (complex signal, 2 H, 3-H and NH), 4.74–4.65 (m, 1 H, 4-
H), 4.64–4.56 (br. t, J = 6.1 Hz, 1 H, NH), 4.40–4.32 (m, 2 H, 5-
Ha,b), 3.41–3.31 (m, 2 H, CH2NH), 2.96–2.87 (m, 2 H,
CH2NHBoc), 1.44 (s, 9 H, Boc), 1.37–1.26 (m, 2 H, CH2) ppm.
13C NMR (100 MHz, C6D6, 40 °C): δ = 166.0, 165.3, 165.2, 156.9,
156.4, 153.7, 150.4, 133.3, 133.2, 130.4, 130.1, 129.8, 129.5, 128.8,
128.6, 128.5, 120.6, 103.0, 89.1, 86.9, 80.6, 78.6, 75.0, 72.3, 64.1,
37.5, 30.7, 28.6 ppm. IR (KBr pellet): ν˜ = 3411, 3382, 2980, 2936,
1728, 1687, 1602, 1562, 1513, 1451, 1270, 1175, 1127, 1027,
711 cm–1. UV (CH2Cl2): λmax = 235, 280 nm. HRMS (ESI): m/z =
836.1911 [M + Na]+ (C40H40BrN5O9Na requires 836.1907).
Compound 11: A solution of compound 10 (250 mg, 0.29 mmol) in
CH2Cl2 (1.0 mL) was cooled to 0 °C. TFA (1.0 mL) was added in
one portion. The mixture was then warmed to room temperature
and stirred for 1 h (TLC monitoring: CH2Cl2/MeOH, 8:2). Solvents
were evaporated under reduced pressure, and the crude material
containing compound 11 as its TFA salt was used for the next
step without purification. Oil (238 mg, 99%). [α]D = –76.8 (c = 0.5,
CH2Cl2). 1H NMR (400 MHz, CD3OD): δ = 8.18 (s, 1 H, 2-H),
8.10–8.05 (m, 2 H, arom.), 8.01–7.96 (m, 2 H, arom.), 7.85–7.89
(m, 2 H, arom.), 7.65–7.30 (complex signal, 10 H, 8-H and arom.),
6.61 (d, J = 5.3 Hz, 1 H, 1-H), 6.26–6.19 (m, 1 H, 2-H), 6.16–
6.11 (m, 1 H, 3-H), 4.95–4.80 (complex signal partially covered by
residual solvent signal, 2 H, 4-H and 5-Ha), 4.67 (dd, J = 11.7,
3.5 Hz, 1 H, 5-Hb), 3.71 (t, J = 6.7 Hz, 2 H, CH2NH), 3.01 (t, J
= 7.2 Hz, 2 H, CH2NH3+), 2.08–1.97 (m, 2 H, CH2) ppm. 13C
NMR (100 MHz, CD3OD): δ = 167.5, 166.7, 166.4, 161.2 (q, J =
37.7 Hz), 156.6, 151.5, 149.8, 134.9, 134.6, 130.9, 130.8, 130.7,
130.2, 129.8, 129.6, 123.9, 115.8, 103.4, 89.8, 88.1, 81.5, 75.4, 72.8,
64.8, 38.5, 37.9, 28.7 ppm. IR (neat): ν˜ = 3060, 2884, 1722, 1682,
1599, 1448, 1269, 1204, 1127, 711 cm–1. UV (MeOH): λmax =
277 nm. HRMS (ESI): m/z = 736.1390 [M + Na]+
(C35H32BrN5NaO7 requires 736.1383).
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Compound 13: Racemic acid 12 (177 mg, 0.58 mmol) was dissolved
in dry DMF (4 mL) and then DIPEA (0.4 mL, 2.3 mmol), EDC
(222 mg, 1.2 mmol), and HOBt (157 mg, 1.2 mmol) were added.
The mixture was stirred for 30 min at room temperature. Com-
pound 11 (200 mg, 0.24 mmol), dissolved in dry DMF (2 mL), was
added to the previous solution, and the mixture was stirred for 16 h
at room temperature (TLC monitoring: n-hexane/AcOEt, 4:6). The
solvents were removed under reduced pressure, and the crude mate-
rial was diluted with AcOEt (20 mL) and extracted with brine (3
20 mL). The organic layer was separated, dried (Na2SO4), filtered,
and concentrated under reduced pressure. The crude material con-
taining compound 13 was purified by chromatography (silica gel,
EtOAc in n-hexane, gradient up to 70%). The fractions containing
the product were collected and concentrated to afford pure 13 as a
mixture of diastereomers. Amorphous white solid (200 mg, 83%).
1H NMR (400 MHz, CD3OD): δ = 8.19 (s, 2 H, 22-H), 8.12–
8.07 (m, 4 H, arom.), 8.02–7.97 (m, 4 H, arom.), 7.91–7.86 (m, 4
H, arom.), 7.66–7.33 (complex signal, 20 H, 28-H and arom.),
6.61 (d, J = 5.5 Hz, 2 H, 21-H), 6.25–6.19 (m, 2 H, 22-H),
6.18–6.12 (m, 2 H, 23-H), 4.93–4.78 (complex signal partially
covered by residual solvent signal, 4 H, 24-H and 25-Ha),
4.67 (dd, J = 3.6, 12.2 Hz, 2 H, 25-Hb), 4.15–4.08 (m, 2 H,
2CH), 3.71–3.54 (m, 4 H, 2CH2NH), 3.41 (dd, J = 4.7,
14.1 Hz, 2 H, 2CHaNHBoc), 3.36–3.26 (2 H, 2CHbNHBoc,
covered by residual solvent signal), 3.24–3-14 (m, 4 H,
2CH2NHCO), 1.83–1.72 (m, 4 H, 2CH2), 1.41 (s, 9 H, Boc),
1.39 (s, 9 H, Boc), 1.37 (s, 9 H, Boc), 1.36 (s, 9 H, Boc) ppm. 13C
NMR (100 MHz, CD3OD): δ = 173.2, 167.5, 166.7, 166.4, 158.9,
157.9, 157.7, 153.9, 150.4, 134.8, 134.7, 134.5, 130.9, 130.8, 130.7,
130.3, 129.9, 129.7, 129.6, 129.5, 122.5, 103.4, 89.7, 87.7, 81.4, 80.9,
80.5, 75.4, 72.9, 64.9, 57.4, 43.1, 38.4, 37.0, 30.7, 28.7 ppm. IR
(KBr pellet): ν˜ = 3330, 2923, 1723, 1597, 1262, 1160, 1117,
708 cm–1. UV (MeOH): λmax = 275 nm. HRMS (ESI): m/z =
1000.3085 [M + H]+ (C48H55BrN7O12 requires 1000.3092).
Compound 14: Compound 13 (150 mg, 0.15 mmol) was dissolved
in MeOH (10 mL) in a Parr reactor; NaOAc (13 mg, 0.16 mmol)
and Pd/C (10% w/w, 42 mg, 0.04 mmol) were added and air was
removed by insufflating H2. The apparatus was then charged with
H2 (1.0 MPa), and the system was stirred for 2 h (TLC monitoring:
n-hexane/AcOEt, 3:7) at room temperature. H2 was removed, and
the mixture was filtered through a Celite 545 pad that was then
washed with MeOH (3 10 mL). The solvent was evaporated un-
der reduced pressure, and the crude was diluted with AcOEt
(20 mL) and extracted with brine (3 20 mL). The organic layer
was separated, dried (Na2SO4), filtered, and concentrated under
reduced pressure. The crude material containing compound 14 was
used for the next reaction step without purification. Oil (137 mg,
99%). 1H NMR (400 MHz, CD3OD): δ = 8.21 (s, 2 H, 22-H),
8.16–8.08 (m, 4 H, arom.), 8.04–7.97 (m, 4 H, arom.), 7.92–7.83
(m, 4 H, arom.), 7.66–7.34 (complex signal, 18 H, arom.), 7.23 (d,
J = 3.7 Hz, 2 H, 28-H), 6.67 (d, J = 5.9 Hz, 2 H, 21-H), 6.58
(d, J = 3.7 Hz, 2 H, 27-H), 6.28–6.20 (m, 2 H, 22-H), 6.19–
6.12 (m, 2 H, 23-H), 4.93–4.77 (complex signal partially covered
by residual solvent signal, 4 H, 24-H and 25-Ha), 4.71–4.64
(m, 2 H, 25-Hb), 4.15–4.08 (m, 2 H, 2CH), 3.70–3.45 (m, 4
H, 2CH2NH), 3.44–3.36 (m, 2 H, 2CHaNHBoc), 3.36–3.26 (2
H, 2CHbNHBoc, covered by residual solvent signal), 3.22–3.11
(m, 4 H, 2CH2NHCO), 1.83–1.73 (m, 4 H, 2CH2), 1.40 (s, 9
H, Boc), 1.38 (s, 9 H, Boc), 1.36 (s, 9 H, Boc), 1.35 (s, 9 H, Boc)
ppm. 13C NMR (100 MHz, CD3OD): δ = 173.0, 167.5, 166.7,
166.5, 158.9, 158.3, 157.7, 153.1, 150.8, 134.8, 134.7, 134.5, 130.9,
130.8, 130.7, 130.3, 129.9, 129.7, 129.6, 129.5, 122.5, 105.2, 101.6,
87.2, 81.2, 80.9, 80.5, 75.3, 73.0, 65.2, 57.5, 43.0, 38.5, 37.2, 30.6,
Properties of a Tethered Tubercidin–PtII Complex
28.7 ppm. IR (neat): ν˜ = 3341, 2972, 1723, 1602, 1503, 1262, 1160,
1119, 708 cm–1. UV (MeOH): λmax = 276 nm. HRMS (ESI) m/z =
922.3989 [M + H]+ (C48H55N7O12 requires 922.3987).
Compound 15: Compound 14 (115 mg, 0.12 mmol) was dissolved
in MeOH (1.5 mL) and then MeONa (32 mg, 0.60 mmol) was
added. The solution was stirred for 2 h at room temperature (TLC
monitoring: AcOEt/MeOH, 9:1). The solution was neutralized with
a few drops of glacial acetic acid; the solvents were removed under
reduced pressure, and the crude was diluted with AcOEt (20 mL)
and extracted with brine (3 20 mL). The organic layer was sepa-
rated, dried (Na2SO4), filtered, and concentrated under reduced
pressure. The crude material was purified by column chromatog-
raphy (silica gel, MeOH in AcOEt, gradient up to 10%). The frac-
tions containing the product were collected and concentrated to
afford pure 15. Amorphous solid (67 mg, 95%). 1H NMR
(400 MHz, CD3OD): δ = 8.12 (s, 2 H, 22-H), 7.25 (d, J = 3.6 Hz,
2 H, 28-H), 6.57 (d, J = 3.6 Hz, 2 H, 27-H), 5.96 (d, J =
6.6 Hz, 2 H, 21-H), 4.71–4.65 (m, 2 H, 22-H), 4.30–4.26 (m,
2 H, 23-H), 4.18–4.08 (complex signal, 4 H, 24-H and
2CH), 3.84 (dd, J = 2.1, 12.4 Hz, 2 H, 25-Ha), 3.71 (dd, J =
2.3, 12.4 Hz, 2 H, 25-Hb), 3.68–3.48 (m, 4 H, 2CH2NH),
3.46–3.39 (m, 2 H, 2CHaNHBoc), 3.36–3.26 (2 H,
2CHbNHBoc, covered by residual solvent signal), 3.24–3.11 (m,
4 H, 2CH2NHCO), 1.86–1.75 (m, 4 H, 2CH2), 1.42 (s, 18 H,
2Boc), 1.38 (s, 18 H, 2Boc) ppm. 13C NMR (100 MHz,
CD3OD): δ = 173.0, 158.8, 158.3, 157.7, 152.2, 149.5, 124.7, 105.9,
100.0, 91.6, 87.3, 80.9, 80.5, 75.3, 72.7, 63.7, 57.4, 43.0, 38.4, 37.2,
30.6, 28.7 ppm. IR (KBr pellet): ν˜ = 3307, 2917, 1695, 1607, 1503,
1366, 1256, 1160, 1048 cm–1. UV (MeOH): λmax = 277 nm. HRMS
(ESI): m/z =610.3184 [M + H]+ (C27H44N7O9 requires 610.3201).
Compound 16: A solution of compound 15 (50 mg, 0.082 mmol) in
CH2Cl2 (0.5 mL) was cooled to 0 °C. TFA (0.5 mL) was added in
one portion. The mixture was then warmed to room temperature
and stirred for 1 h (TLC monitoring: CH2Cl2/MeOH, 8:2). The sol-
vents were evaporated under reduced pressure. The crude was
treated with conc. NH4OH solution (1 mL), evaporated under re-
duced pressure, dissolved in water (1 mL), and eventually lyophi-
lized. The crude material containing compound 16 was used for
the next reaction step without purification. Oil (33 mg, 99%). 1H
NMR (400 MHz, CD3OD): δ = 8.12 (s, 2 H, 22-H), 7.27 (d, J =
3.7 Hz, 2 H, 28-H), 6.58 (d, J = 3.7 Hz, 2 H, 27-H), 5.95 (d,
J = 6.6 Hz, 2 H, 21-H), 4.69–4.63 (m, 2 H, 22-H), 4.29–4.24
(m, 2 H, 23-H), 4.13–4.08 (m, 2 H, 24-H), 3.84 (dd, J = 2.6,
12.4 Hz, 2 H, 25-Ha), 3.72 (dd, J = 2.8, 12.4 Hz, 2 H, 25-
Hb), 3.58 (t, J = 6.7 Hz, 4 H, 2CH2NH), 3.33–3.26 (6 H, covered
by residual solvent signal, 2CH and 2CH2NHCO), 2.85 (dd,
J = 5.0, 13.1 Hz, 2 H, 2CHaNH2), 2.85 (dd, J = 6.7, 13.1 Hz, 2
H, 2CHbNH2), 1.91–1.80 (m, 4 H, 2CH2) ppm. 13C NMR
(100 MHz, CD3OD): δ = 176.1, 158.1, 152.0, 149.7, 124.6, 105.9,
100.1, 91.5, 87.3, 75.3, 72.7, 63.7, 57.7, 46.7, 38.9, 37.7, 30.4 ppm.
IR (neat): ν˜ = 3269, 1610, 1551, 1365, 1314, 1248, 1079, 725 cm–1.
UV (MeOH): λmax = 274 nm. HRMS (ESI): m/z = 410.2147 [M +
H]+ (C17H28N7O5 requires 410.2152).
Compound 17: Compound 16 (20 mg, 0.031 mmol) was dissolved
in H2O/MeOH (1:1, 1 mL). K2PtCl4 (13 mg, 0.031 mmol) was
added, and the solution was stirred in the dark at room tempera-
ture for 16 h. The pale-yellow precipitate (15 mg, 70%) was col-
lected by filtration, washed sequentially with H2O and MeOH, and
then dried. 1H NMR (400 MHz, [D6]DMSO): δ = 8.21 (br. t, 2 H,
2NHCO), 8.12 (s, 2 H, 22-H), 7.55–7.50 (m, 2 H,
2NHCH2), 7.33 (br. d, J = 3.6 Hz, 2 H, 28-H), 6.60 (br. d, J
= 3.6 Hz, 2 H, 27-H), 5.98 (br. d, J = 6.3 Hz, 2 H, 21-H),
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5.50–5.41 (br. s, 8 H, 2PtNH2CH2 and 2PtNH2CH), 5.29
(br. t, 2 H, 25-OH), 5.23 (br. d, 2 H, 22-OH), 5.09 (br. d, 2
H, 23-OH), 4.38–4.45 (m, 2 H, 22-H), 4.11–4.04 (m, 2 H,
23-H), 3.93–3.85 (m, 2 H, 24-H), 3.66–3.40 (complex signal
partially covered by residual solvent signal, 14 H, 25-Ha,b,
2CH2NH, 2PtNH2CH2, 2PtNHCH), 3.19–3.11 (m, 4 H,
CH2NHCO), 1.80–1.66 (m, 4 H, 2CH2) ppm. 13C NMR
(100 MHz, [D6]DMSO): δ = 167.0, 157.0, 152.3, 150.1, 123.1,
104.3, 100.1, 88.4, 86.0, 74.6, 71.6, 62.7, 61.9, 38.4, 37.7, 29.7 ppm.
IR (KBr pellet): ν˜ = 3247, 1665, 1610, 1561, 1363, 1311, 1245,
1089, 721 cm–1. UV (H2O): λmax = 274 nm. HRMS (ESI): m/z =
717.1531 [M – Cl + DMSO]+ (C19H33ClN7O6PtS requires
717.1549). C17H27Cl2N7O5Pt (675.44): calcd. C 30.23, H 4.03, N
14.52; found C 30.27, H 4.08, N 14.58.
Reaction of 17 with dGMP: Complex 17 (2 mg, 3.010–3 mmol)
was dissolved in [D7]DMF (50 μL) and then added to 450 μL of a
solution of dGMP (4 equiv.) in H2O/D2O (9:1) containing 50 mm
KH2PO4 and 50 mm KCl, pH 7. The mixture was transferred to a
NMR tube and was incubated at 37 °C. Water-suppressed
1H NMR spectra (500 MHz, 37 °C) were then recorded as de-
scribed in the general methods section and in the text.
Acknowledgments
This work was supported by POR Campania FESR 2007-2013 –
Rete delle Biotecnolgie in Campania (project “FARMA-
BIONET”).
[1] B. Rosenberg, L. VanCamp, J. E. Trosko, V. H. Mansour, Na-
ture 1969, 222, 385–386.
[2] A.-M. Florea, D. Büsselberg, Cancers 2011, 3, 1351–1371.
[3] A. Sigel, H. Sigel, Metal Ions in Biological Systems: Metal
Complexes in Tumor Diagnosis and as Anticancer Agents, CRC
Press, London, UK, 2004.
[4] E. Wexselblatt, E. Yavin, D. Gibson, Inorg. Chim. Acta 2012,
393, 75–83.
[5] L. Kelland, Nat. Rev. Cancer 2007, 7, 573–584.
[6] B. W. Harper, A. M. Krause-Heuer, M. P. Grant, M. Manohar,
K. B. Garbutcheon-Singh, J. R. Aldrich-Wright, Chem. Eur. J.
2010, 16, 7064–7077.
[7] L. R. Kelland, N. P. Farrell (Eds.), Platinum-Based Drugs in
Cancer Therapy, Humana Press, Totowa, NJ, USA, 2000.
[8] F. Arnesano, G. Natile, Coord. Chem. Rev. 2009, 253, 2070–
2081.
[9] J. Zhang, L. Wang, Z. Xing, D. Liu, J. Sun, Curr. Med. Chem.
Anti-Cancer Agents 2010, 10, 272–282.
[10] K. Wang, E. Gao, Curr. Med. Chem. Anti-Cancer Agents 2014,
14, 147–169.
[11] P. Sengupta, S. Basu, S. Soni, A. Pandey, B. Roy, M. S. Oh,
K. T. Chin, A. S. Paraskar, S. Sarangi, Y. Connor, V. S. Sabbi-
setti, J. Kopparam, A. Kulkarni, K. Muto, C. Amarasiriward-
ena, I. Jayawardene, N. Lupoli, D. M. Dinulescu, J. V. Bonven-
tre, R. A. Mashelkar, S. Sengupta, Proc. Natl. Acad. Sci. USA
2012, 109, 11294–11299.
[12] R. Cincinelli, L. Musso, S. Dallavalle, R. Artali, S. Tinelli, D.
Colangelo, F. Zunino, M. De Cesare, G. L. Beretta, N. Zaffa-
roni, Eur. J. Med. Chem. 2013, 63, 387–400.
[13] J. S. Butler, P. J. Sadler, Curr. Opin. Chem. Biol. 2013, 17, 175–
188.
[14] A. Arouri, A. H. Hansen, T. E. Rasmussen, O. G. Mouritsen,
Curr. Opin. Colloid Interface Sci. 2013, 18, 419–431.
[15] C. Tomuleasa, O. Soritau, A. Orza, M. Dudea, B. Petrushev,
O. Mosteanu, S. Susman, A. Florea, E. Pall, M. Aldea, G.
Kacso, V. Cristea, I. Berindan-Neagoe, A. Irimie, J. Gastrointe-
stin. Liver. Dis. 2012, 21, 187–196.
G. Oliviero et al.FULL PAPER
[16] Y. H. Quan, B. Kim, J.-H. Park, Y. Choi, Y. H. Choi, H. K.
Kim, Exp. Lung. Res. 2014, 40, 475–484.
[17] Y. Min, C.-Q. Mao, S. Chen, G. Ma, J. Wang, Y. Liu, Angew.
Chem. Int. Ed. 2012, 51, 6742–6747; Angew. Chem. 2012, 124,
6846–6851.
[18] S. Wang, W. Chu, Y. Wang, S. Liu, J. Zhang, S. Li, H. Wei, G.
Zhou, X. Qin, Appl. Organomet. Chem. 2013, 27, 373–379.
[19] Dubyak, G. R, Am. J. Physiol. Cell Physiol. 2013, 304, C403–
C405.
[20] A. H. Guse, Curr. Mol. Med. 2002, 2, 273–282.
[21] H. C. Lee, J. Biol. Chem. 2012, 287, 31633–31640.
[22] G. Oliviero, S. D’Errico, N. Borbone, J. Amato, V. Piccialli, M.
Varra, G. Piccialli, L. Mayol, Tetrahedron 2010, 66, 1931–1936.
[23] R. S. Hosmane, Curr. Top. Med. Chem. 2002, 2, 1093–1109.
[24] S. D’Errico, G. Oliviero, J. Amato, N. Borbone, V. Cerullo, A.
Hemminki, V. Piccialli, S. Zaccaria, L. Mayol, G. Piccialli,
Chem. Commun. 2012, 48, 9310–9312.
[25] R. M. Huang, Y. N. Chen, Z. Zeng, C. H. Gao, X. Su, Y. Peng,
Mar. Drugs 2014; 12, 5817–5838.
[26] S. Meike, T. Yamamori, H. Yasui, M. Eitaki, A. Matsuda, M.
Morimatsu, M. Fukushima, Y. Yamasaki, O. Inanami, Mol.
Cancer 2011, 10, 92.
[27] C. K. Chu, Antiviral Nucleosides: Chiral Synthesis and Chemo-
therapy, Elsevier, Amsterdam, The Netherlands, 2003.
[28] L. P. Jordheim, D. Durantel, F. Zoulim, C. Dumontet, Nat.
Rev. Drug Discovery 2013, 12, 447–464.
[29] M. F. Caso, D. D’Alonzo, S. D’Errico, G. Palumbo, A. Guar-
agna, Org. Lett. 2015, 17, 2626–2629.
[30] D. Montagner, V. Gandin, C. Marzano, B. Longato, J. Inorg.
Biochem. 2011, 105, 919–926.
[31] P. Starha, I. Popa, Z. Trávnícˇek, J. Vancˇo, Molecules 2013, 18,
6990–7003.
[32] M. Coluccia, A. Boccarelli, C. Cermelli, M. Portolani, G. Nat-
ile, Met. Based Drugs 1995, 2, 249–256.
www.eurjoc.org © 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 2015, 7550–75567556
[33] C. Nervi, M. A. Vigna, G. Cavigiolio, M. Ravera, D. Osella,
Inorg. Chim. Acta 2005, 358, 2799–2803.
[34] S. D’Errico, G. Oliviero, V. Piccialli, J. Amato, N. Borbone, V.
D’Atri, F. D’Alessio, R. Di Noto, F. Ruffo, F. Salvatore, G.
Piccialli, Bioorg. Med. Chem. Lett. 2011, 21, 5835–5838.
[35] S. D’Errico, G. Oliviero, N. Borbone, V. Piccialli, B. Pinto, F.
De Falco, M. C. Maiuri, R. Carnuccio, V. Costantino, F. Nici,
G. Piccialli, Molecules 2014, 19, 9339–9353.
[36] L. V. Frolova, I. V. Magedov, A. E. Romero, M. Karki, I. Ot-
ero, K. Hayden, N. M. Evdokimov, L. M. Y. Banuls, S. K. Ras-
togi, W. R. Smith, S.-L. Lu, R. Kiss, C. B. Shuster, E. Hamel,
T. Betancourt, S. Rogelj, A. Kornienko, J. Med. Chem. 2013,
56, 6886–6900.
[37] G. Acs, E. Reich, M. Mori, Proc. Natl. Acad. Sci. USA 1964,
52, 493–501.
[38] M. F. Biabani, S. P. Gunasekera, Pharm. Biol. 2002, 40, 302–
303.
[39] B. K. Hwang, B. S. Kim, Pestic. Sci. 1995, 44, 255–260.
[40] A. Marcelis, C. G. Van Kralingen, J. Reedijk, J. Inorg. Biochem.
1980, 13, 213–222.
[41] E. Pantoja, A. Gallipoli, S. van Zutphen, S. Komeda, D.
Reddy, D. Jaganyi, M. Lutz, D. M. Tooke, A. L. Spek, C. Nav-
arro-Ranninger, J. Reedijk, J. Inorg. Biochem. 2006, 100, 1955–
1964.
[42] F. Seela, X. Ming, Tetrahedron 2007, 63, 9850–9861.
[43] S. Moradell, J. Lorenzo, A. Rovira, S. van Zutphen, F. X. Av-
ilés, V. Moreno, R. de Llorens, M. A. Martinez, J. Reedijk, A.
Llobet, J. Inorg. Biochem. 2004, 98, 1933–1946.
[44] E. A. Véliz, P. A. Beal, J. Org. Chem. 2001, 66, 8592–8598.
[45] E. Di Gennaro, F. Bruzzese, S. Pepe, A. Leone, P. Delrio, P. R.
Subbarayan, A. Avallone, A. Budillon, Cancer Biol. Ther. 2009,
8, 782–791.
[46] T. L. Hwang, A. J. Shaka, J. Magn. Reson., Ser. A 1995, 112,
275–279.
[47] C. Dalvit, J. Biomol. NMR 1998, 11, 437–444.
Received: July 29, 2015
Published Online: November 3, 2015
Molecules 2014, 19, 9339-9353; doi:10.3390/molecules19079339 
 
molecules 
ISSN 1420-3049 
www.mdpi.com/journal/molecules 
Article 
Synthesis and Pharmacological Evaluation of Modified 
Adenosines Joined to Mono-Functional Platinum Moieties 
Stefano D’Errico 1, Giorgia Oliviero 1,*, Nicola Borbone 1, Vincenzo Piccialli 2, Brunella Pinto 1, 
Francesca De Falco 1, Maria Chiara Maiuri 1,3, Rosa Carnuccio 1, Valeria Costantino 1,  
Fabrizia Nici 1 and Gennaro Piccialli 1 
1 Dipartimento di Farmacia, Università degli Studi di Napoli “Federico II”, via D. Montesano, 49, 
80131 Napoli, Italy; E-Mails: stefano.derrico@unina.it (S.D.); borbone@unina.it (N.B.); 
brunella.pinto87@gmail.com (B.P.); francesca.defalco@unina.it (F.D.F.); 
mariachiara.maiuri@unina.it (M.C.M.); rosa.carnuccio@unina.it (R.C.); 
valeria.costantino@unina.it (V.C.); fabrizia.nici@unina.it (F.N.); picciall@unina.it (G.P.) 
2 Dipartimento di Scienze Chimiche, Università degli Studi di Napoli “Federico II”, via Cintia, 21, 
80126 Napoli, Italy; E-Mail: vinpicci@unina.it  
3 INSERM U848, IGR, 39 rue C. Desmoulins, 94805 Villejuif, France 
* Author to whom correspondence should be addressed; E-Mail: golivier@unina.it;  
Tel.: +39-081-679-896.  
Received: 26 March 2014; in revised form: 23 June 2014 / Accepted: 25 June 2014 /  
Published: 3 July 2014 
 
Abstract: The synthesis of four novel platinum complexes, bearing N6-(6-amino-
hexyl)adenosine or a 1,6-di(adenosin-N6-yl)-hexane respectively, as ligands of mono-
functional cisplatin or monochloro(ethylendiamine)platinum(II), is reported. The chemistry 
exploits the high affinity of the charged platinum centres towards the N7 position of the 
adenosine base system and a primary amine of an alkyl chain installed on the C6 position 
of the purine. The cytotoxic behaviour of the synthesized complexes has been studied in A549 
adenocarcinomic human alveolar basal epithelial and MCF7 human breast adenocarcinomic 
cancer cell lines, in order to investigate their effects on cell viability and proliferation. 
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1. Introduction 
The discovery of the anti-proliferative properties of cisplatin [1] marked the beginning of modern 
chemotherapy based on the use of metal complexes capable of blocking the replication of cancer cells 
targeting the nuclear DNA [2,3]. In fact, it is widely accepted that cisplatin, once inside the cell, may 
form a highly reactive species [4,5] that can react with DNA through the formation of intra-strand 
linkages [6,7]. Such linkages alter the secondary structure of DNA, resulting in an inhibition of 
transcription and replication, ultimately leading to cell death [4]. However, the poor solubility in 
biological fluids [8], the serious side effects [9,10], and, more importantly, the intrinsic and acquired 
resistance of many types of tumors [5], have limited its use in the clinic. Carboplatin and oxaliplatin, 
second and third generation anti-neoplastic agents, respectively, are able to enhance the quality of life 
of patients in terms of dosage and drug administration. However, they can still trigger mechanisms of 
resistance (intrinsic and/or acquired) during repeated cycles of oncological treatment [5]. It was then 
discovered that the presence of more charged metal centres separated by unbranched alkylamine chains 
leads to complexes capable of being uptaken by cells via active import [11] and of overcoming the 
intrinsic and/or acquired resistance in some tumors [6,12–15]. Based on the understanding that they 
may exert anti-tumoral activities through inter-strand linkages with DNA that cannot be repaired by 
enzymes [16], many multinuclear platinum complexes have recently been synthesized, by varying the 
diamine backbone chain length, or by introducing modified linkers [8,10–12,17,18]. In addition, new  
Pt-based compounds have been obtained by conjugating biologically important substances or drugs to 
Pt-containing subunits [19–24] and novel drug-delivery based methodologies have been explored to 
vehiculate platinum-based anti-cancer complexes directly against tumors [25,26]. 
Nucleoside and nucleotide anti-metabolites and their base analogues are able to inhibit specific 
pathways of the cancer cell metabolism by blocking the biosynthesis or the function of nucleic acids. 
For example, the combination of cisplatin and 5-fluorouracil, a chemotherapeutic agent that inhibits 
thymidylate synthase, has been extensively used in clinical practice to treat various types of cancer. 
Acyclovir, a guanosine nucleoside analogue containing an open-chain sugar surrogate, has been used 
as a ligand for platinum and the corresponding complex exhibits high in vitro activity against various 
herpes viruses [27]. Furthermore, the synthesis and the preliminary pharmacological activity of novel 
modified adenosines and thymidines, employed as N-donor ligands of platinum(II) dichloride 
complexes, have been recently reported [28,29]. 
Recently, we have reported the solid-phase synthesis and the pharmacological activity of the first 
examples of bis-platinated nucleoside complexes in which the mono-functional metal is linked both to 
N-7 of the purine nucleus of inosine and to the terminal amino-group of a hexylamine side chain 
installed on N-1 (compounds 1–3, Figure 1) [30]. The amino-alkyl chain was introduced on the purine 
base system through a chemical strategy recently developed by us [30–36]. These complexes showed 
very good water solubility thanks to the charged platinum centres and to the ribose hydroxyl groups. 
They were tested against four different human tumor cell lines and, in particular, the complex bearing 
two monofunctional cisplatin units was revealed to be more cytotoxic than cisplatin against the MCF7 
cancer cell line in a short-term exposure assay [30].  
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Figure 1. Bis-platinated nucleoside complexes synthesized starting from inosine [30]. 
 
In the light of the above results, to investigate the importance of nucleoside scaffolds in the 
construction of novel platinum complexes we have speculated about the antitumoral activity of 
cisplatin-adenosine complexes. As a result, in this paper we report on the synthesis of four dinuclear 
platinum complexes 8a,b and 10a,b (Scheme 1) carrying N6-(6-aminohexyl)adenosine (compound 5, 
Scheme 1) or a 1,6-di-(adenosin-N6-yl)-hexane (compound 9, Scheme 1) respectively, as ligands of 
mono-functional cisplatin or monochloro(ethylene diamine)platinum(II) (compounds 7a and 7b, 
respectively, Scheme 1). 
Scheme 1. Synthesis of complexes 8 and 10.  
 
Reagents and conditions: (i) NH2(CH2)6NH2 (7 equiv.), TEA, EtOH, 3 h, reflux; (ii) 4 (1.5 equiv.), 
TEA, EtOH, 5 h, reflux; (iii) AgNO3 (0.9 equiv.), DMF, 16 h, r.t.; (iv) 7a,b, 16 h, r.t.. 
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In the case of complexes 8a,b the monofunctional platinum centres are linked to the N-7 of the 
purine base and to the terminal amino group of a hexylamine side chain bonded to N-6, whereas for the 
complexes 10a,b they are both linked to N-7. 
Platinum complexes, endowed with particular structural strains, have been designed to evaluate 
alternative interactions with DNA strands [8,12,17,37,38]. The novel prepared complexes 8a,b and 
10a,b are characterized by a rigid planar purine substructure joined to a flexible hexylamine chain. On 
this basis, it could be expected that they may alter the binding mode with DNA through, for example, 
base-stacking or by the formation of multiple hydrogen bonds. Therefore, we have investigated the 
preliminary effects of these compounds on viability and proliferation in two different human cancer 
cell lines. 
2. Results and Discussion 
2.1. Synthesis and Characterization 
The synthesis of the novel modified adenosine-based platinum complexes 8a,b and 10a,b is 
depicted in Scheme 1. 6-Cloropurine riboside 4 proved to be a good candidate to obtain the key 
intermediate 5 from which the construction of complexes 8a,b and 10a,b has been accomplished. As 
reported by Schammells et al. [39] seven equivalents of 1,6-diaminohexane have proved sufficient to 
convert 4 into 5 in a very good yield (86%), avoiding the formation of dimeric species, which would 
complicate the purification procedure. In fact, the recovery of 5 from the reaction mixture was easily 
performed thanks to its insolubility in EtOH upon cooling. Compound 9 was prepared by reacting 4 
with a slight excess of 5. During the reaction, this substance precipitated from the reaction mixture as a 
white solid which was then collected in 93% yield by filtration. This represents a very good 
improvement on the reported yield for 9 (12%) [40]. 
Next, the platinum-containing moieties were installed. In particular, treatment of 5 and 9 with a 
seven-fold excess of the suitable platinating complex 7a,b, activated by overnight reaction with 
AgNO3 (0.9 equiv.) in DMF, furnished the bisplatinated compounds 8a,b and 10a,b. Purification  
of these substances could be accomplished by reverse-phase HPLC only using a gradient of CH3CN  
in 0.1 M triethylammonium bicarbonate buffer (TEAB) as the solvent mixture, whereas complex 
chromatographic patterns were observed in the absence of the TEAB. 
The structures of complexes 8a,b and 10a,b (yields 58%–62%) were supported by 2D-NMR and 
positive mode high resolution mass spectrometry (HRMS) data; whereas their purity was ascertained 
by CHN analyses.  
In Figure 2 (panel A) the representative HRMS spectrum of complex 8a is reported; in particular, 
the isotopic pattern of the base peak (expansion, panel B) perfectly fits with that of the calculated one 
(expansion, panel C), confirming the presence of two Pt and two Cl atoms and a net 2+ charge. 
In the1H-NMR spectra of 8a,b and 10a,b the downfield shift of H-8, compared with the resonance 
of the same proton in 5 and 7 (?? = 0.6 and 0.5, respectively), confirmed the presence of the  
N(7) ? Pt bond in all these substances [41,42]. In Table 1 the differences between the 13C-NMR shifts 
of the Pt-coordinated and not-coordinated purine carbon atoms (?? = ?complex ? ?ligand, ppm) are listed: 
in the case of complexes 8a,b significant coordination shifts were found for the C-5 and C-8 atoms, 
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whereas for the complexes 10a,b the C-5 atoms underwent the major shifts. Further evidence of 
metallation at N-7 come from the increased acidity of the H-8 as indicated by the reduced intensity of 
the pertinent signal in the 1H-NMR spectra of 8a,b and 10a,b, when these complexes were dissolved in 
D2O and the spectra acquired after several hours [43]. 1H-NMR analyses excluded also the presence of 
equilibria involving migrations of the platinum moieties from N-7 to N-1 of the nucleobases; such 
migrations would shift the H-2 resonances of complexes 8a,b and 10a,b to higher frequences in 
comparison to the same signals of compounds 5 and 9, respectively [44]. The resonances of the 
methylene protons belonging to the CH2-NH2-Pt moieties were seen as broad partly overlapped triplets 
in the range 2.3–2.7 ppm, in the proton spectra of 8b and 10b, likewise the protons of the methylene 
group geminal to platinum in 8a resonated as a triplet at ? 2.6. In 13C-NMR spectra of 8a and 8b the  
5 ppm downfield shift of the ?-methylene carbon could be a consequence of the NH2 platination. 
Figure 2. HRMS spectrum of complex 8a (panel A). Expansion of the isotopic pattern of 
the base peak (panel B) and of the corresponding calculated one (panel C). 
 
In the UV spectra of the complexes 8a,b and 10a,b the maxima of absorption appeared red-shifted 
(?? = 10–13 nm) in respect to those of the free ligands, in accordance with literature data [45]. 
Comparison of the IR spectra of the ligands and complexes did not provide evidence about the bonding 
mode of the ligands in the complexes; in fact in the 4000–2700 cm?1 region very little information 
could be obtained about the nature of metal-ligand interaction, because of the presence of broad and 
intense bands belonging to hydrogen-bonded hydroxyls of the ribose moieties. The 1800–400 cm?1 
region, where vibration frequencies of purine and ribose skeletons fall, did not furnish significant 
differences between platinated and not-platinated nucleosides. Furthermore, in the region 550–400 cm?1, 
where the resonances of Pt-N could be expected [45,46], no distinctive bands were observed. 
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Table 1. Differences between the 13C-NMR shifts of the Pt-coordinated and not-coordinated 
purine carbons (?? = ?complex ? ?ligand, ppm). 
Entry 
13C-NMR (??, ppm) 
C-2 C-4 C-5 C-6 C-8 
8a [39] ?1.0 ?1.4 ?2.9 0.9 2.1 
8b [39] ?1.0 ?1.3 ?2.8 0.9 2.1 
10a ?1.9 ?2.3 ?4.2 ?0.1 0.9 
10b ?2.0 ?2.5 ?4.2 0.1 1.1 
2.2. Cytotoxicity Studies 
The synthesized complexes were subjected to preliminary cell viability and proliferation assays.  
In particular, the cytotoxic behaviour was studied in A549 adenocarcinomic human alveolar basal 
epithelial and MCF7 human breast adenocarcinomic cancer cell lines by MTT and BrdU assays, to 
investigate the potential effects of platinum complexes on cell viability and proliferation, respectively. 
The incubation of A549 cells with 8a,b and 10a,b (50, 100 and 200 μM) for 72 h caused a 
concentration-dependent reduction of cell survival (Figure 3, panel A) as well as an inhibition of cell 
proliferation at the higher concentrations (Figure 3, panel B) compared to untreated cells. Indeed, 
comparable results were obtained when the cell number was directly determined by cell counting (data 
not shown).  
Figure 3. Effect of 8a, 8b, 10a and 10b on cell viability and proliferation. A549 cells were 
incubated with cisplatin, 8a, 8b, 10a and 10b (50, 100 and 200 μM) for 72 h. Thereafter, 
cell viability (panel A) and proliferation (panel B) were determined, respectively, by MTT 
and BrdU assay as described in the Experimental Section (*** p < 0.001, ** p < 0.01,  
* p < 0.05 vs. untreated cells).  
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Figure 3. Cont. 
 
The compounds 8b, 10a and 10b (50, 100 and 200 μM) modified the viability and proliferation of 
MCF7 cells at higher concentrations, according to the published evidence that these cells have been 
associated with cisplatin resistance [47]. The compound 8a proved to reduce the proliferation of the 
MCF7 cell line with a greater ability than the other compounds. Strikingly, compound 8a was able to 
inhibit the cell proliferation slightly better than cisplatin, but only at 50 μM concentration (Figure 4). 
Figure 4. Effect of 8a, 8b, 10a and 10b on cell viability and proliferation. MCF7 cells 
were incubated with cisplatin, 8a, 8b, 10a and 10b (50, 100 and 200 μM) for 72 h. 
Thereafter, cell viability (panel A) and proliferation (panel B) were determined, respectively, 
by MTT and BrdU assay as described in the Experimental Section (*** p < 0.001,  
** p < 0.01, * p < 0.05 vs. untreated cells).  
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3. Experimental Section  
3.1. General Methods 
All the reagents and solvents were obtained from commercial sources and used without further 
purification. 1H- and 13C-NMR spectra were acquired on Varian Mercury Plus 400 MHz instrument 
using D2O or (CD3)2SO as solvents. Chemical shifts were reported in parts per million (?) relative to 
the residual solvent signal (1H: HDO 4.80; 13C: (CD3)(CD2H)SO 40.4) and assigned by 2D-NMR 
experiments. UV spectra were recorded on a Jasco V-530 UV spectrophotometer. IR spectra were 
recorded on a Jasco FT-IR 430 spectrophotometer. High-resolution MS spectra were recorded on a 
Thermo Orbitrap XL mass spectrometer using the electrospray ionization (ESI) technique in positive 
mode. Elemental analyses were performed on a Thermo Finnigan Flash EA 1112 CHN analyzer.  
RP-HPLC analyses and purifications were carried out on a Jasco UP-2075 Plus pump, equipped with a 
Jasco UV-2075 Plus UV detector, using a C-18 reverse-phase column (5 μm, 4.8 × 150 mm), eluted 
with a linear gradient of CH3CN in 0.1 M triethylammonium bicarbonate (TEAB) buffer (System A: 
from 0% to 50% in 90 min, flow 1.3 mL/min, or System B: from 0% to 100% in 90 min, flow  
1.3 mL/min). Human alveolar basal carcinoma epithelial cells (A549) and human breast cancer cells 
(MCF7) were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
Foetal bovine serum (FBS), 100 U/mL penicillin and 100 U/mL streptomycin at 37 °C under 5% CO2. 
The cell lines were all from the ATCC catalogue. All media and supplements for cell culture were 
purchased from Gibco-Invitrogen (GE Healthcare). 
N6-(6-Aminohexyl)adenosine (5). Compound 5 (326 mg) was obtained by reaction of 4 (297 mg,  
01.04 mmol) in accordance to the procedure by Schammells et al. [37]. Spectroscopic data and yields 
were in agreement with those reported by the authors. 
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1,6-Di-(adenosin-N6-yl)-hexane (9). Compound 5 (100 mg, 0.27 mmol), 6-chloropurine riboside (4, 
116 mg, 0.40 mmol), Et3N (41 μL, 0.30 mmol) were refluxed in EtOH (1 mL). During the reaction, a 
colourless solid precipitated from the reaction. After 5 h it was filtered, washed with boiling EtOH and 
dried, giving 9 as a colourless powder (164 mg, 93%). El. An. Calcd. for C26H36N10O8: C, 50.64; H, 
5.88; N, 22.72. Found: C, 50.68; H, 5.90; N, 22.69. 1H-NMR and UV data were in agreement with 
those reported in literature [38]. 13C-NMR (100 MHz, (CD3)2SO) ? 155.6 (C-2), 153.3 (C-6), 149.1  
(C-4), 140.5 (C-8), 120.7 (C-5), 88.9 (C-1'), 86.9 (C-4'), 74.4 (C-2'), 71.6 (C-3'), 62.6 (C-5'), 40.8 
(CH2NH, covered by residual solvent signal), 30.0 (CH2), 27.1 (CH2); IR (KBr pellet) 3336, 2935, 
2861 1630, 1587, 1537, 1474, 1418, 1369, 1334, 1307, 1221, 1185, 1130, 1097, 1058, 985, 866, 822, 
793, 641, 554 cm?1; m/z 639.2620 (HRESIMS) ([M + Na]+, C26H36N10NaO8, requires 639.2615). 
3.2. General Procedure for the Preparation of Dinuclear Platinum Complexes 8a,b and 10a,b 
In a representative experiment, cisplatin (57 mg, 0.19 mmol) was activated by treatment with 
AgNO3 (29.0 mg, 0.17 mmol) in DMF (2 mL) in the dark (16 h, r.t.). AgCl was removed by filtration 
and the resulting solution of [Pt(NH3)2(Cl)DMF]+(NO3)? in DMF was added to compound 5 (10 mg, 
0.027 mmol). The solution was shaken in the dark (16 h, r.t.) and then filtered over a GHP Acrodisc  
13 mm syringe filter (0.45 μm GHP membrane). The filter was washed with the minimal amount  
of DMF and the clarified solution was then subjected to HPLC purification [system A for 8a,b (tR: 
38.7 min and 38.4 min respectively) and system B for 10a,b (tR: 31.0 min and 31.5 min respectively), 
see General Methods]; the fractions containing the title compound were evaporated under reduced 
pressure and then lyophilized affording pure 8a. 
Compound 8a. Bis-bicarbonate salt (17 mg, 60%). El. An. Calcd. for C18H40Cl2N10O10Pt2: C, 21.24; H, 
3.96; N, 13.76. Found: C, 21.21; H, 3.98; N, 13.79. 1H-NMR (400 MHz, D2O) ? 8.84 (s, 1H, H-8), 
8.33 (s, 1H, H-2), 6.12 (bs, 1H, H-1'), 4.78–4.76 (m, 1H, H-2', partially covered by solvent signal), 
4.43–4.36 (m, 1H, H-3'), 4.31–4.25 (m, 1H, H-4'), 3.97–3.76 (m, 2H, Ha,b-5'), 3.67–3.55 (m, 2H, CH2N), 
2.62 (t, J = 6.4 Hz, 1H, CH2NH2Pt), 1.86–1.72 (m, 2H, CH2), 1.71–1.59 (m, 2H, CH2), 1.57–1.34 
(complex signal, 4H, 2 × CH2); 13C-NMR (100 MHz, D2O) ? 160.2 (2 × HCO3?), 153.7 (C-2), 153.2 
(C-6), 146.8 (C-4), 141.6 (C-8), 116.8 (C-5), 89.1 (C-1'), 85.9 (C-4'), 73.9 (C-2'), 70.1 (C-3'), 61.0  
(C-5'), 45.7 (CH2NH2), 40.7 (CH2NH), 29.8 (CH2), 28.0 (CH2), 25.4 (CH2), 25.2 (CH2). IR (KBr 
pellet) 3246, 2930, 1626, 1589, 1492, 1339, 1084, 1058, 835, 790, 553 cm?1; UV (H2O) ?max = 277 nm; 
HRESI-MS: (m/z) 447.0870, calcd. [M]2+ 447.0859. 
Compound 8b. Bis-bicarbonate salt (17 mg, 58%). El. An. Calcd. for C22H44Cl2N10O10Pt2: C, 24.70; H, 
4.15; N, 13.09. Found: C, 24.73; H, 4.13; N, 13.06. 1H-NMR (400 MHz, D2O) ? 8.85 (s, 1H, H-8), 
8.39 (s, 1H, H-2), 6.16 (d, J = 5.0 Hz, 1H, H-1'), 4.80 (m, 1H, H-2', covered by solvent signal),  
4.48–4.41 (m, 1H, H-3'), 4.37–4.30 (m, 1H, H-4'), 4.00–3.84 (m, 2H, Ha,b-5'), 3.78–3.67 (m, 2H, 
CH2N), 2.85–2.50 (complex signal, 10H, CH2NH2Pt and 4 × CH2 ethylene diamine moieties)  
1.91–1.78 (m, 2H, CH2), 1.77–1.62 (m, 2H, CH2), 1.61–1.36 (complex signal, 4H, 2 × CH2); 13C-NMR 
(100 MHz, D2O) ? 160.2 (2 ×?HCO3?), 153.7 (C-2), 153.2 (C-6), 146.9 (C-4), 141.6 (C-8), 116.9  
(C-5), 89.1 (C-1'), 85.9 (C-4'), 73.9 (C-2'), 70.1 (C-3'), 61.0 (C-5'), 48.3, 48.0, 47.1 (4 × CH2 ethylene 
diamine moieties), 45.9 (CH2NH2), 40.7 (CH2NH), 29.9 (CH2), 28.1 (CH2), 25.5 (CH2), 25.2 (CH2); IR 
Molecules 2014, 19 9348 
 
(KBr pellet) 3406, 3208, 2931, 1627, 1589, 1470, 1336, 1303, 1232, 1079, 1054, 834, 790, 555,  
472 cm?1; UV (H2O) ?max = 278 nm; HRESI-MS: (m/z) 473.1037, calcd. [M]2+ 473.1031.  
Compound 10a. Bis-bicarbonate salt (12 mg, 60%). El. An. Calcd. for C28H50Cl2N14O14Pt2: C, 26.53; 
H, 3.97; N, 15.47. Found: C, 26.50; H, 3.95; N, 15.45. 1H-NMR (400 MHz, D2O) ? 8.85 (s, 2H, 2 × H-8), 
8.26 (s, 2H, 2 × H-2), 6.14 (bs, 2H, 2 × H-1'), 4.80 (m, 2H, 2 × H-2', covered by solvent signal),  
4.50–4.40 (m, 2H, 2 × H-3'), 4.38–4.29 (m, 2H, 2 × H-4'), 4.03–3.76 (complex signal, 6H, 2 × Ha,b-5' 
and 2 × CHaN), 3.67–3.53 (m, 2H, 2 × CHbN), 1.94–1.75 (m, 4H, 2 × CH2), 1.73–1.51 (m, 4H, 2 × CH2); 
13C-NMR (100 MHz, D2O) ? 160.2 (HCO3?), 153.7 (C-2), 153.2 (C-6), 146.8 (C-4), 141.4 (C-8), 116.5 
(C-5), 89.1 (C-1'), 85.8 (C-4'), 74.0 (C-2'), 70.0 (C-3'), 61.0 (C-5'), 40.5 (CH2NH), 27.8 (CH2), 25.2 
(CH2); IR (KBr pellet) 3280, 2933, 1626, 1589, 1492, 1415, 1339, 1306, 1230, 1085, 1059, 985, 864, 
790, 552 cm?1; UV (H2O) ?max = 277 nm; HRESI-MS: (m/z) 572.1213, calcd. [M]2+ 572.1226. 
Compound 10b. Bis-bicarbonate salt (13 mg, 62%). El. An. Calcd. for C32H54Cl2N14O14Pt2: C, 29.12; 
H, 4.12; N, 14.86. Found: C, 29.15; H, 4.10; N, 14.83. 1H-NMR (400 MHz, D2O) ? 8.81 (s, 2H, 2 × H-8), 
8.24 (s, 2H, 2 × H-2), 6.14 (bs, 2H, 2 × H-1'), 4.80 (m, 2H, 2 × H-2', covered by solvent signal),  
4.49–4.41 (m, 2H, 2 × H-3'), 4.37–4.31 (m, 2H, 2 × H-4'), 4.04–3.83 (m, 4H, 2 × Ha,b-5'), 3.81–3.60 
(m, 4H, 2 × CH2N), 2.84–2.50 (complex signal, 8H, 4 × CH2, ethylene diamine moieties), 1.95–1.74 
(m, 4H, 2 × CH2), 1.72–1.52 (m, 4H, 2 ×?CH2); 13C-NMR (100 MHz, D2O) ? 160.1 (HCO3?), 153.6 
(C-2), 153.2 (C-6), 146.6 (C-4), 141.6 (C-8), 116.5 (C-5), 89.1 (C-1'), 85.7 (C-4'), 74.1 (C-2'), 70.1  
(C-3'), 61.2 (C-5'), 48.1, 47.3 (2 × CH2 ethylene diamine moieties) 40.5 (CH2NH), 27.7 (CH2), 25.1 
(CH2); IR (KBr pellet) 3284, 2930, 1625, 1592, 1490, 1417, 1338, 1310, 1233, 1083, 1061, 980, 860, 
791, 554 cm?1; UV (H2O) ?max 276 nm; HRESI-MS: (m/z) 598.1391, calcd. [M]2+ 598.1382. 
3.3. MTT Viability Assay 
The cells were plated in 96 culture wells (20 × 104 cells/well) and allowed to adhere overnight. 
Thereafter, the medium was replaced with fresh medium and the cells were incubated in the absence  
or presence of cisplatin, 8a, 8b, 10a and 10b (50, 100 and 200 μM). After 72 h, the cell viability  
was determined by using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) 
conversion assay [48]. Briefly, 10 μL of MTT (5 mg/mL) were added to the cells and incubated for  
an additional 3 h. After this time point, the cells were lysed and the dark blue crystals solubilized  
with 150 μL of a solution containing 50% (v:v) DMF, 20% (w:v) SDS with an adjusted pH of 4.5.  
The optical density (OD) of each well was measured with a microplate spectrophotometer (Multiskan 
MCCC/340, Titertek, Huntsville, AL, USA) equipped with a 620 nm filter. The experiment was 
performed twice in triplicate. The vitality inhibition, induced by each compound at the indicated 
concentrations, was expressed as a percentage versus the untreated cells (the control). The viable cells 
were also counted by the trypan blue exclusion assay and light microscopy. 
3.4. BrdU Cell Proliferation Assay 
The cells were plated onto 96-well plates (2 × 104 cells/well) overnight. Then, the medium was 
replaced with fresh medium and the cells were incubated in the absence or presence of cisplatin (50, 
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100 and 200 μM), 8a, 8b, 10a and 10b (50, 100 and 200 μM). After 72 h, 5-bromo-2'-deoxyuridine 
(BrdU; 10 μM) was added and the cells were cultured for a further 12 h. The mitogenic activity was 
determined according to the manufacturer’s instructions (BrdU cell proliferation assay kit, Cell 
Signaling). The experiment was performed three times in triplicate. The proliferation inhibition, 
induced by each compound at the indicated concentrations, was expressed as a percentage versus the 
untreated cells (the control).  
3.5. Statistical Analysis 
The results are expressed as the means ± SEM of n experiments. The statistical significance was 
calculated by one-way analysis of variance (ANOVA) and Bonferroni-corrected p-value for multiple 
comparison testing. The level of statistically significant difference was defined as p < 0.05. 
4. Conclusions 
In summary, in this paper we have reported the synthesis of four novel platinum complexes embodying 
a N6-(6-aminohexyl)adenosine or a 1,6-di-(adenosin-N6-yl)-hexane as ligands of monofunctional 
cisplatin or monochloro(ethylene diamine)platinum(II) moieties, starting from commercially available 
6-chloropurine riboside. The designed synthetic route allowed us to obtain the desired platinum 
complexes without blocking the ribose hydroxyl groups and through easy purification steps. 
The effects of these platinum complexes on cell viability and proliferation have been studied in 
A549 and MCF7 cell lines. Our data demonstrate that these compounds are able to inhibit the survival 
and proliferation of sensitive cancer cells. Nevertheless, cisplatin remains the most active molecule 
under our experimental conditions. Further experiments are necessary to understand the mechanism by 
which 8a penetrates into the cells and inhibits cell proliferation in the MCF7 cell line.  
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Synthesis of mixed-sequence oligonucleotides on
mesoporous silicon: chemical strategies and
material stability
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Abstract
Rapid screening tests in medical diagnostic and environmental analysis are often based on oligonucleotide biochips.
In this paper, we studied the stability of functionalized mesoporous silicon supports in the solid-phase synthesis of
oligonucleotides, exploiting several chemical procedures. A 19-mer mixed sequence has been successfully synthesized
on aminosilane-modified porous silicon photonic structures. The process and the materials have been characterized by
optical reflectivity, atomic force microscopy and high-performance liquid chromatography.
Keywords: Mesoporous silicon functionalization; DNA synthesis; Deprotection conditions; Surface stability
Background
DNA chip technology has greatly evolved over the last
decade, moving from pure genomics towards a number
of biotechnology applications such as human disease
diagnostics [1], environmental monitoring and food con-
trol [2,3]. DNA chips can be classified as a special class
of biosensors since they are realized by immobilization
of single-stranded oligonucleotides (ONs), the bioprobe,
on a transducer surface. Any molecular interaction be-
tween the bioprobe and its ligands, such as hybridization
to the complementary DNA sequence or protein bind-
ing, is then transduced into an analytical signal by an
electrochemical-, optical- or surface plasmon resonance-
based or electrical device, depending on the specific
technology used. Porous silicon (PSi) is by far one of the
most popular transducer materials due to its peculiar
physical and chemical properties [4]. PSi is fabricated by
electrochemical etching of crystalline silicon in aqueous
hydrofluoric acid. Depending on etch time, current density
and acid concentration, several porous morphologies can
be obtained, from micropores (average pore size <5 nm)
to macropores (average pore size >50 nm) [5]. The resul-
ting sponge-like matrix possesses a very large specific
surface area (up to 300 m2/cm3): gases and liquids can
easily get into pores, thus changing the optical, chemical
and electrical properties of PSi [6]. Even if electrochemical
etching induces silicon dissolution, the resulting PSi sur-
face is smooth enough to get very good quality optical
devices, also in the case of multilayered structures [7].
Periodic, or quasi-periodic, alternation of high- and low-
porosity layers is used for fabrication of Bragg reflectors,
microcavities and Thue-Morse sequences: all these pho-
tonic devices exhibit resonance wavelengths that can be
used as monitoring peak in quantifying biomolecular in-
teraction from the optical point of view [8-10]. The PSi
surface can be properly passivated and functionalized in
order to covalently bind biological molecules such as
single- or double-stranded DNA, proteins, enzymes, an-
tibodies, aptamers and so on, which act as bioprobes.
There are many routes to achieve surface functionaliza-
tion which are based on proper chemical or biological
processes: the PSi surface can be activated by specific
chemical groups, namely -SH, -NH2 or -COOH, that
could form very stable bonds, such as sulphide or peptide
bond, with the biological molecule considered [11]. For
some biomolecules that are usually synthesized ex situ
and then coupled on the PSi surface, there is also the pos-
sibility of directly growing the molecules using PSi as
support in the so-called solid-phase synthesis [12].
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In this article, we describe the fabrication and the cha-
racterization of a PSi-based DNA chip for biochemical op-
tical sensing through in situ mixed-sequence ON growth.
Since the chemistry used for the solid-phase synthesis of
ON can be quite aggressive against the PSi solid support,
the chemical stability of PSi supports is a key issue that
must be checked and satisfied for each considered sub-
strate. In particular, it is well known that PSi suffers upon
exposure to alkaline solutions (commonly used for the
deprotection of nucleobases) that can easily corrode the
silicon skeleton, so a trade-off between PSi surface passiv-
ation and suitable solid-phase synthesis chemistry must be
found. We focused our studies on silanization of PSi by
using two different siloxanes and also on the exploitation
of different chemical approaches for the ON deprotection
in order to preserve the stability of PSi during all phases
of synthesis and sensing.
Methods
Mesoporous silicon microcavity fabrication
PSi microcavities constituted by a λ/2 layer (optical
thickness) sandwiched between two 9.5-period Bragg re-
flectors (BRs) were obtained alternating low (L) and high
(H) refractive index layers whose thicknesses satisfy the
Bragg relationship nHdH + nLdL =mλB/2, where m is an in-
teger and λB is the Bragg wavelength. The microcavities
were prepared by electrochemical etching of highly doped
p+ crystalline silicon (0.001-Ω cm resistivity, <100 > -ori-
ented, 500 μm thick) in HF solution (HF:ethanol 1:1) in
the dark at room temperature (RT). Before the anodiza-
tion process, the silicon substrate was immersed in HF so-
lution for 2 min to remove the native oxide layer. Since
the PSi fabrication process is self-stopping, it is possible to
obtain adjacent layers with different porosities by chan-
ging the current density during the electrochemical etch-
ing [4]. A current density of 200 mA/cm2 for 1.2 s was
applied to obtain low refractive index layers (nL = 1.542;
dL = 125 nm) while a current density of 100 mA/cm
2 was
applied for 1.4 s for high refractive index layers (nH =
1.784; dH = 108 nm). After the electrochemical process,
the pore dimension was increased to favour the infil-
tration of biological matter by rinsing the fresh-made
PSi microcavities in a KOH ethanol solution (1.5 mM) for
15 min [5]. The structures were then thermally oxidized
against uncontrolled environmental aging and corrosion
in alkaline solutions. The thermal oxidation has been per-
formed in pure O2 by a two-step process: pre-oxidation
at 400°C for 30 min followed by oxidation at 900°C
for 15 min.
Silane surface modifications
Eight oxidized PSi microcavities (PSi-Ma-h) were immersed
in piranha solution (H2O2:H2SO4 1:4) at RT for 30 min to
generate Si-OH groups on the PSi surface. After that, the
samples were extensively washed in Milli-Q® water flow
(Millipore, Billerica, MA, USA) and dried with nitrogen
gas. Structures were then silanized by immersion in differ-
ent 5% aminosilane solutions, (3-aminopropyl)triethoxysi-
lane (APTES) or (3-aminopropyl)-dimethyl-ethoxysilane
(APDMES), in dry toluene for 30 min at RT. Samples PSi-
Ma,c,e,g were silanized by APTES and samples PSi-Mb,d,f,h
by APDMES. The reaction conditions were optimized
on a crystalline silicon-varying solvent for silane dissol-
ution and incubation time [12]. The PSi-silanized samples
were rinsed three times in the solvent used for the process
so as to remove the ungrafted silanes. The last step of sila-
nization is curing at 100°C for 10 min.
Oligonucleotide synthesis
Chemicals and solvents were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Reagents and phosphora-
midites for DNA synthesis were purchased from Glen
Research (Sterling, VA, USA). Solid-phase ON syntheses
were performed on a PerSeptive Biosystem Expedite 8909
DNA automated synthesizer (Framingham, MA, USA).
The 19-mer mixed-sequence oligonucleotide 5′-GATTG
ATGTGGTTGATTTT-3′ was assembled on two different
aminosilane-modified microcavities, following phosphora-
midite chemistry by 19 growing cycles [13]. PSi structures,
PSi-Mg,h-NH2 (Mg = APTES, Mh =APDMES), were in-
troduced in a suitable column reactor to be used in the
automated synthesizer; the syntheses were performed ac-
cording to the scheme reported in Figure 1. In all cases,
the first reaction step involved the attachment of the
Figure 1 Synthetic procedure for solid-phase synthesis of aminosilane-modified mesoporous silicon. (i) Standard procedure for automated
ON synthesis. (ii) NH3/MeOH dry.
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3′-ending nucleobase to the amino group of PSi-bound
APTES or APDMES. This step required the activation of
the protected phosphoramidite dissolved in dry aceto-
nitrile via protonation by weakly acidic tetrazole (0.45 M
in acetonitrile). Once the first nucleobase was installed on
the solid support, the ON growth was obtained by repeat-
ing the following sequential steps of the automated ON
synthesis:
 Coupling: reaction of the protected phosphoramidite
dissolved in dry acetonitrile and activated via
protonation by weakly acidic tetrazole (0.45 M in
acetonitrile) with the 5′-OH ON terminal group.
 Oxidation: oxidation of the unstable phosphite
triester linkage to the more stable phosphotriester
by a standard oxidizing solution of iodine in
pyridine/acetonitrile.
 Capping: acylation of the unreacted 5′-OH ON
terminal groups by acetic anhydride in pyridine and
tetrahydrofuran to minimize deletion products and
simplify the purification process.
 Detritylation: removal of the 5′-dimethoxytrityl
(DMT) protecting group from the support-bound
5′-terminal nucleotide with the deblocking solution
of trichloroacetic acid in dichloromethane (3% w/w).
The amount of DMT cation released by acid treatment
was used as a direct measure of the efficiency of the on-
going synthesis. The release of the protecting group gen-
erates a bright red-orange colour solution in which the
quantity of the DMT cation can be measured online by
UV-vis spectroscopy at 495 nm (ε = 71,700 M−1 cm−1).
At the end of each growing cycle, the support was thor-
oughly washed with acetonitrile before the beginning of
the successive cycle.
Deprotection strategies
The devices PSi-Ma,b-NH2 (Ma = APTES, Mb = APDMES)
were left in contact with 33% aqueous ammonia at 55°C
for different times to investigate the effect of standard ON
deprotection condition (55°C for 17 h) on the PSi matrix
[14]. Two additional aminosilane-modified devices, PSi-
Mc,d-NH2, (Mc = APTES, Md = APDMES) were incubated
in anhydrous K2CO3 (0.05 M)/dry methanol solution at
55°C for different times to investigate the ‘ultra-mild’ ON
deprotection condition (55°C for 2 h) [14]. Finally, the ex-
posure to dry ammonia solution (NH3/MeOH dry) was
also explored as an alternative deprotection strategy [15].
To this aim, the aminosilane-modified samples PSi-Me,f-
NH2 (Me = APTES, Mf = APDMES) were exposed to dry
ammonia overnight at RT. The dry ammonia was gener-
ated by dissolving NaOH pellets in a sidearm flask con-
taining aqueous ammonia; the generated gas was passed
through a KOH drying tube and bubbled into a flask
equipped with a rubber septum and containing anhydrous
MeOH at 0°C.
The explored deprotection strategies carried out on
aminosilane-modified PSi microcavities are summarized
in Table 1.
Atomic force microscopy
A XE-100 AFM (Park Systems, Suwon, South Korea) was
used to study sample morphology. Surface imaging was
obtained in non-contact mode using silicon/aluminium-
coated cantilevers (PPP-NCHR 10 M, Park Systems,
Suwon, South Korea) 125 mm long with a resonance
frequency of 200 to 400 kHz and nominal force constant
of 42 N/m. The scan frequency was typically 1 Hz per line.
The scan area in surface analysis was 1 μm× 1 μm.
Spectroscopic reflectometry
Reflectivity spectra of PSi optical structures were ob-
tained by a simple experimental setup: a white light was
sent on PSi samples through a Y optical fibre (Avantes,
Apeldoorn, The Netherlands). The same fibre was used
to guide the output signal to an optical spectrum ana-
lyser (Ando AQ6315A, Tokyo, Japan). The spectra were
acquired at normal incidence over the range 600 to
1,200 nm with a resolution of 5 nm. The reflectivity
spectra shown in the graphs are the average of three
measurements for each sample.
High-performance liquid chromatography
The purification and control of the synthesized ONs was
carried out using a Jasco PU2089 PLUS HPLC system
(Easton, MD, USA) equipped with an anion exchange
column (1000-8/46, 4.4 × 50 mm, 5 μm, Macherey-Nagel,
Düren, Germany) using a linear gradient from 0% to
100% B in 30 min, flow rate = 1 mL/min and detec-
tion at 260 nm (buffer A: 20 mM NaH2PO4 aq. solution,
pH 7.0, containing 20% (v/v) CH3CN; buffer B: 20 mM
NaH2PO4 aq. solution, pH 7.0, containing 1 M NaCl and
20% (v/v) CH3CN).
Table 1 Deprotection strategies
Deprotection strategy Exposition time Sample
NH3(l) @55°C 30 min; 1 h; 2 h PSi-Ma-NH2
PSi-Mb-NH2
K2CO3/MeOH @55°C 30 min; 1 h; 2 h;
5 h; 8 h; overnight
PSi-Mc-NH2
PSi-Md-NH2
NH3(g) @RT Overnight PSi-Me-NH2
PSi-Mf-NH2
PSi-Mg-NH2-oligo
PSi-Mh-NH2-oligo
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Results and discussion
In our previous work [16], we investigated the passiva-
tion ability of oxidized PSi multilayered structures by two
aminosilane compounds (APTES and APDMES) used for
the in situ synthesis of a 13-mer polythymine ON strand.
We successfully demonstrated that even using the less ag-
gressive carbonate/methanol solution as the ON deprotec-
tion system, hybridization with the complementary ON
target took place, thus confirming that ONs can be syn-
thesized and deprotected on the PSi surface. However,
the synthesis of mixed-sequence ONs using the carbo-
nate/methanol solution in the final ON deprotection
step would require the use of highly expensive ultra-
mild nucleobase-protected phosphoramidites character-
ized by having non-standard very labile protecting groups.
In the present paper, we describe the results of alternative
PSi-friendly ON deprotection conditions during the in situ
synthesis of mixed-sequence ONs on PSi supports by
using standard phosphoramidite nucleoside monomers,
without using ultra-mild reagents.
Measurement of optical spectra by spectroscopic re-
flectometry is very useful since both the position of res-
onance wavelength and the shape of lateral fringes give
quantitative information about PSi corrosion or stability:
the peak wavelengths of each PSi-Ma-h microcavity be-
fore and after silanization are reported in Table 2. Both
APTES and APDMES covered the pore walls by a thin
film: the aminosilane layer substitutes air in the pores and
increases the average refractive index of PSi layers, result-
ing in a shift of reflectivity spectra towards greater wave-
lengths. The thicknesses of the APTES and APDMES
layers coating the pore walls were estimated from red
shifts: in the first case, we observed a 22 nm red shift, cor-
responding to a silane layer of 0.7 nm; in the second, the
red shift was about 10 nm, corresponding to a silane layer
of 0.2 nm [16]. These numbers are consistent with the
different behaviours of the polymers: APTES generally
cross-links after curing, producing a compact and thicker
sheet of silane, whereas APDMES does not polymerize. A
direct evidence of the slightly distinct morphologies of
aminosilane-modified surfaces was given by atomic force
microscopy (AFM). The AFM images of bare oxidized PSi
and APTES- and APDMES-modified porous PSi surfaces
are reported in Figure 2. The AFM image of porous SiO2
reveals a sponge-like structure characterized by hillocks
and voids randomly distributed on the whole surface; pore
size can be estimated to be on the order of 20 nm. After
APTES grafting (porous SiO2 + APTES), most voids dis-
appear due to partial pore cloaking by the silane layer
coating the pore walls. Quite the same result is obtained
in the case of APDMES modification (porous SiO2 +
APDMES): even if APDMES forms a thinner layer, voids
in the porous matrix are strongly reduced. Further investi-
gations about the effect of this steric hindrance on oligo-
nucleotide synthesis are also required.
The reflectivity spectra and graphs of peak shift vs
incubation time for PSi-Ma,b-NH2 microcavities (Ma =
APTES; Mb = APDMES) before and after treatment
with 33% aqueous ammonia (17 h, 55°C) used in the stan-
dard deprotection condition are reported in Figure 3. The
stability of the surfaces was tested by a full dip in ammo-
nia solution for different times. The results showed that
the destructive effect of ammonia solution was about the
same for both samples: a blue shift of 25 or 50 nm was de-
tected after 30 min or 1 h, respectively, and the complete
dissolution of the silicon matrices occurred after 2 h.
Because aqueous ammonia could not be used in depro-
tection steps, we checked the stability of PSi-Mc,d-NH2
(Mc = APTES; Md =APDMES) at the so-called ultra-mild
deprotection condition (0.05 M K2CO3/dry methanol at
55°C for 2 h). Sample PSi-Mc-NH2 showed better che-
mical resistance than sample PSi-Md-NH2. In particu-
lar, a progressive shift of the optical reflectivity spectrum
towards shorter wavelength was observed only after more
than 2 h of incubation for PSi-Mc-NH2, whereas PSi-
Md-NH2 resulted in being partially stable in ultra-mild
deprotection condition only up to 30 min (see plots in
Figure 4).
As the last route in the deprotection strategy, we tested
the saturated dry methanolic ammonia solution. Both the
two aminosilane-modified PSi structures (PSi-Me,f-NH2)
were highly stable at this condition. In Figure 5, we have
reported the reflectivity spectra of PSi microcavities before
and after treatment with NH3/MeOH dry. In both cases,
any shift cannot be observed, thus confirming the feasibil-
ity of this deprotection condition.
Once deprotection conditions were checked and fixed
for PSi samples, two microcavities, namely PSi-Mg,h-NH2,
were used as supports for automated in situ solid-phase
ON synthesis using the standard phosphoramidite chem-
istry. The amount of 5′-dimethoxytrityl released after the
Table 2 Peak shift of devices after surface modification
by APTES or APDMES
Sample Pre-silanization Post-silanization Peak
shift (nm)Peak wavelength
(nm) Er±
Peak wavelength
(nm) Er±
PSi-Ma 631.3 ± 0.3 653.3 ± 0.1 22.2
PSi-Mb 640.1 ± 0.1 651.0 ± 0.2 11
PSi-Mc 635.7 ± 0.5 656.9 ± 0.4 21.2
PSi-Md 628.4 ± 0.6 640.7 ± 0.3 12.3
PSi-Me 708.2 ± 0.2 730.3 ± 0.6 22.3
PSi-Mf 714.7 ± 0.1 722.3 ± 0.4 8
PSi-Mg 706.5 ± 0.3 727.8 ± 0.1 21.3
PSi-Mh 665.6 ± 0.4 673.7 ± 0.2 8.1
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detritylation step was used to quantify the functionaliza-
tion yield of each synthesis cycle by UV-vis spectroscopy
as shown in Figure 6 [16,17]. Up to the fourth coupling
cycle, we observed almost the same coupling yield for
both aminosilane-functionalized PSi supports. From the
fifth cycle on, the coupling yields dropped for both sup-
ports, even if higher functionalization yields were gener-
ally observed for PSi supports functionalized with APTES.
Figure 6 also shows the reflectivity spectra of devices
before and after the in situ synthesis process: red shifts
of 60 and 70 nm were detected, respectively, for APTES-
and APDMES-modified devices, thus indicating that
more ON had grown on the latter device with respect
to the first one. This experimental result is ascribed to
the less steric hindrance of pores due to the thinner
APDMES layer, as already demonstrated in our previous
work [16].
In both samples, we have measured the red shifts
upon exposure to saturated ethanol atmosphere (data
not shown here), in order to check if pores could be
completely filled up by ON growth: in both cases, we
measured red shifts of about 100 nm, just a little bit
lower, but of the same order, than those registered in
the same experiment after fabrication and silane func-
tionalization. Even if this result is not accurate as standard
pore characterization (such as gas adsorption or thermo-
porometry), it clearly confirms a minor variation in pore
dimensions.
We demonstrated the ability of NH3/dry MeOH solu-
tion to completely deprotect the PSi-aminosilane-bound
ON by treating the functionalized samples with NH3/
MeOH at room temperature. We observed by chromato-
graphic analysis that the amide-bound N-2 isobutyryl
(on G), N-6 benzoyl (on A) and N-4 benzoyl (on C) were
Figure 2 AFM images of bare oxidized PSi and aminosilane-modified oxidized PSi surfaces.
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completely cleaved after 3 h at room temperature. Fur-
thermore, it is reported that the ammonia in dry MeOH
is able to quickly remove the 2-cyanoethyl phosphate
protecting group [15]. This data, together with our find-
ings on the compatibility with the silicon structure, indi-
cates the NH3/dry MeOH solution as the best choice to
deprotect the exocyclic amino groups of nucleobases
and the phosphate groups without promoting the basic
hydrolysis on the support, which would instead occur in
aqueous conditions. The blue shift of only 2 to 4 nm,
which we attribute to the removal of N-2, N-4 and N-6
groups, has been detected after this procedure for in situ
ON synthesis on PSi-APTES or PSi-APDMES supports,
respectively (see plots in Figure 7).
Conclusions
In the present study, we propose and validate by optical
measurements a new method to achieve the in situ syn-
thesis of tailored oligonucleotide sequences on porous
silicon supports suitable for label-free optical biosensing.
In particular, we demonstrate that, differently from aque-
ous ammonia, the use of dry ammonia in methanol allows
the effective deprotection of nucleobases without harming
the structural integrity of the porous silicon matrix, thus
opening the way for the direct growing of mixed-sequence
ONs on optically active PSi supports using exclusively in-
expensive standard phosphoramidites. A 19-mer mixed-
sequence 5′-GATTGATGTGGTTGATTTT-3′ has been
synthesized in mesoporous PSi microcavities, resulting
in a medium-yield process, mainly due to the average
pore size (about 20 nm). PSi photonic devices with pore
dimensions greater than that value, but always compat-
ible with high optical quality response in the visible-
near-infrared, therefore between 50 and 100 nm, will
be considered in the next experiments, in order to
maximize yield synthesis. Moreover, more stable PSi
supports could also be considered, such as those pro-
duced by thermal acetylation, which maintains pore
size and makes it very stable from the chemical point
of view [18].
Figure 3 Reflectivity spectra of APTES- and APDMES-modified PSi microcavities before and after incubation in 33% NH3. (A) Left:
reflectivity spectra of APTES-modified PSi microcavity before (solid line) and after 30 (dashed line) and 60 (dotted line) min of incubation in 33%
NH3 at 55°C. Right: corresponding peak shift vs incubation time. (B) Left: reflectivity spectra of APDMES-modified PSi microcavity before (solid line)
and after 30 (dashed line) and 60 (dotted line) min of incubation in 33% NH3 at 55°C. Right: corresponding peak shift vs incubation time.
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Figure 4 Reflectivity spectra of APTES- and APDMES-modified PSi microcavities before and after incubation in K2CO3/MeOH dry. (A)
Left: reflectivity spectra of APTES-modified PSi microcavity before (red solid line) and after (dashed line) incubation in K2CO3/MeOH dry at 55°C for
different times. Right: corresponding peak shift vs incubation time. (B) Left: reflectivity spectra of APDMES-modified PSi microcavity before (red
solid line) and after (dashed line) incubation in K2CO3/MeOH dry at 55°C for different times. Right: corresponding peak shift vs incubation time.
Figure 5 Reflectivity spectra of APTES- and APDMES-modified PSi microcavities before and after exposure to NH3/MeOH dry and
ammonia. (A) Reflectivity spectra of APTES-modified PSi microcavity before (solid line) and after (red dashed line) exposure to NH3/MeOH dry
solution at RT. (B) Reflectivity spectra of APDMES-modified PSi microcavity before (solid line) and after (red dashed line) exposure to ammonia
solution at RT.
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Figure 6 Reflectivity spectra of APTES- and APDMES-modified PSi microcavities before and after ON synthesis. (A) Left: reflectivity spectra of
APTES-modified PSi microcavity before (solid line) and after (dashed line) ON synthesis. Right: corresponding UV intensity vs ON synthesis. (B) Left:
reflectivity spectra of APDMES-modified PSi microcavity before (solid line) and after (dashed line) ON synthesis. Right: corresponding UV intensity vs
ON synthesis.
Figure 7 Reflectivity spectra of APTES- and APDMES-modified PSi microcavities before and after the deprotection process. (A)
Reflectivity spectra of APTES-modified PSi microcavity functionalized with oligonucleotides before (solid line) and after (red dashed line) the
deprotection process with gaseous ammonia solution. (B) Reflectivity spectra of APDMES-modified PSi microcavity functionalized with oligonucleotides
before (solid line) and after (red dashed line) the deprotection process with gaseous ammonia solution.
Terracciano et al. Nanoscale Research Letters 2014, 9:317 Page 8 of 9
http://www.nanoscalereslett.com/content/9/1/317
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MT performed the experiments. LDS and IR designed the research. MT and
IR analysed the data and wrote the paper. LDS and NB corrected the paper.
MT prepared and characterized the samples. GO, SDE and FN performed the
oligonucleotide synthesis and characterization. IvR and GP have given final
approval of the version to be published. All authors read and approved the
final manuscript.
Acknowledgements
This work has been partially supported by the national project PON
Oncology.
Author details
1Institute for Microelectronics and Microsystems, National Council of
Research, Naples 80131, Italy. 2Department of Pharmacy, University of Naples
Federico II, Naples 80138, Italy.
Received: 24 April 2014 Accepted: 12 June 2014
Published: 25 June 2014
References
1. Heller MJ: DNA microarray technology: devices, systems, and
applications. Annu Rev Biomed Eng 2002, 4:129–153.
2. Wang J, Rivas G, Cai X, Palecek M, Nielsen P, Shiraishi H, Dontha N, Luo
D, Parrado C, Chicharro M, Flair MN: DNA electrochemical biosensors
for environmental monitoring. A review. Anal Chim Acta 1997,
347:1–8.
3. Leonard P, Hearty S, Joanne B, Lynsey D, Chakraborty T, O'Kennedy R:
Advances in biosensors for detection of pathogens in food and water.
Enzym Microb Technol 2003, 32:3–13.
4. Lehman V: Electrochemistry of Silicon. New York: Wiley; 2002.
5. Leigh C: Properties of Porous Silicon. London: INSPEC/IEE; 1997.
6. Bisi O, Ossicini S, Pavesi L: Porous silicon: a quantum sponge structure for
silicon based optoelectronics. Surf Sci Rep 2000, 38:1–126.
7. Pavesi L: Porous silicon dielectric multilayers and microcavities. La Rivista
del Nuovo Cimento 1997, 20:1–76.
8. De Tommasi E, Rendina I, Rea I, Di Sarno V, Rotiroti L, Arcari P, Lamberti A,
Sanges C, De Stefano L: Porous silicon based resonant mirrors for
biochemical sensing. Sensors 2008, 8:6549–6556.
9. De Stefano L, Rea I, Giardina I, Armenante A, Rendina I: Protein modified
porous silicon nanostructures. Adv Mat 2008, 20:1529–1533.
10. Moretti L, De Stefano L, Rea I, Rendina I: Periodic versus aperiodic:
enhancing the sensitivity of porous silicon based optical sensor.
Appl Phys Lett 2007, 90:191112.
11. Buriak JM: Illuminating silicon surface hydrosilylation: an unexpected
plurality of mechanisms. Chem Mater 2013, 26:763–772.
12. Terracciano M, Rea I, Politi J, De Stefano L: Optical characterization of
aminosilane-modified silicon dioxide surface for biosensing. J Europ Opt
Soc Rap Public 2013, 8:13075.
13. Ellington A, Pollard D: Synthesis and purification of oligonucleotides.
In Current Protocols in Molecular Biology. New York: Wiley; 2001:2.11.1–
2.11.25.
14. Kuijpers WHA, Huskens J, van Boeckel CAA: The 2-(acetoxymethyl)benzoyl
(AMB) group as a new base-protecting group, designed for the
protection of (phosphate) modified oligonucleotides. Tetrahedron Lett
1990, 31:6729.
15. Iyer RP, Dong Y, Jin X, Wen Z, Sudhir A: The use of gaseous ammonia
for the deprotection and cleavage steps during the solid-phase
synthesis of oligonucleotides, and analogs. Bio Med Chem Lett 1997,
11:1443.
16. De Stefano L, Oliviero G, Amato J, Borbone N, Piccialli G, Mayol L, Rendina I,
Terracciano M, Rea I: Aminosilane functionalizations of mesoporous
oxidized silicon for oligonucleotides synthesis and detection. J R Soc
Interface 2013, 10:20130160.
17. Rea I, Oliviero G, Amato J, Borbone N, Piccialli G, Rendina I, De Stefano L:
Direct synthesis of oligonucleotides on nanostructured silica multilayers.
J Phys Chem C 2010, 114:2617.
18. Salonen J, Laine E, Niinistö L: Thermal carbonization of porous silicon
surface by acetylene. J App Phys 2002, 91:456–461.
doi:10.1186/1556-276X-9-317
Cite this article as: Terracciano et al.: Synthesis of mixed-sequence
oligonucleotides on mesoporous silicon: chemical strategies and
material stability. Nanoscale Research Letters 2014 9:317.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Terracciano et al. Nanoscale Research Letters 2014, 9:317 Page 9 of 9
http://www.nanoscalereslett.com/content/9/1/317
???????????????????????????????
??????????????????????????????
????????????? ???????????????????????????
??????????????????????????????????????
Research Article 
Exploitation of a Very Small Peptide Nucleic Acid as a New 
Inhibitor of miR-509-3p Involved in the Regulation of Cystic 
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Computational techniques, and in particular molecular dynamics (MD) simulations, have been successfully used as a comple- 
mentary technique to predict and analyse the structural behaviour of nucleic acids, including peptide nucleic acid- (PNA-) RNA 
hybrids. This study shows that a 7-base long PNA complementary to the seed region of miR-509-3p, one of the miRNAs involved 
in the posttranscriptional regulation of the CFTR disease-gene of Cystic Fibrosis, and bearing suitable functionalization at its N- 
and C-ends aimed at improving its resistance to nucleases and cellular uptake, is able to revert the expression of the luciferase gene 
containing the 3 UTR of the gene in A549 human lung cancer cells, in agreement with the MD results that pointed at the formation 
of a stable RNA/PNA heteroduplex notwithstanding the short sequence of the latter. The here reported results widen the interest 
towards the use of small PNAs as effective anti-miRNA agents. 
1. Introduction 
In the last twelve years a new group of endogenous, small, 
noncoding fragments of RNA, 18–25 nucleotides in length, 
named microRNAs (miRNAs) emerged for its ability to 
suppress the gene expression at posttranscriptional level [1, 
2]. To date more than 1,400 miRNAs have been identified. 
MicroRNAs regulate the gene expression by annealing with 
the complementary mRNAs, thus preventing their transla- 
tion or inducing their degradation [3, 4]. Although miRNAs 
usually recognize the 3UTR many of them are capable of 
binding the 5UTR or even coding regions of target mRNAs. 
Due to the small number of constituting nucleobases, each 
miRNA can recognize one or many mRNAs and each mRNA 
can be the target of many miRNAs. The result of    this 
network of interactions is the coregulatory role of miRNAs 
on the translation/degradation of one or more mRNAs [5]. 
Despite the potential occurrence of off-target effects, it is 
emerging that the modulation of specific miRNAs represents 
a new approach to achieve the control of gene expression. 
Potential applications of miRNA inhibitors (antimiR) range 
from diagnostics to regulation of important proteins involved 
in numerous cancers [6]. A number of human diseases 
have been associated with a deregulation of specific miRNAs 
[7–12]. Among these is the genetic disease Cystic Fibrosis 
(CF). CF is the most common lethal genetic disorder among 
Caucasians with one in every 3,000 newborns affected. CF is 
due to mutations in the CFTR gene encoding the CFTR chlo- 
ride channel expressed by most epithelial cells [13]. The CF 
phenotype typically includes the altered sweat test, pancreatic 
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insufficiency, and pulmonary infections that gradually lead to 
respiratory insufficiency. To date more than 1,900 mutations 
of CF gene have been described, and a set of miRNAs 
inhibiting the CFTR expression at the posttranscriptional 
level has been described [14]. Furthermore, our group has 
shown that mutations in the 3 UTR of the CFTR gene may 
have a pathogenic effect by enhancing the affinity for the miR- 
509-3p miRNA [15]. 
The approaches to downregulate a specific miRNA essen- 
tially use oligonucleotide (ON) analogues which being com- 
plementary to miRNAs are able to reduce or inhibit their 
activity. For this purpose a number of ribose modified ONs, 
usually bearing a phosphorothioate backbone, have recently 
been used. Interesting results have been obtained by using 
2-O-methyl-ribonucleotides [16, 17] and other  2-modified 
ONs [18, 19]. In addition, locked nucleic acids (LNAs) have 
shown interesting activity [20, 21] especially when used in 
combination with unmodified DNA monomers. Recently, 
several studies have demonstrated that the DNA mimics 
named peptide nucleic acids (PNAs) can be effectively used 
as anti-miRNA [22–24]. In the PNAs a 2-aminoethyl-glycine 
polymer replaces the ribose-phosphate DNA backbone [25]. 
PNA molecules are resistant to protease and nuclease degra- 
dation and recognize with a high affinity complementary 
fragments of DNA or RNA [26]. Many studies have been 
performed on the binding capability of PNAs and on 
the topological way in which they can recognize nucleic 
acids in single strand, duplex, or quadruplex arrangements 
to form heteroduplex, heterotriplex, and heteroquadruplex 
complexes [27–31] or to act as quadruplex ligands, respec- 
tively [32, 33]. The anti-miRNA activity of a PNA can occur in 
the nucleus by targeting the pre-miRNA or in the cytoplasm 
by binding the pre-miRNA and/or the mature miRNA [17]. 
In both cases it is necessary that the PNA can pass through 
the cell membrane and also through the nuclear membrane 
for the former case. The main drawback in the use of PNAs 
as intracellular probes lies in the poor water solubility when 
their length exceeds the 12–14 bases. Furthermore, the cellular 
uptake behaviour of a PNA is not easily predictable because 
it is mostly dependent on the PNA base composition and the 
overall lipophilicity. Recent studies report on the feasibility 
of a miRNA regulation approach by using unmodified PNAs 
and PNAs conjugated with peptides or hydrophilic groups 
[34, 35]. 
PNAs having a poly-lysine tail display increased water 
solubility and cellular uptake [23, 24]. In addition, negatively 
charged PNAs can be obtained by synthesizing PNA-DNA 
hybrid strands or by attaching negative groups to the PNA 
monomers [34, 36]. In the last case, cationic lipids can be used 
as transfection reagents. 
We recently reported that some anionic PNAs, synthe- 
sized by our group, are a potential treatment for CF by 
targeting the miR-509-3p involved in the regulation of CF 
disease-gene expression [37]. In that study we synthesized a 
14-base long PNA fully complementary to the 5-end of miR- 
509-3p and carrying a tetrapeptide tail containing two serine 
phosphates at its C-terminus and a fluorescein group at its N- 
terminus (PNA1, Table 1). We demonstrated, by in vitro stud- 
ies on A549 cell lines, that the serine phosphate tail represents 
a suitable conjugation to improve both the water solubility 
and the cellular uptake of a PNA molecule. Hybridiza- 
tion studies on PNA1 in the presence of miR-509-3p, 
performed by UV and CD spectroscopies and by elec- 
trophoretic mobility shift assay (EMSA), prove that the 
anionic peptide tail does not hamper the formation of the 
miR-509-3p/PNA1 heteroduplex. Finally, by reverting the 
expression of the luciferase gene containing the 3 UTR of the 
CFTR gene, we also demonstrated that PNA1 is able to rec- 
ognize miR-509-3p in A549 cells. In continuing our studies 
on the Cystic Fibrosis and on the control of the related miR- 
509-3p miRNA, we decided to test the capability of the short 
7-mer PNA2 (Table 1), bearing the same functionalization of 
PNA1 and complementary to the seed region of miR-509-3p, 
to bind this miRNA. Our interest towards shorter PNA anti- 
miRNAs was triggered by the consideration that the synthesis 
of longer PNAs (14–16 bases long) is an expensive and not an 
easily achievable task, especially when the PNA is conjugated 
to peptide tails and/or labelled at both ends. In addition, a 
recent study has reported that a very short LNA (8 bases long) 
was able to recognize and silence a family of miRNAs with 
no off-target effects [38]. Furthermore, experimental and 
computational evidence for different types of miRNA target 
sites demonstrated that probes with as few as seven base pairs 
of complementarity to the 5-end of miRNAs are sufficient to 
confer regulation in vivo and are used in biologically relevant 
targets [5, 39]. The synthesis of PNA2 was preceded by a 
molecular modelling study aimed at evaluating the structural 
behaviour of the goal seven bases long miR-509-3p/PNA2 
heteroduplex in comparison with that of the longer miR- 
509-3p/PNA1 heteroduplex. The stability and the structure of 
the miR-509-3p/PNA2 duplex were evaluated by molecular 
modelling and by UV, CD, and EMSA analyses. We here 
anticipate that PNA2, notwithstanding its reduced length, 
was still able to recognize miR-509-3p in A549 cells where it 
reverted the expression of the luciferase gene containing the 
3UTR of the CFTR gene. 
 
2. Materials and Methods 
Synthesis of miR-509-3p and PNAs (Table 1). The miR-
509-3p  mimic  (2-OMe  modified)  was  synthesized and 
purified by the oligonucleotide synthesis facility at 
CEINGE-Biotecnologie Avanzate (Naples, Italy). The 4- 
methyl-benzhydrylamine-resin (MBHA resin, 0.4 mmol/g), 
all Fmoc/Boc protected monomers, and the    2-(2-(flu- 
orenylmethoxycarbonylamino)ethoxy) ethoxyacetic (AEEA) 
spacer-linker were purchased from Link Technologies. Fmoc- 
L-Ser(PO(OBzl)OH)-OH building block, 2-(1-H-benzotri- 
azol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU), 2-(1-H-7-azabenzotriazole-1-yl)-1,1,3,3-tetramethy- 
luronium hexafluorophosphate (HATU), and 1-hydrox- 
ybenzotriazole (HOBt) were purchased from Novabiochem. 
The following abbreviations are used: trifluoroacetic acid 
(TFA), dimethylformamide (DMF), dichloromethane 
(DCM), N,N-diisopropylethylamine (DIPEA), N-methyl- 
pyrrolidone (NMP), 1,8-diazabicyclo(5,4,0)undec-7-ene 
(DBU), and 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5- 
isothiocyanate-benzoic acid (FITC). 
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Table 1: Structures and sequences of miR-509-3p and PNA1–3. PNA sequences are written from C- to N-terminus. 
O 
 
NH2 
 
Peptide 
H O 
N C O NH-FITC 
 
miRNA U G A U U G G U A C G U C U G U G G G U A G 
PNA1 G-S(P)-S(p)-G-a c t a a c c a t g c a g a Linker-FITC 
PNA2 G-S(P)-S(p)-G-a c t a a c c  Linker-FITC    
PNA3 G-S(P)-S(p)-G-t t t t t t t      
 
 
PNA2 and PNA3 were synthesized using the Fmoc- 
solid-phase strategy. The MBHA resin (50 mg, 0.02 mmol), 
after swelling in DCM (30 min) and DMF washings, was 
treated with a solution of 20% piperidine (2 mL) in DMF 
for 10 min. After washings in DMF, the resin was reacted 
with Fmoc-Gly (5 eq., in NMP 0.25 M), HATU (3.6 eq. in 
DMF 0.2 M), and DIPEA (5 eq.)/lutidine (6 eq.) for 1 h at 
room temperature. During the peptide and PNA synthesis 
the Fmoc group was removed by a treatment with a 5% 
DBU in DMF solution (5 min). In the case of Fmoc-Ser 
amino acids the basic treatment was prolonged (20 min). 
Couplings of Fmoc-L-Ser(PO(OBzl)OH)-OH were achieved 
using the following conditions: Fmoc-Ser monomer (8 eq. 
in NMP 0.4 M), HATU (8 eq. in DMF 0.4 M), and DIPEA 
(8 eq.)/lutidine (12 eq.) for 15 h at room temperature. PNA 
monomers and AEEA-COOH linker were reacted using 
the following conditions: monomer building block (8 eq. 
in NMP 0.4 M), HATU (8 eq. in DMF 0.4 M), and DIPEA 
(8 eq.)/lutidine (12 eq.) for 4 h at room temperature. 
For the coupling with the fluorescent group the FITC 
monomer (5 eq., 0.2 M) was dissolved in DMF/DIPEA 
(2.5 : 97.5 v/v) and the solution was added to the resin, which 
was gently shaken in the dark for 15 h. The resin was finally 
treated with TFA/anisole/ethanedithiol (9 : 0.5 : 0.5; v/v/v) for 
Molecular Modelling. The initial structures of the het- 
eroduplexes formed by miR-509-3p with PNA1 and PNA2 
were built by using the NMR structure of the 6-mer 
RNA(GAGUUC)/PNA(GAACTC) heteroduplex (PDB ID = 
176D) [43]. Starting from the lowest energy NMR structure, 
one nucleotide was added aligninga duplicate of the reference 
structure on the PNA backbone. Once the 7-mer heterodu- 
plex was obtained, the bases were mutated to match the PNA2 
sequence. Watson-Crick canonical pairs were then refined 
using distance restraints on the first seven bases of miR- 
509-3p/PNA2 heteroduplex. The same procedure was used to 
build the miR-509-3p/PNA1 heteroduplex, starting from the 
refined structure of miR509-3P/PNA2 heteroduplex. 
The equilibration of the systems and production of 
MD simulations were performed using the Amber 12 suite 
of programs [44, 45]. The Leap module of Ambertools13 
was used to create parameter and topology files for the 
MD simulations using the ff99SB force field for RNA and 
standard amino acids [44, 45]. For PNAs parameterization 
we used the Sanders et al. force field for PNA [46] down- 
loaded from the RESP and ESP charge database (R.E.DD.B. 
http://q4md-forcefieldtools.org/REDDB Project ID = F93) 
[47], whereas the parameters for serine phosphate were taken 
from reference [48]. TIP3P water molecules were added with 
3.5 h and the products were precipitated with cold diethyl a  minimum  spacing  of  10.0 A˚ from the box edges to the 
ether. The precipitates were recovered by centrifugation and 
following two washings with diethyl ether were dissolved in 
water and lyophilized. The PNA2 and PNA3 were obtained 
with a 48–50% overall yield (94-95% medium yield for each 
coupling). 
The purifications were performed by HPLC using a RP- 
18 column (Merck, RT 250–10 5 m) eluted with a 
linear gradient from 10% to 90% of eluent B in eluent 
A in 30 min. Eluent A: 0.1% TFA in water; eluent B: 0.1% 
TFA in acetonitrile. For these purifications the UV/VIS 
detector was set at 495 nm corresponding to the maximum 
of absorption of FITC. The collected yellow fractions were 
lyophilized and stored at −20∘C in the dark. 
The structures of PNA2 and PNA3 were confirmed 
by MALDI-TOF mass spectrometry on a Bruker Aut- 
oflex I instrument using -cyano-4-hydroxycinnamic 
acid, 10 mg/mL in acetonitrile-3% aqueous TFA (1 : 1, v/v) 
as the matrix. 
PNA2 m/z calculated 2812, found 2813 [M + H]+. 
PNA3 m/z calculated 2864, found 2865 [M + H]+. 
RNA:PNA molecules and Na+ counterions were added to 
each system to reach the neutralization of the system. 
The geometry of the system was minimized in four steps 
as follows: (1) optimization of hydrogen atoms (500 steps 
of steepest descent and 4,500 steps of conjugate gradient); 
(2) optimization of water molecules and counterions (2,000 
steps of steepest descent and 8,000 steps of conjugate gra- 
dient); (3) further optimization of hydrogen atoms, water 
molecules, and counterions (3,500 steps of steepest descent 
and 11,500 steps of conjugate gradient); (4) final optimization 
of the whole system (2,500 steps of steepest descent and 
8,500 steps of conjugate gradient). Thermalization of the 
system was performed in four steps of 60 ps, increasing the 
temperature from 10 to 298 K. Concomitantly, interstrand 
distance restraints were applied to the RNA:PNA heterodu- 
plex to preserve all base pairs canonical Watson-Crick bond, 
allowing 0.1 A˚ movement from the equilibrium bond distance 
(either closer or farther). Thus, the force constant applied 
during thermalization was set to 32 kcal mol−1 A˚ −2  and was 
gradually reduced in the next step to 10 kcal mol−1 A˚ −2  and 
subsequently  decreased  by  increments  of  5 kcal mol−1 A˚ −2 
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in the next stages. Then, an additional step of 250 ps was 
performed in order to equilibrate the system density at 
constant pressure (1 bar) and temperature (298 K). Finally, an 
extended trajectory covering was run using a time step of 2 fs. 
SHAKE was used for those bonds containing hydrogen atoms 
in conjunction with periodic boundary conditions at constant 
pressure and temperature, particle mesh Ewald was used for 
the treatment of long range electrostatic interactions, and a 
cutoff of 9 A˚ was used for nonbonded interactions. 
All production simulations were repeated in triplicate 
with random seeding for initial velocities and extended to 
20 ns. In order to further assay the stability of the RNA:PNA 
heteroduplexes, we extended one run of PNA2 up to 50 ns, for 
a total simulation time of 90 ns for PNA2 and 60 ns for PNA1. 
The structural features were determined using the Curves+ 
software package [40], and visualization of trajectories was 
performed in VMD [41], while the trajectory analyses were 
performed using Ambertools13. 
 
Preparation of miRNA/PNA Heteroduplexes (Annealing). The 
miR-509-3p/PNA heteroduplexes (1 : 1.5 or 1 : 5) were 
formed by heating the mixture of the samples dissolved in 
100 mM KCl, 10 mM K2 HPO4 , at 90∘C for 5 min and slowly 
fetal bovine serum (HyClone, USA) without the addition of 
antibiotics. Luciferase construct bearing the 3UTR of CFTR 
gene [15] was used as miR-509-3p sensitive. Transfection of 
A549 cells with miRNA-mimics (Qiagen, Germany, EU) or 
PNA was performed with Attractene Transfection Reagent 
(Qiagen) as previously reported [37]. Briefly, cells seeded 
in 96-well plates were cotransfected with the luciferase 
reporter constructs and the miR-509-3p mimic. 24 h after, 
the cells were transfected with anti-miR-509-3p PNA. The 
transfection efficiency (≈ 80%) was assessed by measur- 
ing the percentage of fluorescent cells relative to the total 
number of cells. The luciferase activity level was measured 
24 h after transfection using the Dual-Glo Luciferase Assay 
System (Promega Corporation). The relative reporter activity 
was obtained by normalization to the Renilla luciferase 
activity. 
 
2.7. Electrophoretic Mobility Shift Assay. The miR-509-3p 
mimic  (2OMe-modified)  was  synthesized  by  the  oligonu- 
cleotide synthesis facility at CEINGE-Biotecnologie Avanzate 
(Naples, Italy). As previously reported [37], the miRNA and 
PNA were annealed in 1X NEBuffer 2 (50 mM NaCl, 10 mM 
Tris-HCl, 10 mM MgCl , 1  mM DTT, and pH 7.9 at 25∘C) for cooling at room temperature for 12 h. The amount of each 2 h at room temperat 2 . All the reactions were loaded into 
PNA sample was estimated by quantitative UV at 80∘C 
using the following molar extinction coefficients: PNA1  = 
149.6 mL mol−1 cm−1 , PNA2  = 69.7 mL mol−1 cm−1 , 
PNA3  = 61.6 mL mol−1 cm−1 , and miR-509-3p  
= 
205.0 mL mol−1 cm−1 . 
 
UV and UV Melting Studies. The UV spectra were 
recorded on a Jasco V-530 UV spectrophotometer equipped 
with a Peltier-type temperature control system (model PTC- 
348WI). Thermal denaturation experiments were carried 
out in the temperature range 5–90∘C by monitoring the 
absorbance at 260 nm at the heating rate of 0.5∘C/min. The 
apparent Tm was estimated from the maximum in the first 
derivative of the melting profile. 
 
CD Studies. CD spectra were recorded with a Jasco J-
715 spectropolarimeter equipped with a Peltier Thermo- 
stat Jasco ETC-505T using 0.1 cm path length cuvettes 
and calibrated with an aqueous solution of 0.06% d-10- 
(1)-camphorsulfonic acid at 290 nm. The molar ellipticity 
[Θ] (deg cm2 dmol−1 ) was calculated from the following 
equation: [Θ] = [Θ]obs/10  , where [Θ]obs is the 
ellipticity (mdeg),  is the oligonucleotide molar 
concentration, and  is the optical path length of the cell 
(cm). CD measurements (220–320 nm) were carried out at a 
scan rate of 100 nm/min with a 2 nm bandwidth. The 
concentration of miR-509- 3p/PNA2 and miR-509-3p was 
1.0 × 10−5 M. The spectra were signal-averaged over at least 
three scans and baseline was corrected by subtracting the 
buffer spectrum. 
 
Cell Line, Construct, and Transfections. A549 human lung 
carcinoma cells were purchased from ATCC (Manassas, 
USA). Cells were maintained in Dulbecco’s modified Eagle’s 
medium (Gibco Invitrogen, USA) with 10% heat inactivated 
ure 
20% polyacrylamide gels in 0.5X Tris-Borate-EDTA (TBE) 
buffer and run at 140 V for 3 h. The fluorescence signal was 
acquired placing the wet gel directly on the plate of the 
Typhoon 8600 scanner. 
 
3. Results and Discussion 
With the aim of evaluating the feasibility of our hypothesis of 
shortening the PNA1 molecule to achieve a more synthetically 
affordable PNA targeted against miR-509-3p that preserves 
the hybridization properties of the parent PNA1, PNA2 
was designed by deleting all the PNA1 bases that were not 
complementary to the “seed region” of miR-509-3p (i.e. the 
first seven bases at its 5end, considered the most important 
target to achieve the anti-miRNA activity). As previously 
done for PNA1 [37], to improve the water solubility and the 
cellular uptake of PNA2 we decided to add the negatively 
charged tetrapeptide G-S(P)-S(P)-G at the C-end, whereas 
the fluorescent AEEA linker-FITC was added at the N-end 
to assess the cellular localization of PNA2. Before proceeding 
to the in-lab synthesis of PNA2, we estimated the stability and 
the conformational features of the goal miR-509-3p/PNA2 
heteroduplex by means of computational techniques and 
compared the results with those of the correspondent het- 
eroduplex formed with the PNA1. Computational techniques, 
and in particular molecular dynamics (MD) simulations, 
have been successfully used as complementary technique to 
predict and analyse the structural behaviour of nucleic acids, 
including PNA-RNA hybrids [46, 49, 50]. 
 
Molecular Dynamics Simulations. The miR-509- 3p/PNA2 
and miR-509-3p/PNA1 heteroduplexes were built 
starting from the NMR structure of the RNA 
(GAGUUC)/PNA(GAACTC)  duplex  (PDB-ID  176D) 
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Figure 1: Root-mean-square deviation in the three MD runs on miR-509-3p/PNA2 (a) and miR-509-3p/PNA1 (b) heteroduplexes. 
Superimpositions were made on the MD-averaged structures for each trajectory taking into account the whole structure (blue, orange, and 
purple) or only the duplex region (black, red, and green). 
(a) (b) 
Figure 2: Superimposition of the MD average structures of miR-509-3p/PNA1 complex (a) and of miR-509-3p/PNA2 complex (b). Duplexes 
regions are represented in licorice coloured by atom type (carbon in cyan, oxygen in red, nitrogen in blue, phosphate in brown, and hydrogen 
in white). The miR-509-3p single strand regions are represented in spheres coloured by MD run (blue, run 1; green, run 2; red, run 3). (c) 
RMSD in A˚ , calculated on phosphates in the duplexes regions, among the average structures of the MD runs. 
[43] as described in Materials and Methods. Each system was 
firstly analysed by means of three runs of 20 ns molecular 
dynamics in order to better sample the conformational 
behaviour of the complexes. Secondly, in order to further 
assay the stability of the miR-509-3p/PNA2 duplex, we 
extended one run of miR-509-3p/PNA2 up to 50 ns, for a 
total simulation time of 90 ns for miR-509-3p/PNA2 and 
60 ns for miR-509-3p/PNA1. 
The macroscopic properties of the systems, such as 
temperature, pressure, volume, density, and energy, were 
fairly constant during the whole simulation for both of 
the systems (data not shown). As expected, the analysis of 
the RMSD in the trajectories of miR-509-3p/PNA2 and miR- 
509-3p/PNA1 complexes showed high flexibility of the single 
stranded miRNA segment (Figure 1). On the contrary, the 
behaviour of the region of miR-509-3p hybridized with PNAs 
was characterized by low RMSD values and low fluctuations, 
thus indicating the presence of a stable secondary structure 
(Figure 1). 
Moreover, the comparison of the average structures 
obtained from each trajectory (Figure 2) revealed the conver- 
gence of the trajectories as shown by the low RMSD values in 
the duplex region of both complexes with PNA1 and PNA2 
(>0.5 A˚ and >0.9 A˚ , resp.). 
RM
SD
 (A
) 
 
 
AVG 
PNA1 
Run 2    Run 3 
PNA2 
Run 2    Run 3 
Run 1 0.36 0.36 0.9 0.56 
Run 2 // 0.5 // 0.9 
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Table 2: Comparison of backbone torsion angles and helicoidal parameters for average structures of each run after 20 ns MD simulation. 
Highlighted in bold are values for structure obtained by averaging all the three runs. Standard deviation is reported in brackets. 
 
(a) 
Helicoidal parameters 
Duplex name Twist (∘) Roll (∘) Tilt (∘) Inclination (∘) H.Ris (∘) H.Twi (∘) Groove width (A˚ ) 
PNA:RNA NMRa 
PNA:RNA MDb 
A-RNAc 
30.1 (4) 
23.7; 23.2 
32 
4.9 (4.3) 
 
12 
1.0 (3.3) 
 
2.8 
9.0 (2.7) 
 
15.8 
2.98 (0.2) 
 
3.3 
30.6 (4.2) 6.1 (0.5) 
 
3.8 
PNA2 AVG tot 24.5 (1.1) 6.5 (1.6) 1 (0.9) 14.2 (0.6) 2.79 (0.10) 25.3 (1.1) 6.8 (0.6) 
PNA1 AVG tot 24.9 (2.8) 5.7 (2.2) 0.9 (1.3) 13 (1.1) 2.77 (0.16) 25.5 (2.9) 6.8 (0.5) 
(b) 
Torsional PNA angles (in degrees) 
 N4–C5 C5–C C–N1 C2–C3 C3–N4 N4–C7  
PNA:RNA  NMRa −84.9 80 105.7 66 −100.1 9.1 50.6 
PNA2 −79.9 125.2 78.6 70.4 −103 −2.9 78 
PNA1 −81.3 129 131.5 69.5 −103.3 −2.1 78.5 
(c) 
Torsional RNA angles (in degrees) 
        
PNA:RNA  NMRa −68.4 111.75 58.4 78.5 −148.7 −72.5 −104.5 
A-RNAc −52 175 42 79 −146 −75 −157 
miR20ad −99.1 162.6 73.1 88.7 −138 −119.4 −147.6 
PNA2 AVG tot −84.4 172.8 81.3 79.2 −160.4 −70.3 −159.5 
PNA1 AVG tot −88.8 145.8 85.5 81.8 −161.1 −70.9 −158.7 
a Calculated on the average of the 10 NMR structures of PDB structure 176D; bfrom [40]; cfrom [41]; dfrom [42]. 
 
 
0.4 
 
 
0.3 
 
 
0.2 
 
 
0.1 
 
 
0 
220 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
240 260 280 300 
Wavelength (nm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
320 
with what was previously observed in other MD simulations 
of RNA/PNA duplexes [43, 49]. The lower roll and tilt values 
observed in the MD run pointed at an expansion of the 
major groove. Finally, the analysis of torsion angles reported 
in Table 2 highlighted the strong similarity between the 
two duplexes. Taken together, the MD results indicated that 
both heteroduplexes assumed a conformation resembling the 
canonical A-type RNA helix rather than the experimentally 
determined NMR structure. Moreover, the torsion angles of 
RNA segments in miR-509-3p/PNA2 and miR-509-3p/PNA1 
duplexes showed values very similar to those adopted by 
miR20a in the 4F3T crystal structure [42] suggesting that 
PNA2 and PNA1 could easily interact with the AGO-miRNA 
Figure 3: UV spectra of miR-509-3p (dashed line), PNA2 (solid 
line), miR-509-3p/PNA2 mixture (1 : 1.5) (dotted line), and the 
arithmetical sum (dashed-dotted line). 
 
 
The analysis of the helicoidal parameters and tor- 
sion angles (Table 2) demonstrated that both miRNA/PNA 
duplexes could be described as A-type double helix with 
few noticeable deviations from the canonical structure. In 
particular, the lower step-averaged twist values reported in 
Table 2 indicated a slight unwinding of the RNA/PNA helices 
with respect to canonical A-RNA structures, in agreement 
complex, not requiring any conformational adaptations. On 
the basis of the positive indications coming from the MD 
studies, we synthesised the PNA2 molecule and studied its 
ability to recognize the 2-OMe mimic of miR-509-3p by CD, 
UV, and EMSA studies and evaluated its ability to restore the 
expression of the luciferase gene containing the 3 UTR of the 
CFTR gene in the presence of miR-509-3p. 
 
3.2. Synthesis of PNA2 and PNA3. PNA2 and PNA3, chosen 
as the negative control and bearing the same functionaliza- 
tion of PNA2, were synthesized using the standard Fmoc- 
solid-phase strategy on the Rink-amide resin following the 
A
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Figure 4: UV melting profile of miR-509-3p alone (dashed line) and 
miR-509-3p/PNA2 mixture (1 : 1.5 dotted line). 
 
 
previously reported synthetic approach [37]. The sequences 
and the complete structures of PNA2 and PNA3 are shown in 
Table 1. 
 
UV and UV Melting Studies. The miR-509-3p/PNA2 
complex, prepared as described in Materials and Methods, 
was analysed by UV spectroscopy in the temperature range 
of 25–90∘C. The data showed for the miR-509-3p/PNA2 
complex a lower value of absorbance than the arithmetic 
sum of each component alone (Figure 3), thus evidencing 
that heteroduplex stacking interactions between the miRNA 
strand and the PNA2 had occurred. The UV melting exper- 
iments performed on the miR-509-3p/PNA2 mixture (1 : 1.5 
ratio) showed a sigmoidal profile, which was indicative for 
the heteroduplex/single strands transition (Figure 4). The cal- 
culated apparent melting temperature of the  miRNA/PNA2 
heteroduplex was 40∘ C. The UV melting profile of the 
sole PNA2 did not show any significant variation in the 
A260 value in 10–70∘C (data not shown), whereas, the UV 
melting of the sole miR-509-3p, in the same experimental 
conditions, showed a sigmoidal profile with an apparent 
melting temperature of 26∘ C, which could be attributed to the 
melting of poorly stable secondary structures of the miRNA. 
This data suggests that PNA2 is able to form a complex with 
miR-509-3p provided with the thermal stability required for 
in vivo experiments. 
 
Circular Dichroism Spectra Analyses. To further con- 
firm the formation of the miR-509-3p/PNA2 heteroduplex 
complex, circular dichroism (CD) spectra were registered 
for the miR-509-3p, PNA2, and their 1 : 1.5 mixture after the 
annealing procedure (Figure 5). In particular, the miR-509- 
3p/PNA2 mixture showed the typical CD profile of antipar- 
allel RNA/PNA heteroduplexes, characterized by maxima at 
around 260 and 220 nm and minima at around 235 and 
196 nm, thus confirming the capability of the PNA2 to form a 
heteroduplex with the miR-509-3p miRNA. 
 
EMSA Results. The recognition phenomena between the 
miR-509-3p and the FITC-labelled PNA2 were also 
 
Figure 5: CD spectra of miR-509-3p alone (dashed line), PNA2 
alone (solid line), and miR-509-3p/PNA2 mixture (1 : 1.5) (dotted 
line). 
 
 
studied by electrophoretic mobility shift assay (Figure 6(a)). 
To allow the visualization of miR-509-3p alone, the gel was 
also visualized after the EtBr staining (Figure 6(b)). The 
superimposition of FITC and EtBr stained gels is shown 
in Figure 6(c). The electrophoretic mobility of PNA2 alone 
(lanes 1) was slower than that of miR-509-3p alone (lane 
2). When miR-509-3p and PNA2 were mixed in the molar 
ratios of 1 : 1.5 and 1 : 5 (lanes 3 and 4, resp.) we observed 
the appearance of a new band, corresponding to the miR- 
509-3p/PNA2 complex, which was upshifted relative to the 
bands of the two components alone. The formation of the 
miR-509-3p/PNA2 complex was further confirmed by the 
disappearance of the band of the free miR-509-3p in the 
miRNA/PNA2 1 : 5 complex (lane 4, Figures 6(b) and 6(c)). 
The EMSA data further corroborated the CD evidence about 
the ability of PNA2 to form a stable complex in the presence 
of miR-509-3p miRNA. 
 
 
Biological Activity. Once the ability of PNA2 to form a 
stable heteroduplex with miR-509-3p was demonstrated, we 
examined its potential of being a miR-509-3p inhibitor in a 
biological context. For this purpose we tested the ability of 
PNA2 to revert the reduction of luciferase activity induced by 
the transfection of the 2-OMe mimic of miR-509-3p in A549 
cells. As shown in Figure 7 the transfection of PNA2, but not 
of PNA3, was able to rescue the luciferase activity in a dose- 
dependent manner. In this experiment A549 cells were first 
transfected with the pLuc-CFTR-3UTR plasmid (a reporter 
luciferase construct sensitive to the miR-509-3p mimic action 
due to the presence of the 3 UTR of the CFTR gene) and 
with miR-509-3p miRNA. As expected, the transfection of 
the miR-509-3p reduced the luciferase activity down to 40%. 
The luciferase activity was rescued after the transfection of the 
PNA2 in a dose-depended manner. In these experiments the 
commercially available Attractene cationic lipid transfection 
reagent was used. The fluorescent microscopy image of the 
A549 cells taken 24 h after the transfection with PNA2 
(Figure 8) confirmed the PNA2 uptake by the cells. 
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Figure 6: EMSA of PNA2 alone (lanes 1), miR-509-3p alone (lanes 2), miR-509-3p/PNA2 1 : 1.5 (lanes 3), and miR-509-3p/PNA2 1 : 5 (lanes 
4) visualized by FITC (a) or EtBr (b) staining. The superimposition of FITC and EtBr stained gels is shown in (c). 
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4. Conclusions 
Previously, we showed that the activity of the miR-509-3p 
miRNA, one of miRNAs involved in the  posttranscriptional 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Representative uptake of FITC-labelled PNA2 by A549 
cells. 
 
 
regulation of CFTR gene of CF and CF-RD, could be inhibited 
through the use of the 14-mer PNA1 fully complementary 
to the first fourteen bases of miR-509-3p [37]. With this 
study, we demonstrate that the activity of miR-509-3p can 
be inhibited even with the use of a PNA as short as seven 
bases long targeting exclusively the seed region of the miRNA. 
This finding, probably due to the higher affinity of PNAs 
over RNAs towards the complementary RNA strand, further 
widens the interest towards the use of peptide nucleic acids 
as effective anti-miRNA agents, considering the number 
of advantages in terms of cost and time saving in the 
synthesis of the PNAs or for what attains their cellular 
uptake. 
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